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I . INTRODUCTION 
Despite the vast amount of accumulated data on inflammation, there are 
still large gaps in our knowledge about the path\-Jays involved in the develop-
ment of an inflammatory response (see Ebert & Grant, 1974). Thus, effective 
therapy of several chronic inflarmnatory diseases is, at this moment, beyond 
medical capabilities. For the control of the inconvenient and painful symp-
toms of diseases like rheumatoid arthritis, physicians still have to rely on 
drugs which have largely been developed empirically and are used in an empi-
rical way (eg. Kaye & Pemberton, 1976). The mode of action of several of these 
"anti-inflammatory drugs", Hhich often only relieve anoying symptoms of the 
disease, has for a long time been shrouded in mystery. Only recently, Vane 
and co-Harkers (1971) discovered the main biochemical action of a group of 
these drugs, kno.vn as non-steroidal anti-inflammatory drugs (NSAIDs), of which 
aspirin (acetylsalicylic acid) is the most familiar representative. It ap-
peared that aspirin-like drugs suppress prostaglandin (PG) biosynthesis, both 
in vitro and in vivo (82,233,254). This led to the concept that inhibition of 
PG release explains the anti-inflammatory effect of NSAIDs. 
Several experimental models are used in the development of new anti-in-
flammatory drugs. For example, both non-steroidal and steroidal anti-inflamma-
tory agents suppress certain inflammatory reactions evoked in animals. These 
models are not only useful for the development of new drugs, but may lead to 
some understanding of their modes of action. Moreover, since such models ap-
parently mimick certain features of human diseases, they may provide informat-
ion about endogenous factors which are of importance for the development -or 
persistence- of the disease or its symptoms. The main purpose of the experi-
ments described in this thesis Has to obtain more insight into the involvement 
of PGs in an in vivo model of acute inflammation. The process is evoked by the 
injection of carrageenin, a material extracted from seaweed and containing 
sulphate polysacharides, into the foot of a rat. This results in a short-last-
ing reaction (CAR edema), that exhibits macroscopical features of inflammation, 
such as swelling, a local increase in temperature, redness and an decreased 
pain threshold. CAR edema, as well as other inflammatory reactions, is part-
ially governed by mediators. These endogenous substances are formed or releas-
ed at the inflammatory site, and are able to induce one or more signs of in-
flammation. 1dhenever their release is depressed by a drug or depletion, the 
inflammatory reaction should be reduced (see 267,274). On the basis of the 
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sensitivity of CAR edema to aspirin-like drugs, it is generally assumed that 
PGs are involved as mediators in this inflammatory model. However, unequivocal 
meaurements of local PG levels have never been published using CAR edema, one 
of the most used models of acute inflammation. Thus, it was tempting to see 
if the PGs fulfill the first criterion of a mediator, namely enhanced local 
concentrations during the inflammatory reaction in the paw. Secondly, the 
pro- or anti-inflarnmtory activities of PGs were examined on CAR edema. These 
studies were partly carried out with essential fatty acid deficient (EFAD) 
rats. EFAD rats lack the precursors from which PGs are formed. With the aid 
of these rats, it was further investigated if the anti-inflammatory activity 
of tHo aspirin-like drugs, \Vas indeed explained by inhibition of PG biosyn-
thesis. 
Since PGs are formed easily as a result of only minor tissue damage, the 
assessment of PG levels in vivo is a procedure full of pitfalls. Therefore, 
another in vitro model was used, in which biosynthesis of PGs and related 
products by aggregating rat platelets was studied. In this model the NSAIDs 
are active as inhibitors of aggregation and PG biosynthesis. Certain PG pro-
ducts are necessary for aggregation of human blood platelets. In fact, the 
prolonged bleeding-time, vhich is sometimes observed after ingestion of as-
pirin, can now be explained as a consequence of its inhibition of PG bio-
synthesis. Thus, apart from PG biosynthesis per se, the significance of this 
formation for rat platelet behaviour has also been studied. As with the in 
vivo model, the activity of certain drugs and the influence of EFA deficiency 
on both platelet PG release and aggregation \vere investigated. 
Short reviews of recent literature on several aspects of the studies are 
given in chapter 2. ~ot all selected data are of direct relevance to the ex-
perimental section (Chapters 3-7). Hotvever, the reader, tvho is interested, may 
find more information on certain basal aspects, which are of importance for a 
better understanding of the processes studied. 
In order to facilitate the understanding of some biological aspects, the 
experiments >vith the in vitro model will be described first (Chapter 4), and 
will be folloved by description of the in vivo studies (Chapter S-7). Most 
results have already been published, or will be published elstvhere. In this 
thesis, the results have been rearranged, sometimes within a broader frame 
than that offered by editors of journals. 
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2. LITERATURE 
2. I. Prostaglandin (PG) biosynthesis. 
2. I. 1. Summary. 
The term prostaglandins, first used by Von Euler (1937), is now the 
generic name for a number of related lipids. The basic structure of these 
fatty acids (prostanoic acid), was proposed by BergstrOm et al. (1963; see 
fig 2.1). 
Fig. 2. I. Prostanoic acid and 
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The naturally occurring, "classical" PGs are classified according to 
functional groups attached to c9 and c11 . Numerical subscripts (e.g. PGE 2) 
indicate the number of double bonds in the aliphatic chain of the PGs. The 
"a" and ''6 11 subscripts of PGF designate whether the c9 hydroxylgroup points 
forward or dmm (a) or backwards ( S). 
The first reports of PG biosynthesis (7,250,251) showed, that certain 
n-6 unsaturated fatty acids were precursors of PGs. Thus, PGE 1, PGE2 and 
PGE 3 can be formed by incubating more-or-less purified preparations of PG 
endoperoxide synthetase (also called cycle-oxygenase) with dihomo-y-linolslic 
acid (20:3, 
(20:5, n-3) 
structures, 
n-6), arachidonic acid (AA, 20:4, n-6) and eicosapentaneoic acid 
. . . respect~vely In the decade following the d~scovery of their 
the activities of PGs have been intensively studied because of 
their various effects on physiological (eg. reproductive, gastrointestinal, 
cardiovascular and renal system} and pathological processes (eg. inflamma-
*for fatty acid nomenclature and notation; see 109,146 and fig. 2.3. 
ll 
tory reactions and blood platelet aggregation). 
They may be considered as local hormones or autacoids. It 1:vas assumed (eg. 
221) that the conversion of AA into stable PGs proceeded as follows: 
arachidonic acid PG endoperoxides 
The isolation of the unstable endoperoxide intermediates in PG biosyn-
thesis was described by Nugteren & Hazelhof and Hamberg & Samuelsson in 1973. 
Since these unstable PG endoperoxides (PGG2 , PGH2 ) are much more potent than 
the classical PGs in certain aspects (eg. platelet aggregation), their iso-
lation has opened new areas of PG research. 
Recently two new enzymatic conversions of these endoperoxides have been 
discovered (see fig. 2.2). The first path1:vay, initially found in platelets 
(120, 179) leads to the formation of the non-prostanoic thromboxanes. Throm-
boxane A2 (TXA2) is highly unstable in aqueous solution and is even more 
potent than the endoperoxides in producing platelet aggregation and in con-
tracting an isolated rabbit aorta strip. TXA2 is proabbly identical to the 
elusive rabbit aorta contracting substance (RCS), first described by Piper & 
Vane (1969). It has now become apparent that in several cells (eg. platelets, 
lung and spleen cells) the classical PGs are only formed in minute amounts 
\Vhen compared to the amounts of thromboxanes, 
The second new pathway leads to prostacyclin (pr,x, PGI 2 ; 170) and was 
first discovered in rat stomach and cells of arterial walls. Interesting-
ly the effects of prostacyclin are directly opposed to those of TXA2 : it re-
laxes arterial smooth muscle and is a very potent inhibitor of platelet ag-
gregation. 
Since the PG endoperoxides possess important biological actions, and can 
he almost completely transformed to and released as highly active non-
prostanoic products, the importance of PGs in physiological and pathological 
processes should be reappraised. Some of the more important factors for PG 
biosynthesis vill be described in the following paragraphs (Key to other 
literature: Samuels son et al., 1975). 
2.1 .2. Cycle-oxygenase substrates. 
A large number of polyunsaturated fatty acids (PUFA's) with 18 to 22 C 
atoms, and at least 3 double bonds in a skipped position, can act as P~-pre-
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cursors (143,236,265). The methylene-interrupted all cis double bond system 
is normally at n-6. Location at n-5 or n-7 still allows conversion into PGs, 
but a larger shift of the double bond system, tm:vards the carboxylgroup (fmm 
(n-8), prevents any conversion at all (17,236,251). Thus, the 20:3(n-9) aci~ 
which accumulates during essential fatty acid (EFA) deficiency is not a PG 
precursor, nor is it converted to an hydroperoxy fatty acid by the cyclo-
oxygenase (see 236). The main naturally occurring substrates are dihomo-y-
linolenic acid and AA. AA is by far the most common in different species and 
tissues (eg. 146, 180), except for the vesicular gland where dihomo-y-lino-
lenic acid is predominantly present (143,265). 
2. 1.3. Phospholipase A2 : the rate limiting factor in PG release? 
In most cells the bulk of PUFA's, including EFA's is esterified at the 2 
position of phospholipids (109). Phosphatidylethanolamine (PE), phosphatidyl 
serine (PS) and phosphatidyl inositol (PI) are generally the richest sources 
of EFA's. These phospholipids are mainly present on the inside of the lipid 
bilayer in mammalian plasma membranes (eg. platelets (54), erythrocytes (285)~· 
liver cells (75)) and phosphatidylcholine (PC) and spingomyelin (Sph), which 
contain very little AA, are predominantly found in the outer half of the 
lipid bilayer. 
Thus, in most mammalian cells a phospholipase A2 (PLA2) is likely to play 
a role in the liberation of PG-precursors and its activation or its access to 
the substrate has been postulated as a regulating factor in endogenous PG 
biosynthesis (Kunze & Vogt, 1971). The importance of endogenous PLA2 in con-
trolling PG release has recently been established in spleen and lung tissue, 
and platelets (see 2.4). In spleen slices, preincubated with 14c-AA, the 
substrate is indeed released from the 2 position in phospholipids, and not 
from neutral lipids. This release increases during gentle tissue damage 
(produced by vibration), and anaphylactic shock, and is antagonized by the 
anti-malarial drug mepacrine (88). In guinea pig perfused lungs an increased 
PLA2 activity coincided 1-Jith an enhanced PG production (26). 
Apart from the possibility that activation of PLA2 is rate limiting for 
release of AA, the increased release of PG precursors may be explained with-
out recourse to changes in basal endogenous PLA2 activity. Some alternatives 
are: !· Changes in membrane structure, such as in interfacial pressure be-
tween the phospholipids in the bilayer (68,286), and/or changes in fluidity, 
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can lead to enhance degradation of phospholipids. Both below and above the 
transition temperature, the ordered lipid molecules_ in liposomes are not 
accesible to pancreatic PLA2 , but during phase-transition hydrolysis takes 
place, Some venom phospholipasesare able to degrade their substrate in the 
liquid phase (228). The transition of phospholipidbilayers, from the solid 
to the liquid-crystalline form is influenced by the unsaturation and/or 
length of the acyl chains, the properties of the polar head groups, the in-
corporation of cholesterol into the bilayer, and the presence of divalent 
cations (eg. 67,199,247). ~· A reduced reacylation (eg. 213) of liberated 
AA. l· PLA2 may liberate other PUFA's than AA, eg. linoleic acid, which are 
competitive inhibitors of PG synthetase (198). A decreased liberation of 
these fatty acids in favour of an increased AA-release will result in an 
enhanced PG formation. 
Some of the stimuli that increase endogenous PG production, are given 
in table 2.2. It is obvious that one of the explanations for the increased 
PG output is an enhanced availability of substrate, but only in the perfus-
ed guinea pig lung has a possible increase in PLA2 activity been demonstra~ 
ed to be responsible for the enhanced hydrolysis of fatty acids (Blackwell 
et al., 1977). They injected sn 2 (1- 14c} oleoyl PC into the pulmonary 
artery and observed a small basal release of hydrolyzed label. Histamine 
(H), RCS-releasing factor (RCS-RF) and bradykinin (Bk) stimulated this re-
lease 3 to 5 times, These results indicate that H, Bk and RCS-RF stimulate 
PLA2 activity, provided that the flow of the label through the lungs is 
unaltered by H, Bk and RCS-RF, and that reacylation of free fatty acids 
remains unchanged. 
~iE~~§· In contrast to most tissues, PG release in adipose tissue might 
also be dependent on the activities of lipases. Data on the origin of PG 
precursors in adipose tissue are however, lacking at this moment. The con-
comitant release of substrate analogues, such as oleic and linoleic 
acid (see 2.2.1) which inhibit PG biosynthe~;~. might be considerable if 
triglycerides serve as source of AA. 
2.1.4. Fatty acid cyclo-oxygenase (E.C. 1 .14.99. I.}. 
PG endoperoxide synthetase (= cyclo-oxygenase), which forms PGG2 from 
AA, is present in many vertebrate and non-vertebrate tissues (57). Rich 
sources include: seminal vesicles, kidney medulla, gastro-intestinal tract, 
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spleen, lung and platelets. The enzym is membrane bound and has been solub-
ilized and purified to a high extent (121,166,167,219,246). Estimates of its 
molecular weight range bet1:veen 69,000 and 85,000 (121 ,219,246). The initial 
step in PG biosynthesis from AA is removal of the 13-L-hydrogen, followed by 
introduction of one molecule of oxygen at C 1 I in a lipoxygenase-like reaction 
(see 221 and fig. 2.2). The peroxyfatty acid is subsequently transformed by a 
complex reaction to PGG2 , with the introdution of second molecule of oxygen. 
Hith certain PUFA's (eg. 20:2,n-6; 22:3,n-8) the initial reaction occurs with-
out PG formation and the corresponding hydroxyfatty acids are formed. Eico-
satrienoic acid (20:3,n-9) does not lead to formation of an hydroxyfatty acid 
(188,236). 
Purified synthetases of bovine (166) and ram seminal vesicles (246) dis-
played both cycle-oxygenase and peroxidase activity. The cyclo-oxygenasereact-
ion (eg. AA+PGG2 ) requires haemin, free or protein bound. Haemin acts as 
prosthetic group and is possibly lost during purification. Haemin and some 
non-haem iron were found to be present in the preparation described by Hemler 
et al. ( 1976). A suitable hydrogen donor, such as tryptophane ( 166) or hydro-
quinone (189,246), is necessary for the reduction of the 15-hydroperoxygroup 
by the peroxidase activity. Thus, in the presence of haem compounds and a 
hydrogen donor the major endproduct of the purified enzyme is PGH 1, if 20:3 
(n-6) is used as substrate (166,246). Without a hydrogen donor a very rapid 
in activation occurs. 
The rather complex kinetics of the enzyme have been studied by the group 
of Lands, who used microsomal preparations from ram and bovine seminal vesicl-
es. The enzyme shows a positive feedback, in being activated allosterically 
by its own products, and a negative feedback in catalyzing its mm destruction 
(eg. 142). The initial lag-phase, 1:vhich is a feature of the possitive feedback 
was not observed in a solubilized cycle-oxygenase from ram seminal vesicles, 
and the delayed start in a microsomal preparation might be the result of a slow 
access of subtrate and/or oxygen to the active site (233). 
The in vitro self-destruction of the enzyme has been established for dif-
ferent microsomal preparations (eg. 142,209,280) and a purified cyclo-oxyge-
nase ( 166). The self-catalyzed breakdmvn of enzymatic activity takes place 
within a very short time at high substrate concentrations. If this self-
destruction also occurs in intact cells, it might be a limiting factor in 
PG biosynthesis. Due to the limiting substrate concentrations, it seems un-
likely that autocatalytic breakdown of enzymatic activity, does normally 
15 
occur in vivo. 
2.5.1. The metabolism of PG endoperoxides. 
Non-enzymatic conversion. The half life (t~) of PGH 2 in buffer (pH 7.4, 
37°C) is 5 min. PGH 1 and PGH2 decompose non-enzymatically to form PGE, PGFa:, 
PGD and a 12-hydroxy-C 17 fatty acid with concomitant production of MDA. 
Hithout reducing agents and haem the yield of PGE and PGD is 85-90%, PGE 
being the main product (189). Certain serum albumins (cow, sheep and pig) 
facilitate the decay of PG endoperoxides, probably via a fatty acid binding 
site, with an enhanced yield of PGD (58,1 13). 
Enzymatic conversion. Presumably, the metabolism of PG endoperoxides in-
to PGE, TXA2 and prostacyclin (PGI 2) takes place at, or very near the site 
of the cycle-oxygenase activity. In the situations studied, the endoperoxi-
des are rapidly metabolized by the specific enzyme system present, and very 
little endoperoxides can accumulate. Examples of these preferred pathtvays in 
certain tissues are: seminal vesicles (20:3, n-6-+PGE 1), renal medulla 
(AA-+PGE 2), platelets (AA-+TXA2), heart and vessel wall (AA-+PGI 2). Some of 
these enzymes have only recently been described and have only been subject-
ed to preliminary characterization. 
~Q~~-~Q~-i~Q~~~~~~- This reaction occurs in homogenates of several rat 
tissues such as spleen, lung, small intestine and skin. The enzyme is not 
membrane bound (189). 
~Q~~~~Q~-i~Q~~E~~~· This enzyme is localized in membranes of bovine 
(167) and ram (189) seminal vesicles and rat renal papilla (196) and has 
been solubilized (167). In all cases GSH is needed for the reaction. 
~Q~_-+_~QI_~~£~£~~~~- The reductive cleavage of the 9,11-endoperoxide ring 
of PGH2 , which yields PGF 2a:, is performed by rat liver glutathione-S-trans-
ferases (58). According to some authors PGF formation from PGH seems to be 
a non-enzymatic process (eg. 209). 
I~EQ~£Q~~~~-~Y~!Q~~~~~-i~QH2~-!~2_i§2~~E~~~). Biosynthesis of throm-
boxane A2 (TXA2) takes place in washed human platelets (120), and in lungs 
and spleen of guinea pig (I 12,1 18) and rat (197). TXA2 is very labile (t~= 
~ 30 sec, at 37°C) and decays either into TXB2 (112,120) or into }IDA and a 
C-17-hydroxy fatty acid (HHT; 84,101 ,239). A recent report indicates that 
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Fig. 2.2. Pathways in PG biosynthesis. The cyclo-oxygenase may act 
as catalyst in the conversion of free (see 2. 1.2 & 2. 1.3) arachi-
donic acid into PG-endoperoxides (PGG2 and PGH2; see 2. I .4). The 
latter may be enzymatically (~) or non-enzymatically (--~) trans-
formed into HHT and HDA, stable PGs, prostacyclin (Pcr 2) and throm-
boxane A2 (TXA2 ) (see 2.1.5), 
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TXA2 is more stable in human plasma (232). Since TXA2 is a much more potent 
constrictor of rabbit aorta strips than the PG endoperoxides, PGG
2 
and PGH2 
( 178, 179) it is now assumed (120) that TXA2 is the main constituent of rab-
bit aorta contracting substance (RCS), which is released from the guinea pig 
lung during anaphylactic shock (Piper and Vane, 1969). 
The platelet enzyme is membrane bound and can be obtained in a microso-
mal fraction. PGG2 , PGG3 , PGH 2 and PGH3 , but not PGH 1, serve as substrate 
for the microsomal preparation from platelets (178,179,187). The enzyme of 
human platelets showed little pH dependence between pH 5-8.5, was not in-
hibited by NSAIDs, and not affected by azide, GSH and AA metabolites PGE2 , 
PGD 2 , PGFla' RETE or TXB2 . However, this preparation was strongly inhibited 
by stable substrate analogues such as 9,11 epoxymethano prostanoic acid and 
9,11 EM (239). 
Other inhibitors of thrombxane synthetase have been described. Benzyda-
mine is somewhat more effective as inhibitor of TXA2 synthetase, than as 
cycle-oxygenase inhibitor (172). A non-acidic anti-inflammatory agent, 
18027, has been claimed to be a selective inhibitor of TXA synthetase (104). 
Imidazole selectively inhibits platelet TXA2 synthesis (rc50= 22wg/ml) when 
compared with its effect on cycle-oxygenase (IC 50= 800~g/ml; 168). Future 
research may reveal whether imidazole exerts its analgesic, anti-pyretic 
and anti-inflammatory activities in carrageenin edema and adjuvant arthritis 
in rats through interference with TXA2 biosynthesis, and/or through one of 
its other activities (208). 
~E~~!~£Y£l~~-i~Q!22_~Y~!~~!~~~-i~Q~2=-~Q!2_~~~~~E~~~). This enzyme is 
present in the endothelium of arteries and veins of several species and can 
be obtained in a microsomal fraction (48, 170). Prostacyclin (originally des-
ignated as PGX, and now designated as PGI 2 ; 9) is unstable at pl-I 7.6 (t~ = 
JO min, 20°C), when it disintegrates into 6-keto-PGFla' and stable at pH 8.4 
and above. In most solvent systems the chromatographic properties of 6-keto-
PGF1a are very similar to PGE 2 , but are not changed during treatment with 
mild alkali (eg. 130, 195). The discovery of 6-keto-PGFla followed earlier 
observations that homogenates from rat tissues synthetize 2 cyclic enole~ 
thers from AA (194). Thus, it is now evident that PGI 2 synthesis occurs 
also in tissues other than vascular endothelium. A comparison of rat tissues 
indicated a significant formation in the stomach (especially fundus) and 
lung (197), and PGI 2 is the main metabolite of AA in the isolated perfused 
rabbit heart (66, 130). 
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PGI2 , but not its degradation product 6-keto-PGF 1 ~, is a very uotent 
inhibitor of platelet aggregation (48,170). Moreover, it causes pro-
found relaxation of isolated strips of mesenteric, coeliac and coronary 
artery (48,72). PGI 2 synthetase is not inhibited by indomethacin, but 15-
hydroperoxy arachidonic acid inhibits the conversion of PG endoperoxides 
into PGI2 (48,72). It has been postulated that PGI 2 is important for prevent-
ion of deposition of platelets on the vessel wall and that the inhibition 
of PGI2 generation by hydroperoxy arachidonic acid is a factor in the de-
velopment of diseases where increased lipid peroxidation occurs, such as 
atherosclerosis (171). 
2.1.6. Prostaglandin transport and metabolism. 
Most of the catabolism of the nclassical" PGs occurs intra-cellularly 
(see below). Thus, if they are released into circulation, they must pene-
trate cell membranes before degradation can take place. Free diffusion 
through a biomembrane generally does not occur (eg. 22). This implies that 
PGs may be long-acting substances when present in extracellular fluid (eg. 
inflammatory exudate), provided that metabolizing enzymes are not present 
in the same compartment, and that metabolism requires an initial step of 
transport across a membrane. 
~~-!~~~~E~E£· Energy dependent, uni-directional transport of PGE 1 and 
PGF 2a has been demonstrated in vitro (rabbit vagina, lung and kidney cortex) 
and in vivo (24). It is a rapid, saturable, temperature dependent process 
that can establish a relatively high concentration gradient and is inhibit-
ed by metabolic inhibitors, PGF 28 , probenecid, bromcresol green and indo-
methacin (rc50 : 10-50 ~M; 23). 
~~-~~£~£~1!~~· In several tissues, i.e. brain, liver, spleen, heart, 
lung and erythrocytes, PGE can be stereospecifically reduced to PGFa by a 
PG-9-keto reductase (115; see fig. 2.2). Its in vivo activity may be re-
gulated by the balance between oxidized and reduced coenzymes (145), namely 
NADH for the cytoplasmatic and NADPH for the microsomal enzymes (eg. 122, 
145,147). PG metabolizing enzymes were found to be absent in plasma, except 
for PGA isomerase in sheep plasma (133). 
When injected intravenously PGs are rapidly metabolized in the lung 
(>97% within 1.5 min) by 15-hydroxy-PG dehydrogenase (E.C. I. I. 1.141) to 
15-keto-PGs (177) which are substrates for a reduction at Cl3 by ~-13 re-
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ductase. 15-keto-PGs were shmvn to be considerably less active in several 
biological systems (7,61,203). Both cytoplasmatic enzymes are present in se-
veral tissues, especially in lung, spleen and kidney cortex (8). The meta-
bolism of PGs proceeds further in mitochondria with B-oxidation (one or 
two steps) of the carboxyl end. Moreover, w-oxidation, yielding u-hydroxy 
compounds and eventually dicarboxylic acids may take place. In some species, 
S-oxidation of the w-end of the dioic acids leads to formation of c14 meta-
bolites. Pathways, Hhich are rather complex, have been elucidated, for in-
stance for man (eg. 100), and rat (238). 
2. 1.7. Other fatty acid oxygenating pathHays. 
Non-enzymatic lipid peroxidation of PUFA's, either as free acids or 
Hhen esterified in phospholipids proceeds easily in the presence of oxidiz-
ed haem compounds and iron sulphur compounds (136). The membrane fatty acids 
are protected against this destructive oxidation by a-tocopherol (vitamin E). 
Once an autocatalytic lipid peroxidation has started, cell damage can be re-
duced by glutathione peroxidase, that converts hydroperoxides to the less 
damaging alcohols (eg. 126). During auto-oxidation of PUFA's a small per-
centage of PGs can be formed (190,207). 
In platelets a lipoxygenase transforms AA in 12-L-hydroperoxy eicoste-
traenoic acid, which is finally converted into the corresponding hydroxy-
fatty acid (RETE) (fig. 2.3). It is a soluble enzyme, for Hhich free ara-
chidonic is the "best" substrate, but other eicosapolyenoic acids, possess-
ing at least t\vo cis double bonds at n-9 and n-12 (eg. 20:3 (n-9)) are also 
metabolized into L-12 hydroxyfatty acids (Nugteren, 1975). In contrast to 
the "explosive'' burst in cycle-oxygenase activity in platelets, the lipoxy-
genase activity is relatively long lasting in vitro (Nugteren, !977). Rab-
bit neutrophils contain a lipoxygenase that transforms AA into 5-hydroxy-
eicosatetraenoic acid (38). The physiological role of both lipoxygenases is 
unclear, but RETE is claimed to be chemotactic in vitro for human polymor-
phonuclear leukocytes (244). The plant lipoxygenase product 15-hydroperoxy 
AA is an inhibitor of PGI2 biosynthesis (see 2. 1.5). 
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2.1 .8. Prostaglandin assay methods. 
Fig. 2, 3, Lipoxygenase path•·.ray 
in blood platelets. 
-+-- HETE 
For the determination of nanogram (ng) quantities of PGs several methods 
are available: gaschromatography with electron capture detectors, gaschroma-
tography- mass spectrometry, radioimmunoassay (see review 222), and bioassay 
(eg. 98,204). lhth bioassay the unknown sample is tested on an isolated tis-
sue immersed in, or superfused •vith, a physiological salt solution, and the 
contraction (or relaxation) of the tissue is calibrated ~:vith standard doses 
of the agonists (eg. PGs). For practical reasons, the cascade superfusion 
technique (Vane, 1964), \vhich permits simultaneous parallel bioassay with 
several tissues, \Vas used (see chapter 3). Both radioimmunoassay and bioas-
say are rather non-specific, since compounds other than those which are 
supposed to be detected, may interfere ~:vith the assay. The selectivity can 
be improved by extraction and purification of biological samples. Moreover, 
the physiological salt solution, that superfused the tisseus, contained a 
mixture of antagonists to rule out as many interfering substances as possi-
ble (98). Bioassay has one advantage over the other methods in that it ena-
bles a relative assessment of unstable, biologically active compounds, such 
as TXA2 (eg. 179), to be carried out. The selectivity of some assay tissues 
is shown in table 2. 1. 
Suspension of the superfused tissue in mineral oil raises the sensitivity 
and permits assay of autacoids in the picogram (pg) range (Ferreira & De Sou-
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Table 2.!. Different biological activities of PG endoperoxides, TXA2 , PGI 2 , PGE 2 and PGFZa' 
Tissue Agonists References 
TXA2 PGG2 PGH2 
PGE2 PGFZo: PGI 2 
RAS +++ ++ + + 0 48, 114, 179' 204 
RCA* +++ + + 0 rel. 42, 47, 48 
RSS ++ +++ ++ + 98, 114, 204 
RC 0 + ++ ++ + 98, 48, 104 
BCA + + + ? rel. 72 
+, ++, +++: increasing contractile potency. +: without clear-cut 
activity or conflicting data. 0: without activity. rel.: causes 
relaxation. ?: biological activity not yet reported. *= the rab-
bit mesenteric artery has a similar selectivity. RAS: Rabbit aorta 
strip. RCA: Rabbit coeliac artery strip. RSS: Rat stomach strip. 
RC: Rat colon. BCA: Bovine coronary artery strip. 
za Costa, 1976). An adaption of this laminar flow technique permitted super-
fusion of several tissues (Bult et al., 1977; chapter 3). 
2.2. Compounds which interfere with prostaglandin biosynthesis. 
2.2.1. Substrate analogues (see review by Flower, 1974) 
~~~~~~· Some naturally-occurring all cis unsaturated fatty acids, such 
as oleic (18:1, n-9), linoleic (1~:2, n-6), linolenic (18:3, n-3), and ei-
cosatrienoic (20:3, n-9) acid are competitive inhibitors of cycle-oxygenase 
from seminal vesicles, rat stomach (198,282), and human skin (280). Oxygen 
uptake was undetectable \Vith 18:1 (n-9), 20:3(n-9) and 20:3(n-3), which 
again indicated that eicosatrienoic acid (n-9) was not a substrate for the 
cycle-oxygenase (282). This competition of naturally-occurring PUFA's with 
AA may be a regulating factor in PG biosynthesis (Pace-Asciak & Wolfe, 1968). 
~f~~y~~g~~-~g~beg~~~· Eicosatetraynoic acid (TYA, or 20:4, n-6), an 
analogue of AA with acetylenic bonds, is a potent inhibitor of cycle-oxy-
genase, soybean lipoxygenase (3) , and platelet AA lipoxyr;"enase (117). TYA 
inhibits PG biosynthesis in microsomal enzyme preparations (245), intact 
platelets (275), and in vivo (8). 
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gf~:~E~g~-~~~i~g~~~~-~g~~~~E~~~~-~~~~~~- The 8-cis, 12-trans, 14-cis 
analogues of 20:3(n-6) and AA are competitive inhibitors of PG biosynthesis 
and could be recovered at the end of the reaction (185,248). 
2.2.2. Non steroidal anti-inflammatory drugs (~SAIDs). 
The drugs which comprise this group have diverse chemical structures, 
but they all share (to varying degrees) the antipyretic, analgesic and anti-
inflammatory aspects of aspirin (acetylsalicylic acid; see for revietvs: 
Flower (1974); Ferreira & Vane (1974)). Indomethacin, phenylbutazone, para-
cetamol and salicylate, together with aspirin, are the more familiar NSAlDs. 
In 1971 3 important reports appeared together, shmving that ~SAIDs inhibit 
PG synthesis (82,233,254), a finding that has been confirmed in numerous 
assay-systems (see Flmver, 1974). The rank order of potency of the N"SAIDs is 
independent of the enzyme preparation tested, and, in vitro, the rank order 
or decreasing potency is: indomethacin> phenylbutazone> aspirin (see 83,86), 
Salicylate does not inhibit cycle-oxygenase in vitro (eg. Vane, 1971). Al-
though the above rank order of potency is generally consistent with most 
papers, the rc50 v'alues of the different drugs may vary by 100 fold for dif-
ferent enzyme sources (see 86). 
In assessing rc 50 values, the follmving factors may be of importance: 
1. The substrate concentrations influence the apparent Ic 50 data (62). The 
potency of indomethacin was identical in several rabbit tissues, if similar 
experimental conditions were employed (205). ~· The time of preincubation 
of the enzyme nreparation with the drug may affect the nature of inhibition 
(see below). l· The presence of albumin in the assay-system may lead to an 
underestimate of the Ic 50 value. For instance, the binding of indomethacin 
to plasma proteins may range from 90% to 99% (see 86,159) and is influenced 
by other substances that bind to albumin (eg. 63,160). 
In general, the in vivo anti-inflammatory potency correlates Hell vith 
actions against PG production in vitro (see 83,86), with the exception of 
salicylate, which has a much \Veaker activity than aspirin in vitro (82,89, 
254). It has been suggested that salicylate requires metabolic transform-
ation for activity (86,90). Gentisic acid, one of the minor metabolites of 
salicylate, has indeed, been found to possess greater efficacy than sali-
cylate in inhibiting subcellular PG synthesis, but was still less potent 
than aspirin (90) .Therefore, salicylate, vmich is as active as aspirin as anti-
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inflammatory drug, probably acts independentlyofcyclo-oxygenase inhibition (230). 
!~~-~~~~-~~-~~~~~~-~~-~?~!~~-~~-~-~~1~~~1~!_1~~~1· Due to the compl~ ki-
netics of the PG synthetase, there are several possibilities for inhibition. 
NSAIDs, except for paracetamol, act at the substrate binding site (142). The 
binding of the drug is initially reversible, but then a time dependent, ir-
reversible inhibition occurs, for which the free carboxylic groups of NSAIDs 
are necessary since their methylesters and their primary alcohols lack the 
destructive properties of the parent NSAIDs (205,210,216). It has been con-
clusively shown that the acetyl group of aspirin selectively acetylates 
purified oxygenase in proportion to the amount of native, undenaturated en-
zyme (216,217). Indomethacin and AA interfere Hith this acetylation by as-
pirin (121,219). The irreversible blockade seems an important feature of 
aspirin since the prolonged presence of low concentrations, 1:vhich interact 
with only 10% of the total enzyme, may result in a progressive loss of all 
enzymatic activity (Flower, 1974). 
~!!~£!~-~~-~§~!~~-~~~£~-~E~-g~!-~~E~£!~l-~~!~£~~-!2_~Q-~~2~Y~£b~~~~· It 
is now generally accepted that NSAIDs, 1:vith the exception of salicylate, act 
preferently via inhibition of PG biosynthesis. However, no drug has a single 
mechanism of action and a number of side effects have been summarized by 
Flower (1974). The only effects occurring at, or just above, the concentrat-
ions that suppress PG biosynthesis, are inhibitory actions on phosphodieste-
rase, PG metabolism and inhibition of neutrophil mobilization in vivo. 
~~~~Eb£ii§~~~E~~~:igbi2i£i£~_ll2~2~~2l· The concentrations needed for 
SO% inhibition are relatively high, but aspirin Has only 3 times less active 
in inhibiting phosphodiesterase from guinea pig ~astric mucosa than as in-
hibitor of PG biosynthesis (152). 
I~£~Ef§I~~£~-~~!b_~Q_!E~~~E~E£_{~~2_§~i-~~!§2~!!~~-l~~1· LoHer concen-
trations of NSAIDs stimulate, \vhile higher concentrations suppress PG trans-
port. The rc 50 of indomethacin in some preparations was bet1veen 10 and 12 vH, 
which was higher than the ICSO m subcellular cycle-oxygenase preparations 
( 23) , but it must be realized that higher concentrations of indomethacin are 
needed to block PG biosynthesis in tissue slices (eg. 210). For inhibition 
of 15-hydroxy PG-dehydrogenase the reader is referred to Flower (1974). 
lgb!Q~£i2~_£f_!~~t££l!~-~!gE~~~£g· Migration of rat neutrophils in vivo 
is inhibited by high doses of NSAIDs (262). This inhibition is not due to a 
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reduction in PGs, since 80% inhibition of PG biosynthesis by TYA did not 
alter leukocyte migration (93,230). 
Some miscellaneous actions of ~SAIDs may possibly be related to their 
anti-inflammatory activity. NSAIDs increase membrane permeability in cells, 
cell-organells and liposomes and uncouple mitochondrial ATP formation (eg. 
76). NSAIDs have metal chelating properties (161), which led to the suggest-
ion that salicylates, and especially their copper complexes, enhances dis-
mustation of superoxide anion, generated from phagocytizing leukocytes and 
thereby protect phagocytizing cells and synovial cells from destruction by 
hydroxyl radicals (212). Salicylate arid aspirin, in contrast to other NSAIDs, 
increase urinary excretion of imidazole acetic acid, a metabolite of hista-
mine and L-histidine, which is reported to have analgesic activity (12). 
2.2.3. Corticosteroids (review: see Gryglewski, 1976). 
Recent reports (table 2.2) indicate that hydrocortisone and synthetic 
corticosteroids inhibit the release of PGs from intact cells, tissues and 
organs, but do not inhibit the formation of PGs from AA. A reasonable ex-
planation for these observations is that corticosteroids reduce availability 
of endogenous PG precursors. This is supported by data on inhibition of AA 
release by corticosteroids from guinea pig lung and transformed mouse fibro-
blasts. The spontaneous, RCS-RF-induced and H-induced, but not the Bk-induc-
ed release of AA from guinea pig lungs is suppressed by corticosteroids (26, 
182). The liberation of AA in transformed mouse fibroblasts, stimulated by 
serum, bradykinin or thrombin (128) is also inhibited by corticosteroids. 
The inhibition of PG-release by different steroids correlates well with 
their potencies as anti-inflammatory drugs (!82). There is some specificity 
with respect to different types of steroids since neither aldosterone (85, 
103) nor progesterone (85) are able to reduce AA release, but an oestrogen 
showed some inhibitory activity (182). The in vitro inhibitory action in 
guinea pig lungs reached a maximum only after 60 min (26), and the route of 
administration may influence the efficiency of corticoids in vitro (102). 
Corticoids fail to inhibit AA and/or PG release from disrupted cells (26, 
82,254). This in contrast to the tveak anti-PLA2 drugs mepacrine (257) and 
procaine, which inhibited PLA2 activity in homogenates of guinea pig lung 
(26). Thereby a direct action on PLA2 seems to be ruled out. As stated in 
2. 1.3 an apparent increase in PLA2 activity may result from: 
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Table ?.2. Inhibition of PG and AA release by corticosteroids. 
tissue species stimulus inhibition ref. 
of release of 
AA PGs 
IN VIVO 
inflammatory exudate rat CAR + 80,105a 
hind leg dog exercise + 123 
I)[ VITRO 
perfused spleen cat NA ? + 102 
fat pad I adipocytes rabbit ACTH + 51, 150 
mesenteric artery rabbit NA + 106 
lung guinea pig none + + 26, 182 
histamine + + 
RCS-RF + + 
Bk 
sensitized lung guinea pig antigen + + 26, 182 
transformed fibroblasts mouse culturing + + 128~241 
serum + + 
Bk + + 
thrombin + + 
rheumatoid synovia human culturing + 135 
synovial fibroblasts human Bk + + 181 
synovia rat arthritis + 85 
+ : inhibited, - : not inhibited, ? : not measured. a : the inhibition 
was possibly due to interference with neutrophil migration. 
ACTH: adrenocorticotropic hormone. 
l· Activation of PLA2 . ~- Increase in zymogen pro-PLA2 from lysosomal sour-
ces. 3. Alterations in the fluidity of the phospholipid bilayer in biomem-
branes, allowing a PLA2 attack (68,228,286). i· Reduced reacylation of 
liberated AA. 
These factors may be influenced by steroids. The introduction of choles-
terol into a phospholipid membrane markedly influences the properties of the 
bilayer (eg. 67, 199). Cholesterol in monotectic mixtures interacts non-
randomly with different phospholipids in membranes (67). Data on the effects 
of corticoids on membrane behaviour with respect to fluidity, packing, per-
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meability and vulnerability towards attack by different phospholipases are 
lacking. Such data might provide a basic understanding of their pharmacol-
ogical actions, and for the suggestion that their stabilization of membranes 
results in a reduced PG release (103). Lewis & Piper (1975) suggested an 
alternative mode of action for corticosteroids, based on their experiments 
with adipocytes. They suggested that, during lipolysis, PGs are transported 
(or leak) from the inside to the outside of the adipocyte and that corti-
coids inhibit this transport. 
In conclusion, the mechanisms of corticosteroid inhibition of PG release 
in different situations are still a subject for controversial dispute. More 
biochemical and cellular research is needed to clarify the various bioche-
mical and pharmacological actions of these compounds. 
2.3. Essential fatty acid deficiency (EFA deficiency) 
2.3. I. Description 
EFA deficiency was first described by Burr & Burr (1929). Some of the 
symptoms that may occur are listed in table 2.3. (for reviews, see 1,4). 
Table 2.3. Some symptoms of EfA deficiency in the r~t 
I. weight 
2. skin 
3. kidney 
4. heart 
5. adrenals 
6. reproduction 
decreased 
increased permeability to water, epithelial hyper-
plasia (scaly lesions), tail necrosis. The latter 
symptoms are favoured by low humidity 
enlarged, intertubular haemorrhage 
enlarged 
weight decreased in females and increased in males 
females: irregular oestrus, impaired reproduction 
males: degeneration of seminiferous tubules 
The biochemical basis of EFA deficiency is well known (see 109,146). In 
higher organisms certain saturated fatty acids (eg. 18:0} may be transformed 
into monoenoic acids (eg. 18:1, n-9) by a desaturase reaction in the endo-
plasmatic reticulum. Additional double bonds are introduced between the first 
double bond and the carboxyl group in animals (fig. 2.3), and towards the 
methyl end in plants. Thus linoleic acid (18:2, n-6) may be formed from 
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oleic acid in plants. It is the first member of the n-6 family, which are 
necessary to maintain animals in a healthy state. The inability of animal 
tissues to desaturate oleic acid tmvards the methyl end of the chain implies 
that linoleic acid must be supplied in the diet. Linoleic acid and related 
n-6 PUPA's are therefore, called essential fatty acids. A simplified scheme 
of the path1:vay leading to AA (n-6 family) and the pathv.my that predominates 
if linoleic acid is omitted from the food, is shown in fig. 2.3 (see also 
18, 109,234). 
During elongation and desaturation competitive inhibition occurs among 
different series of PUPA's which normally maintains the balance between fat-
ty acyl residues of different biomembranes (eg. 18,234). It is possible to 
induce EFA deficiency by feeding with several different diets, as long as 
unsaturated fats are lacking. In all cases, the synthesis of 5,8,11 eicosa-
trienoic acid increases (eg. 95) and it replaces AA in several tissues. 
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Fig. 2.3. Pathways of fatty acid biosynthesis in animals (adapted from 
109,146). The normal pathway starts from linoleic acid and leads to 
formation of arachidonic acid (shown on the left). "hThen an EFAD diet, 
lacking linoleic acid, is given to the animals, the pathway from ol-
eic acid to 5,8, 11 eicosatrienoic acid becomes more important (shown on 
the right). d=desaturation, e=elongation. 
Data on fatty acids are often reported using a shorthand notation, 
showing the number of carbon atoms, followed by a colon and then a 
figure denoting the double bonds. The position of the double bonds is 
defined by counting the carboxylgroup as l, and indicated by the pre-
ceding numbers. Thus, linoleic acid is 9,12 c18 . 2 . The position of the 
methylene-interupted can also be defined by coullting from the methyl-
group (n). This facilitates the identification of fatty acids that are 
derived from one another by chain elongation. Thus, oleic acid can be 
referred to as IS:l(n-9), 
Holman (1960) has suggested that the ratio of 20:3 to 20:4 might be used 
as an indication of the degree of EFA deficiency, and that a ratio of 0.4 
or less indicates normal EFA status in rats. This 0.4 ratio is taken rather 
arbitrarily in the gradual transition from a normal status into an EFAD con-
dition, and is dependent on lipid class and cell type. AA is removed less 
quickly from phosphilipids than from neutral fats, and Ar\ is retained much 
longer in brain, in intestinal muscle and in mucosa cells, than in erythro-
cytes, liver and heart cells (see 4). Thus, conclusions on the basis of EFA 
deficiency as a model for AA (PG precursor) deficiency are only possible if 
a fatty acid analysis of the tissue under study is carried out. The Holman 
criterion does not give a quantitative indication (as it is only a ratio) 
of the absolute reduction of AA in a certain cell type. 
The induction of EFA deficiency is accellerated by feeding the animals 
before birth •vith an EFAD diet, as otherwise linolec acid in the mothermilk 
can provide a pool of EFA's for the neonates (eg. 96). Horeover, EFA defi-
ciency is more easily induced in male rats than in female rats, and is re-
tarded '>Vhen the animals have access to their faeces (see I). 
2.3.2. EFA deficiency and prostaglandins. 
PGs are synthetized from EFA's (17,250,251). Van Dorp and colleagues 
tried to find evidence for the hypothesis that the EFA's are irreplaceable 
because no biologically active PGs can be formed from other PUFA's. Several 
PUFA's, "'-'hich do not occur naturally in animal tissues were synthetized and 
their rates of conversion to PGs increased from 19:3 (n-5), 21:3 (n-7), 19:4 
(n-5), 21:4 (n-7), 20:3 (n-6) to 20:4 (n-6) and, ~:vhenmeasuredbyweight 
gain and the skin permeability test, their EFA activity increased in the 
same order. Horeover, the "artificial" PGs possessed several biological acti-
vities (14,236,248). The discovery of odd-numbered PUFA's with EFA activity 
lead to the revision of the hypothesis that a pair of n-6 and n-9 double 
bonds (present in linoleic acid) is a prerequisite for EFA activity (223). 
In all PUFA's that have an EFA activity, 3 methylene-interrupted cis double 
bonds are present at c8, cl l, cl4, and a parallelism does exist between EFA 
potency and the substrate requirements of the cycle-oxygenase (223,249). 
Direct evidence for a causal relationship between a decreased PG product-
ion and the variety of EFAD symptoms is relatively scarce. In rat adipose 
tissue does experimental evidence exist for the lack of PG precursors being 
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food --------
linoleic acid 
I 
arachidonic acid 
l 
CYCLO-OXYGENASE 
I 
PGH2 and PGG2 
I \ 
EFA deficiency 
. I . 
olelc acld 
I 
eicosatrienoic acid(n-9) 
---------- (inhibitor) 
Fig. 2.4. Lack of linoleic acid in food leads to EFA deficien-
cy. This is attended with shortage of PG endoperoxide precursors. 
positively correlated with an enhanced lipolysis during EFA deficiency (53). 
EFA deficiency reduces the capacity of rat platelets to aggregate in res-
ponse to threshold doses of collagen (42, chapter 4). This coincided with 
a reduced endogenous synthesis of TXA2 . Daily topical treatment with PGE 2 
in high doses (50-100 vg/paw), reduced the scaly lesions, which might be as-
sociated with an inhibition of abnormal sterol esterification in EFAD rat 
skin (281). Decreased PG biosynthesis during EFA deficiency has been observ-
ed in rat epidermis and rabbit inner kidney medulla (248). 
2.3.3. EPA deficiency influences properties of biological membranes 
A shortage of EFA's is accompanied by morphological and biochemical 
changes (see 4), for example in mitochondria (enlarged, increased tendency 
to swell, uncoupling of oxidative phosphorylation) and erythrocytes (more 
liable to osmotic lysis), which are unlikely to be dependent on changes in 
PG metabolism. This is supported by the fact that daily PG-metabolite pro-
duction in man is 10 4 times less than the daily intake of linoleic acid (eg. 
249). 
Thus,EFA's must be essential in other respects, for instance, as consti-
tuents of certain phospholipids, where their acylchains will contribute to 
fluidity and hydrophobicity of biomembranes. Several reports indicate that 
a reduction of double bonds in phospholipids during EFA deficiency influen-
ces membrane properties and leads to changes in activities of membrane-bound 
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enzymes. Some examples are: decreased basal and stimulated adenylate cyclas~ 
d . ( + + Z+) ATP . . . . A . 11 (40) an 1ncreased Na , K , Mg ase actlvltLes 1n EF D rat l1ver ce s , 
increased (Na +, K+) ATPase activity in EFAD mouse brain cells (240), and de-
creased monoamine oxidase activity in rats (19). The Hill coefficients (in-
dicating the number of allosteric binding sites) of several rat enzymes were 
correlated with the double bond index, and the allosteric behaviour of ~a+ 
and rt ATPase (erythrocytes), acetylcholine esterase (erythrocytes), Mg 2+ 
ATPase (erythrocytes, heart, kidney and brain) \Vas directly influenced by 
EFA deficiency. It is likely that similar membrane studies will provide deep-
er insights into several metabolic aspects of EFA deficiency, such as un-
coupling of phosphorylation, increased heat production, increased loss of 
+ + 
water and decreased capacity to excrete Na and K in response to loading 
( 21 8) . 
~~~~~Y· The amounts of PG precursors are diminished during EFA defi-
ciency. It is, however, doubtful if all EFA symptoms are controlled by PGs. 
A basic role for AA in controlling membrane behaviour might be equally im-
portant. 1Tien using EFA deficiency as a model for PG precursor (AA) defi-
ciency, the measurement of AA levels is an obvious prerequisite for clear 
cut conclusions. Experimental data have to be interpreted with caution since 
EFA deficiency does alter membrane properties, eg. activities of adenylate 
cyclases and ATPases. 
2.4. Blood platelet aggregation 
1Tien blood vessels are damaged, platelets stick at the site of injury, 
aggregate and stabilize the haemostatic clot that is formed in order to stop 
bleeding. Platelet aggregation can be studied in vitro. Recently the im-
portant role of PG metabolism in controlling platelet function has become 
more clear. 
2.4.1. General aspects (for reviews see: 175,269). 
The data in this chapter refer to human platelets, unless another species 
is indicated. They are disc-shaped (thickness: 0.5-J l-lH, diameter: 2-5 ]JH), 
their number ranges from 200,000 to 400,000 per l-11 of blood, and they are 
produced in bone marrow by invagination of the megakaryocyte plasma membrane 
(15). Normally, thrombocytes circulate in the blood for 10 days (shorter than 
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red blood cells), being nonadherent to each other or to vascular endothelium. 
~~en a blood vessel is damaged their capacity to adhere to collagen, or other 
substances, becomes apparent (269). Adhesion initiates a secretory process 
during which substances, present in subcellular granules, are extruded from 
the cell, while the other cell constituents (eg. mitochondria, cytoplasm) are 
retained. A short, morphological description is given below. 
~1~~~~-~~~£E~~~- Proteins (176) and phospholipids are asymmetrically dis-
tributed in the plasma membrane. PE and PS are mainly localized in the inner 
half of the lipid bilayer, whereas PC and Sph are present in the outer half 
(54,224). Some PE is detectable on the outside during thrombin treatment (22~. 
Invaginations of the membrane, forming a sponge-like system of open channels 
which penetrate through the platelet cytoplasm, enlarge the surface of the 
platelet and facilitate both the uptake of substances from blood plasma and 
release of granule bound products (IS). 
QE~~~!~~- Platelets have no nucleus or DNA, and contain few ribosomes, 
little RNA, and few mitochondria. At least 2 types of granules are disting-
uishable, a granules (the majority) and dense granules. The former contain 
lysomal enzymes and the dense granules are filled with ADP, ATP (the non-
metabolic or storage pool), calcium and serotonin (eg. 269}. A band of cylin-
drical structures (microtubules) line the peripheral edge of platelets and 
probably maintain their asymmetrical form. Microtubules and actin-like fila-
ments seem to be involved in the clustering of a granules in the centre of the 
cytoplasm, while dense granules are forced to the periphery during the shape 
change (64}. 
~ggE~£~~~~~· Platelet aggregation can be studied in vitro in an aggrego-
meter. For this purpose, platelet-rich plasma (PRP) is prepared from blood, 
to which anti-coagulants have been added. The choice of anti-coagulant may 
have implications for platelet behaviour (eg. 175). PRP is then obtained from 
blood by centrifugation at relatively low G forces. Platelets are extremely 
sensitive to manipulation and may stick to each other in response to haemoly-
sis and changes in temperature, pH, G forces, etc., etc. (175,220). The merits 
of different methods for preparing PRP have been discussed (65). The PRP is 
placed in a cuvette, continuously stirred at a constant temperature, and the 
light transmission is monitored (39). During aggregation, an increase in tr~ 
mitted light is observed (see fig. 4.1, page 59). 
~~=~~~~£~~-~g&E~g~~~~~· ADP (not ATP, or AHP) 
ge, from discs to spiny spheres (a process that is 
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induces a rapid shape chan-
2+ 
not Ca dependent), and 
2+ . . . 
when Ca and fLbrlnogen are present, the platelets reversLbly aggregate. 
With higher ADP concentrations the contents of the dense bodies are released 
2+ (Release I; release of ADP, Ca and 5-I-IT; eg. 175,269). This reaction is 
energy-dependent and ATP from the metabolic compartment is used. It is suggffi~ 
ed that the released ADP induces the second Have of aggregation (eg. 175,269). 
The secondary wave of aggregation is not visible if a higher initial dose of 
ADP is used, and is absent in several other species (eg. rat) and if heparin-
ized instead of citrated PRP is used (175). The suggested sequence of events 
is depicted schematically below: 
ADP-+ primary aggregation-+ release reaction I-+ 2nd phase of aggregation 
lets, either directly or by inducing release reaction I. During platelet 
aggregation phospholipids become available, and serve as a catalytic surface 
(platelet factor, 3) for the conversion of prothrombin into active thrombin 
2+ by factor X, factor V and Ca . Thus, both clot formation and platelet aggre-
gation are interrelated and reinforce each other via thrombin (see 269). 
Collagen: after adhesion to soluble collagen, aggregation and the release 
reaction can occur (269). High doses of both collagen and thrombin may induce 
a "second release reaction" (release II), during Hhich the contents of a-gra-
nules are liberated in addition to the substances that are secreted during 
release I (269). 
2.4.2. The role of cycle-oxygenase products in platelet aggregation. 
Zucker and Peterson (1968) discovered that aspirin abolished release I and 
the second phase of ADP-induced aggregation. The discovery that aspirin inhi-
bits endogenous PG biosynthesis in platelets (233)_ made the role of PGs in 
platelets rather paradoxical: classical PGs had little activity in platelets, 
except for PGE 1, which inhibited aggregation (140). Vargaftig & Zirinis (1973) 
were the first to show that AA induces aggregation with the concomitant form-
ation of RCS (TXA2 + PG endoperoxides) and classical PGs, and that both react-
ions are prevented by NSAIDs. The generation of RCS provided the clue to the 
role of PGs in platelet behaviour. It appeared that purified PG endoperoxides 
(PGG2 , PGH2 ) are potent platelet-aggregating agents (10-300 ng/ml; 1 16). More-
over, during aggregation of washed platelets with thrombin, the PG endoperox-
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ides are released into the medium in similar concentrations (1 19). This has 
been confirmed in PRP, stimulated with AA, collagen and adrenaline (231). 
Later on it was suggested that the PG endoperoxides require a conversion 
into TXA2 in order to induce aggregation (120). The isomerization of PG endo-
peroxides into TXA 2 is indeed the major patht·laY in platelets. TXB 2 , and at 
least a part of the released HHT and MDA, are derived from TXA 2 (84, 101,239). 
The hypothesis that TXA2 is essential for induction of aggregation is streng-
thened by the fact that the endoperoxide PGH 1 is not converted to TXA 1 (178, 
187) and fails to induce aggregation (276). On the other hand, it has been 
proposed that the physiological function of TXA2 is to produce marked local-
ized vasoconstriction, that enhances haemostasis by sharply reducing the 
blood vessel lumen (178). Specific inhibitors of TXA2 isomerase may clarify 
the role of thromboxanes in platelet aggregation. 
Exposure of washed platelets to collagen and thrombin leads to increased 
liberation of AA from phospholipids, through the action of a PLA2 (20,25,225). 
Upto 80% of the AA is released during collagen-induced aggregation and PE 
(58%), PC (25%) and PI (14%) are the major sources of PG precursors (25). PLA2 ?+ 
activity can be initiated with theCa- ionophore A 23187, and the mobiliza-
. . 2+ ( ) tlon of lntracellular Ca may regulate AA release 202 . Platelet PLA2 , 
which is not present on the platelet surface, preferentially hydrolyzes PE, 
PI and PS (the internal phospholopids), \.Jhich contain 72% of the AA of human 
platelets. Dibutyryl cfu~P inhibits thrombin- but not A 23178 - induced AA 
release (202). Evidence for the inhibitory action of dibutyryl cMfP on PLA2 
activity has been provided by Hinkes et al., (1977), and byLapetina et al. 
(1977). Cyclic ~fP had no effect on cycle-oxygenase activity (144). Since 
cAHP failed to inhibit the ionophore-induced PLA2 activity, its inhibition 
. 2+ . ( 
may result from a reduction of free cytoplasmlc Ca levels ln platelets see 
fig. 2.6). The phospholipid (and ,\A) distribution in platelet plasma membrane 
makes it unlikely that, in intact platelets, an exogenous PLA2 can mimick the 
events, which occur during aggregation induced by thrombin and collagen Hith-
out lysis. 
Once the AA has been liberated, it is either incorporated into plasma-
logen PE (213) or converted to a large extent into PG endoperoxides (eg. 20). 
An explosive burst in oxygen consyrnption by the platelets is observed (eg. 
173), ,..;rhich is inhibited by aspirin (174). According to most authors, the 
endoperoxides exert their effects via induction of the release I reaction 
(eg. 156,231,269,276), as shmvn in fig. 2.5. Other reports indicate that PG 
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Fig. 2.5. Pathway leading to aggregation induced by AA, collagen and 
thrombin, and its inhibition by NSAIDs and TYA. 
endoperoxides can induce aggregation without release reaction (139), or that 
the release reaction may start before PG endoperoxide formation (165, 174). 
The subcellular mechanisms of TXA2 are unknown. PGG2 , PGH2 and TXA2 are 
inhibitors of PGE 1-stirnulated cM1P accumulation in human platelets, but have 
no effect on basal levels of either cAliF or cGMP (163,164). Thus, it is un-
likely that the pro-aggregatory effect of TXA2 is directly connected to cyclic 
nucleotide metabolism. 
~~Qi£i~2~Z-~f~~£~~-2~-~Q~-£~_£!~~~!~~-£~Q~~i2~~· Recently, 2 prostanoic 
inhibitors of platelet aggregation, which are more potent than PGE 1 (140), 
have been discovered: PGD 2 (183) and PGI 2 (170). PGE 2 is less active as an 
inhibitor of platelet aggregation and may potentiate aggregation induced by 
other stimuli (eg. 154). The potencies of PGE 1 and PGD 2 are reduced when he-
parinized, instead of citrated PRP is used (154). The inhibition is species 
dependent, since PGD 2 fails to inhibit rat platelet aggregation (154,183). 
The inhibition is mediated by platelet adenylate cyclase. PGI2 , the stron6 
est inhibitor of platelet aggregation discovered so far, is also the most 
powerful activator of adenylate cyclase in intact platelets and isolated mem-
2+ branes (99,242). Ca ions alone can inhibit PGE 1-induced stimulation of ade-
nylate cyclase (215) and this may explain why PGE 1 and PGD 2 are less effective 
in heparinized PRP (see above). 
How the increased intracellular levels of cAHP suppress platelet function 
is not clear yet. An interesting hypothetical scheme of the interrelations 
. . 2+ . between PG productlon, cAMP rnetabollsrn, Ca levels and platelet functlon has 
been given by Salzman (1976). An adaption of this scheme, in order to make it 
consistent with recent data, is shown in fig.2.6. It has many areas of uncer-
35 
tainty, but it may help to understand some of the many interrelations which 
have been briefly summarized above. It proposes that platelet function is con-
. l+ 1 AMP trolled by a balance between free, 1ntracellular Ca leve s and c concen-
trations. It is postulated that cAMP reduces Ca2+ levels and that TXA2 and/or 
. . 1 1 2+ . . h b PG endoperox~des can elevate 1ntracel u ar Ca concentrat1ons e1t er y an 
ionophore-like action or by an inhibitory effect on Ca 2+ pumps. There is no 
evidence for the latter suggestions, and little evidence is available for some 
other features of the scheme, such as the location of the AA metabolizing en-
zymes. 
PGG2 ----"~'"''~o~<h~•C1 ;£o1C'0""""'-------+PGI2 
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Fig. 2.6. Hypothetical interrelations between calcium transport, cyclic 
AMP metabolism, thromboxane Az production and platelet function. The 
hatched area's represent plasma membrane (horizontal area) and the mem-
brane which lines an internal calcium pool (curved area). The enzymes 
(PLAz, cycle-oxygenase, TXAz isomerase and calcium pump) may be located 
in either one or both membranes. DTS: dense tubular system; 
+++~: stimulation; ---~: inhibition; ~: possible interaction not yet 
known (After Salzman, 1976). 
2.5. Acute inflammatory reactions. 
2.5. I. Introduction 
Inflammation has been defined as a process which begins following sub-
lethal injury to tissue and ends with complete healing or permanent destruct-
ion of the tissue (suggested by Ebert & Grant, 1974). It implies that it is a 
process, in which various hom~ostatic mechanisms influence one other, possi-
bly in an attempt to preserve the viability of tissues. However, in certain 
cases, the inflammatory signals seem to be scattered and disarranged, leading 
as a consequence, to a chronic process, rather than proceeding stepwise, 
through a homeostatic cascade, to a non-imflammatory end-point (see 73,74,19~. 
2.5.2. Carrageenin-induced hind paw edema (CAR edema). 
In vivo models have been developed in order to evaluate the anti-inflam-
matory activity of drugs (review: 105). In several acute models, the exudation 
in response to injury is measured. As a consequence, the drugs, which have 
been discovered with these models are capable of suppressing edema, but do not 
necessarily interfere with essential steps in the chain of events between in-
jury and the end of the process. These models have also been employed for more 
basic studies. The carrageenin-induced reactions in rats are described as an 
example of acute, non-immunological inflammatory reactions. The seaweed ex-
tract carrageenin (carrageenan, CAR; 277) has become one of the most used 
irritants and a multi-step pathway has been proposed in CAR edema development 
(262). 
~~~~~~~~~~-~f-~~~-~~~£~~2~~· Vinegar et al. (1976) discriminate between 
edemagens 0HT, H), that lead to vascular leakage of plasma, without cell-
mobilization, and inflammatory agents (such as CAR) that elicit edema and 
mobilization of inflammatory cells (see also 192). The action of edemagens is 
counteracted by their antagonists and not by anti-inflammatory drugs, whereas 
anti-inflammatory drugs suppress the edema evoked by inflammatory agents. The 
site of injection of the irritant is of importance. Thus, 5-HT is an edemagen 
in the rat hind paw, whereas the same dose is without effect in the pleural 
cavity. 
~~~£~iE~i2~-2~-~~~-E~2£~~~· After injection of CAR (0.5 - 1 rug) into the 
paw, a biphasic swelling is observed (262). The initial exudation (0 -30 min), 
which is absent in CAR-induced pleurisy, tapers off (30 - 60 min) and is fol-
37 
lm.;red by a second, longer-lasting S\velling. The maximal swelling is. reached 
between 4 and 6 hours. After about lOh, the swelling decreases. 
2.5.3. Cellular events in carrageenin-induced edema. 
~~~~E~E~~l~· The involvement of the following cell types seems to be es-
tablished: mastcells, vascular endothelial cells and neutrophils. The neutro-
phil (also called polymorphonuclear leukocyte) is an active, motile, relati-
vely short-living scavenger cell, which acts as the first line of defence 
against tissue damage (73). After injection of CAR (0.5 mg) into the pleural 
cavity the number of these cells increases from undetectable (Oh) to about 
10xJ06 cells (3h; 70,200,262). It has been suggested (262) that edema form-
ation is a consequence of neutrophil infiltration, but experimentally induced 
leukopenia yielded varying results (13,70,262). In the proposed pathway of 
CAR edema the first steps are the generation and release of an hypothetical 
neutrophil-attracting factor, and the subsequent peri- and extravascular lo-
calization of neutrophils (262). 
~Qg££Yf§~· The numbers of these more persistent scavenger cells are less 
than 10% of all mobilized cells during acute CAR edema (200,2621. 
~!~~~!§£~·Their possible involvement in CAR edema has been reviewed (227, 
256). Positive evidence for their role in CAR edema has been obtained, since 
after i.v. injection of 51 cr-labelled platelets, the label increased at the 
inflamed site (261). This was not due to an increased blood volume since ery-
throcyte accumulation was virtually absent (J.E. Vincent & F.J. Zijlstra 
personal communication). Whether an increased number of platelets stick to 
vessel walls at the inflammatory site or whether the label also appears out-
side the vessels is unknown as yet. Rabbit platelets release several putative 
mediators of inflammation during incubation with CAR (256,258), but several 
authors, using thrombocytopenic rats, failed to obtain an indication of in-
volvement of platelets in CAR edema (see review by Vargaftig, 1977). 
~Y~E~~£Y~~~· Leukopenia affected the absolute number of lymphocytes more 
than that of neutrophils and reduced both CAR edema and swelling induced by 
edemagens (211). Injection (i.v.) of lymphocytes, but not neutrophils, restored 
both processes substantially. In leukopenic, lymphocyte supplemented rats, a 
normal histological CAR-edema was seen, except for the striking absence of 
neutrophils (13,21 1). 
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2.5.4. Mediators of CAR edema (see 262,267,274). 
The charactecistics of a potential mediator have been given in the intro-
duction (see 274). In most studies pharmacological methods have been employed 
to study the involvement of a pivotal mediator in CAR edema. Local levels of 
putative mediators are seldom reported. A short description of possible me-
diators is given below. 
~i~~~~i~~-i~l-~~£-~~~~~~~i~-i~~J_l· Both Hand SHT are simultaneously re-
leased directly after application of CAR into the pleural cavity and the gra-
nuloma pouch model, possibly by mast cells (50,262,274). After an initial peak 
presumably also present if saline is used as irritant, prolonged high levels 
of H and SHT are present for up to 48h. The levels of H are approximately 
1000 times higher than those of SHT The latter is somewhat more potent as 
edemagen in the rat paw, but both are inactive in the pleural cavity (262). 
Both probably mediate the pedal CAR edema, from the start, by increasing vas-
cular permeability. Pretreatment of the animals with compound 48/80, which 
depletes Hand SHT stores, or treatment with a combination of their antago-
nists (mepyrapine plus methysergide) gives a reduction of the pedal edema. 
The H1 and SHT blockers do not suppress the CAR edema when given separately 
(70, 92, 262). 
~E~£Yti~i~-i~~l· Bk may be formed from kininogen by the kallikrein enzyme, 
that is activated after prior activation of the Hageman factor. Bk is readily 
inactivated by kininase (see 74). Bk has been claimed to be present in CAR 
edema (10). Depletion of kininogen by elagic acid or cellulose sulphate re-
sults in a short- (70) or long- (184) lasting reduction of CAR edema. Exoge-
nous Bk is an edemagen in the rat paw (59), but not in the pleural cavity. Bk 
activates PG release in numerous situations (see Vane 1976 and table 2.2). 
~~~E!~~~~~· In contrast to the suggestion by DiRosa et al. (1971) no in-
dication for a role of the complement system in Car edema has been found in 
recent reports (eg. 184,262). 
2.5.5. Prosta3landins and CAR edema. 
The role of PGs in inflammatory reactions has been reviewed several times 
(see 87,255,274,284), and only the role of PGs in CAR edema will be discussed 
here. The following evidence suggests the pro-inflammatory involvement of PGs 
in CAR edema; 
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l. NSAIDs inhibit the later phase of the edema (from 2-3h onwards). The main 
in vitro activity of NSAIDs (except for salicylic acid) is inhibition of 
PG biosynthesis (see 2.2.2). 
2. In rats, immunized against PGE 1, CAR edema is reduced (255). 
3. EFA deficient rats displayed a reduced CAR edema (34). 
4. It is rather surprising that the report by Hillis (1969)_ in which the pre-
sence of PGs is described in edema fluid that was squeezed from the paws in 
a rather traumatic way, if often cited as an indication of the presence of 
PGs in CAR edema. In this report, controls are lacking and the author ad-
mits that all PG in the fluid could be due to tissue damage. 
Since the discovery of the main action of NSAIDs, several investigators 
have tried to establish pro-inflammatory effects of PGs. 
g~~~~!~£~~£-~£~~~~!Y· PGE 1 has been claimed to be chemotactic in vitro 
for rabbit peritoneal neutrophils (124). It is unlikely that this has physio-
logical importance since the precursor of PGE 1 is relatively scarce (also in 
neutrophils, 279). Another report indicates that PGs are not chemotactic for 
peripheral neutrophils from rat, rabbit and man, and high doses of PGE 1 only 
attract neutrophils harvested from the rabbit peritoneal cavity (266). PGs 
possibly enhance overall mobility of neutrophils (2261, a phenomenon observed 
with a variety of oxygenated PUFA's (see 268}. It is, therefore, not surpris-
ing that TXB2 (37) and HETE (244) display a moderate leucotactic activity. 
The in vivo significance of these observations is unclear yet. 
~Q~-~~-~1~~~g§g~. It has been claimed that PGE 1 and PGE 2 increase local 
vascular permeability in rat skin, as assessed by dye leakage (60,134). How-
ever, this method does not discriminate between increased blood flow and en-
hanced permeability, due to concomitant liberation of amines from mastcells 
(134). Hith more sophisticated techniques it appeared that PGs do not induce 
plasma leakage either in the rat paw (193) or in rabbit skin (271). 
~Q:?__§:!!~LY~:?.S?.1~~~!~2.!!· It is .....-ellknown that PGs (A2 , E1, E2 and especially 
r2 ) cause vasodilation, although species and tissue differences exist (see 
review by }Iessina et al., 1976). The marked increase in local blood flow in-
duced by PGE 1 and PGE 2, but not by Bk, H or SHT (132,193,271) is most probably 
the explanation for the "potentiation" by PGs of edema formation induced by 
H, SHT and Bk (151,169,243,272). Thus, PGs can modulate the pro-inflammatory 
effects of edemagens that are normally stored (amines) or not formed (Bk). 
This may explain tvhy NSAIDs can inhibit PG synthesis almost completely, while 
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a residual edema still exists, and why PG synthesis can continue physiolog-
ically in tissues without the production of edema. 
~~§.-~~9:_!.~~-E.§:i'3_£!_i~f!§:~!.i2~· PGE2 contributes to pain by 
11
sensitiz-
ing sensory nerve endings" towards Bk, but has little effect of its own (see 
review by Vane, 1976). The peripheral, analgesic activity of ~SAIDs in CAR 
edema is in close agreement with their anti-inflammatory activity, and a re-
duction in CAR edema results in an "apparent" analgesic effect (263), 
~~-~~9:2E~~2~i~~§.2_!~~l-~~~-~~g-~~~~~· Pro-inflammatory activities of these 
short living molecules are difficult to assess. PGG2 reduces local blood flow 
transiently, but then vasodilation dominates. Potentiation of Bk-induced plas-
ma exudation was then observed, as would be expected from the formation of 
PGE2 or PGI 2 (151). As discussed earlier it is unlikely that the endoperoxides 
normally accumulate when formed. TXB2 has been found in CAR exudates (52) and 
the "importance" of TXB 2 as a leukotactic agent has been mentioned. Since pla-
telets form TXA2 and adhere mainly to venules in an inflamed tissue (287), 
one might speculate that TXA2 may increase exudation by contracting endothe-
lial cells in the post-capillary part of micro-circulation. 
~~~!_i~_!h~_£Ei&i~_2_f_~Q~-i~-~£~!~_igfl~~~!i2g_I No direct answer is pos-
sible to this question, but platelets, vascular cells, tissue cells, and in-
vading cells, such as neutrophils are possible candidates. It is suggested 
that phagocytosis of CAR by neutrophils was responsible for both release of 
lysosomal enzymes and PGs (262,274). Other reports indicate that in acute exu-
dates from CAR impregnated sponge implants, the neutrophil invasion can be re-
duced (to 80%) without affecting PG formation (93,230), and that the presence 
of PGE preceded neutrophil invasion in urate crystal-induced inflammation (97). 
§~~§:~X· Several cell types and mediators are probably involved in CAR 
edema. Most results indicate that in the absence of a certain type of media-
tor the edema will still develop. PGs are weak inducers of plasma leakage and 
have little chemotactic activity. PGs enhance the effects of mediators, such 
as H and Bk. This modulation, which seems to be of importance for edema de-
velopment, is probably exerted through a local increase in blood flow. This 
idea explains why a physiological PG biosynthesis per se (for instance in 
kidney, seminal vesicles, etc.) is not accompanied by exudation or attraction 
of neutrophils. 
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3. GENERAL METHODS 
3.1. Animals. 
Male Wistar rats, obtained from the animal breeding farm of TNO (Zeist, 
The Netherlands) were used, except for the experiment shown in fig. 6.2 (Chap-
ter 6). The rats were fed with standard food (Hope Farms, ·Hoerden, The Nether-
lands) . EFA deficiency was induced by feeding pregnant rats a diet containing 
4% hydrogenated cocosfat (prepared by Hope Farms, Hoerden), starting 5 days 
before the expected day of delivery. After weaning, the newborn rats were kept 
on EFA deficient food. The EFAD rats were placed in "wire screen bottom 
cages 11 • The development of EFA deficiency was monitored by weighing normal and 
EFAD rats once a 1veek (see fig. 3.1). Apart from the diminished growth(~ 35% 
reduction), some other symptoms of EFA deficiency \.Jere noticed: enhanced \Vater 
intake, absence of yellowish-brmm pigmentation of abdominal skin and some 
scaly lesions of the skin. In edema tests EFAD rats were compared with normal 
rats of approximately the same weight (220-270 g; see fig. 3.1). For platelet 
studies blood was obtained from normal and EFAD rats of identical age (18-23 
weeks). 
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Fig. 3.1. Growth curves of normal and EFAD rats. The lines are dra\m 
along the means of N average weights. These weights \vere determined 
by weighing N groups of five rats once weekly. The thin lines are 
dra-wn along the s.e.m.; squares indicate the >veight ranges utilised 
in the edema experiments reported in the text. 
3.2. Carrageenin-induced hindpaw edema (CAR edema). 
HindpaH edema was induced by injecting 0.1 ml carrageenin (CAR) or saline 
subplantar into the footpad (see fig. 5.1 for the site of injection). In one 
experiment (fig. 6.2) an additional 0.05 ml was injected into the footpad at 
2h. 
~~!i~~· Sterile, pyrogen-free, 0.9% NaCl was obtained from the pharmacist 
(Dijkzigt Academic Hospital, Rotterdam, The Netherlands). 
CAR (carrageenan, Viscarin, Harine Colloids, N.J., USA) 1:vas dissolved 
overnight at 40°C in distilled water, and diluted to 1% (w/v) \Vhile the so-
lution was slowly stirred. In several experiments additional irritants were 
included in the CAR solution (see Chapter 6). For this purpose a solution 
containing 2% (•v/v) CAR was prepared and diluted (1 /1; v/v) with the other 
irritant. Thus, in all experiments I mg CAR \Vas injected into the foot. 
~2:§:~.e-~§:~.§~f§:~~:£!.§· Pmv edema Has measured with 3 techniques: 
1. Diameter. Increase in paw thickness ( 6 nun) was measured with the apparatus 
described by Bonta & Noordhoek (1973). Paw swelling >..ras expressed as percent 
increase of the pre-irritant diameter: ( 6 mmt,x/mmt=O) I 00 
~· Volume. Increase in pa>V volume was measured using the mercury displace-
ment method with an apparatus produced by U.Basile (Milan, Italy), 
2· Height. After killing with ether, the paws were severed at the tibiotarsal 
joint with a small guillotine and their weights measured. The differences (g) 
in wet weights bet1:veen the control and inflamed paw served as a measure of 
the edema. 
3.3. Measurements of prostaglandins, thromboxane A2 and serotonin. 
The compounds were bioassayed using isolated, superfused tissues (see 2.1 .8). 
Contractions of the tissues, induced by addition of samples Hith unknown 
quantities of autacoids, were calibrated Hith standard doses of agonists. The 
selectivity of the assay was raised by using several tissues, arranged in a 
cascade (Vane 1964) and by addition of antagonists to the superfusing physio-
logical salt solution. The antagonists prevented the tissues from responding 
to interfering substances. The sensitivity of the bioassay can be increased 
by means of a laminar flow technique (79). An improvement of the laminar flow 
technique permitted superfusion of more than one tissue (Bult et al., 1977). 
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Fig. 3.2. Superfusion of isolated 
tissues, arranged in a cascade. 
f~~~~~~-~~~~~iS~~· Isolated tissues were arranged in a cascade as shown 
schematically in fig. 3.2. The organs were superfused (2.5 ml/min, 37°C) by 
means of a two channel roller pump (Verder, Vleuten) with gassed (95% 02 , 5% 
C02) Krebs, containing (rnM): NaCl (I 18), KCL (4.17), CaCl 2 (2.5), MgS04 (1.18), 
KH 2ro4 (I.l8), NaHC03 (25) and glucose (5.6). The injection of substances onto 
the lower tissues was simplified by placing funnels on the organ chambers and 
this permitted the use of a relatively low flow rate, since it prevented 
changes in temperature and humidity in the organ chamber. Contractions were 
recorded with Harvard heart/smooth muscle transducers, connected either to a 
Rikadenki SA series multi-pen recorder, or to a Harvard chart mover. 
b~~i~~E-i1£~-~~~b~ig~~· This elegant method was developed by Ferreira & 
De Souza Costa (1976). The tissue is superfused with a very thin layer of 
Krebs and is protected from desiccation by suspending it in mineral oil. An 
adaption (see fig. 3.3; for details: Bult, Farnham & Bonta, 1977) made it pos-
sible to use a laminar flow technique in a cascade. The technique gave satis-
factory results with all the tissues that were used in the normal cascade, 
provided that: 
1. All glasHare was siliconized, 
2. Thick threads were used to attach the tissu~ to the transducers, 
3. The bath was filled with Krebs and the mineral oil was poured down the 
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inside of the bath after the installation of the tissues Has finished, 
4. The flow rate of the Krebs was directed (if necessary) to the correct side 
of tissue strips (original inside (in vivo) for vascular tissues and original 
outside (in vivo) of stomach strips). 
The increase in sensitivity is demonstrated in fig. 3.4, where a normal 
cascade (already optimally sensitive, flmv rate 2. 5 ml/min) has been compared 
with the laminar flow technique (0.1 ml/min). Due to the fact that the bolus 
doses of PGE 2 are 25 fold less diluted in the laminar flow, the same factor 
predicts the apparent increase in sensitivity. Experimental data confirmed 
this. Doses of PGE 2 (ng), needed for half-maximal contractions were: cascade 
59.6.:::_7.3 (12) and laminar floH technique: 2.4+0.35 (10). The ratio between 
these values is: 24.8+4.7 (see fig. 3.4). 
Ii~~~~-~~l~~!i~~-~~~-E~~E~E~!i~~· The following tissues were used: 
Rat stomach strip (RSS). Rats were killed by a blow on the head and bleed-
ing. The stomach was dissected out and two strips of about 2 rum were cut from 
the pale rumina! part of the stomach (Vane, 1957). The strips reached a stable 
base line within 120 min. This tissue is very sensitive to SHT and PGs, es-
pecially PGE 1 and PGE 2 . It is rather non-selective since it is also contracted 
by PGI 2 , FZa' D2 , G2 , H2 (see fig. 3.5, and ref. 98,1 14,170). Generally PGE 2 
and 5HT were used as standards. 
Rat colon (RC). Pieces (2 em) of colon were dissected out, their contents 
were washed out and adipose tissue was removed. The upper end was closed with 
a thread, Hhile the distal end was left open. Test substances >vere added after 
Fig. 3.3. Organ bath, containing an 
inner cylinder >vith a small, slop-
ing drain, in Hhich the upper tis-
sue 1:vas secured. At the beginning 
of the experiment, the level of the 
parafin oil was adjusted Hith the 
syphon. 
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Fig.3.4. The apparent sensitivity of rat stomach strips in a normal 
cascade (closed circles, n=l2) and in a cascade with a laminar flow 
(open symbols, n=JO). The results, expressed as percentages of the 
maximal contraction, were obtained with the cumulative technique. 
The flow rates \-Jere 2.5 ml/rnin (normal cascade) and 0.1 ml/rnin (la-
minar flow cascade). Log DSO values: -7.25+0. 12 (2.5 ml/min) and 
-8.62+0.09 (0.1 ml/min). 
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Fig. 3.5. Cumulative dose response curves to PGE2, PGD 2 and SHT in 
superfused (2.5 ml/min) rat stomach strips. Triangles represent 
single doses of PGH2 , from which the linear regression was calcula-
ted. All results are expressed as percentage of maximal PGE 2 con-
traction. Log DSO values: -7.25~0. 12(PGE2), -6.83(PGH2), -6. 12~0.20 
(PGD2) and> -5 (5HT). All antagonists were present in the Krebs. 
a stabilizing period of lh. Spontaneous activity Has often present. The colon 
is about equally sensitive to PGE 2 and PGF 2a as shown in fig. 3.6. PGH2 and 
its stable analogue 9,11 E:H (upto 100 ng, 0.1 ml/min) did not contract this 
tissue. PGE 2 and PGF 2a Here used as standards. The RC may be used in combinat-
ion with a RSS Ll discriminate between PGE 2 and PGF 2a(as shotm in fig. 3.6), 
since the RSS is less sensitive to PGF 2a than to PGE 2 . 
Rabbit aorta strip. (RAS). Male ~ew Zealand white rabbits (2.5-3.5 kg) were 
blown on the base of the skull and exsanquinated. The chest was opened and 
the aorta removed. A spiral strip, about 2.5 mm wide was cut, and pieces of 
3 em length tvere used. Strips tvere often stored overnight at 4°C before use. 
The tissue is stimulated by 5HT, PGG2 , PGH 2 and especially TXA2 (179). The 
classical PGs are also active but much higher doses are needed (see Bult & 
Bonta, 1976a). PGH2 and 9,11 EM were used as standards. 
Rabbit coeliac artery (RCA), After dissection the artery Has freed from 
otheradjacent tissues, spiralized, and a 2 em strip (close to aortic trunk) 
was used. The tissue Has stored (4°C) overnight before use. It is selective 
tmvards .\A metabolites, since it is stimulated by TXA2 (Bunting et al., 1976), 
but neither PGE 2 nor the endoperoxide PGH 2 had any effect (Bult & Bonta, 1976). 
In another report (47) a relaxation is described in response to PGE 2 or 
PGH 2 . This discrepancy might be explained by a difference in preparation 
technique (storage at 4°C overnight) or by a different loading of the tissue. 
TXA2 , with its half life of 32 s, is of little use as standard and is not yet 
available in a highly purified form. Therefore, the 9,11 EH synthetic ana-
logue of PGH2 was used. In pharmacological respect this substance has the in-
teresting property that it mimicks TXA 2 and not PGH2 or PGG2 . 
Fig. 3.6. Dose response curves to PGE 7 
and PGFza· The cascade consisted of a-
rat stomach strip (RSS) and a rat colon 
(RC), which "-'ere superfused \Vith a lami-
nar floH (0.38 ml/min). Test doses of 
PGE 2 and PGFza-tromethamine salt (PGFza) Here given in 50 ul volumes. 
~I 
em 
.os .2 1 ngPGE2 .s 1 2 ngPGF2cx 
.1 .5 2 
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~§§~§§~~~!_2f-~~!i~i!i~§· Agonist solutions were freshly prepared before 
each exneriment. After equilibration of the tissues, n.o5 or 0. I ml (2.5 ml/ 
min) or 0.01-0.05 ml (0. 1 ml/min) was injected into the Krebs (Eppendorf pi-
pette). Assessment of unknown activities 'ivas carried out by bracketing assay. 
An interesting discovery Has that a "cumulative'' procedure of obtaining dose-
response curves produced data, such as maximal contraction and the logarithm 
of the dose of an agonist achieving a half-maximal contraction (log n50), 
that were not significantly different from those obtained by a conventional 
stepwise procedure (see Bult & Bonta, 1976a, and fig. 3.7). In the cumulative 
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Fig. 3.7. Dose response curves obtained with the step-wise procedure 
(--o--) and 'ivith the cumulative technique (----a-----). Results (n=S) were 
obtained on superfused (2.5 ml/min) rabbit aorta strips, stimulated by 
noradrenaline (NA), and expressed as percentages of the maximal con-
tractions obtained using the step-wise technique. The upper traces 
shaH a single aorta strip, responding to step-\vise doses of NA (up 
to 100 ~g) and finally to cumulative doses of NA. In the latter 
case, 0.01 ,0.05, 0.1, 0.5, 1.0, 10 and 100 ).lg NA was given at the 
vertical bars. In these experiments, phentolamine (0.1 mg/1) was in-
cluded in the Krebs instead of phenoxybenzamine. Log Dso values: 
-5.95+0.14 (step-wise) and -5.80+0.11 (cumulative). 
technique, increasing doses were given to 2 min after each other. This 
technique has a considerable time-saving effect, especially with sluggishly 
responding tissues such as rabbit arterial and rat stomach strips. 
~~~~g~~~~~~- Substances, other than the AA-metabolites can stimulate or 
relax the tissues. A number of these materials can be couteracted by anta-
gonists. A mixture of these antagonists (98) was included in the Krebs, in 
order to block acetylcholine, a- and s-adrenergic agonists, histamine, 5HT 
and PG-biosynthesis. Thus, for routine assay of AA-metabolites, the tissues 
were superfused with; atropine sulphate, 0.1 mg/1; phenoxybenzamine-HCl, 0.1 
mg/1; sotalol-HCl, 0.1 mg/1; mepyramine-HCL, 0.! mg/1; methysergide hydrogen 
maleinate, 0.1 mg/1; and indomethacin, 1.0 mg/1. Sometimes, one of the anta-
gonists \-Jas omitted from the Krebs and added to selective tissues, via the 
second channel of the roller pump. 
R.A.S. (\ 
{Pheno:qbenzomine) _J l 
R.F.S. 
R.A.S. 
ox. lin. 
min. 30 
om, 
lin. 5-HT PRP PRP ox. lin. 
1' 7' 
130 ~g 5 mg 1 ~g 0.1 ml 0.1 ml 10 ng 5 ng 0.1 ml 130,260~g 
Fig. 3.8. Phenoxybenzamine blocks SHT-induced contractions of the rabbit 
aorta strip (RAS). The cascade consisted of I RAS (incubated overnight with 
3 ]..1~1 phenoxybenzamine at 4°C), 1 rat fundus strip and I rabbit aorta 
strip (incubated overnight at 40C, without phenoxybenzamine). The 
Krebs (2.5 ml/min) contained 0.05 l..iM methysergide and other anta-
gonists (~1ith phentolamine instead of phenoxybenzamine). The tissues 
were calibrated with PGE2 (E2), SHT, linoleate (lin) and oxygenated 
linoleate (ox. lin). Rat PRP (0.1 ml) was also tested at time inter-
vals of I, 7 and 40 min after addition of collagen (40 ).lg/ml). Oxyge-
nated linoleate was prepared according to Whitney Warton (1974), as des-
cribed earlier (41). RFS: rat fundus strip~ rat stomach. 
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In initial experiments, phentolamine-HCl (0. I mg/1), a competitive a-
blocker, was used instead of the irreversible blocker ohenoxybenzamine. This 
permitted the use of high doses of noradrenaline for calibration of the aorta 
strips. However, it then appeared that under these conditions methysergide 
only partially blocked SHT-induced RAS contractions (see Bult & Bonta, 1976a 
and fig. 3.8). 
The nature of the 5HT blockade by methysergide was further investigated. 
The RAS exhibited tachyphylaxis towards SHT. This resulted in a decreased 
maximal contraction without significantly influencing the log D50 of SHT (see 
Bult & Bonta, 1976a). The estimated affinity (pA2) of methysergide for the 
SHT receptor was: pA2= 7.8.!_0.2 (first curves) or pA2"' 7.5.!_0.3 (third or 
later curves). These values are lm-J in comparison to the pA2 (10.4 .!_ 0.4) 
given for the RSS (Frankhuizen & Bonta, 1974). Moreover, methysergide showed 
only competitive inhibition on the RAS 'i·Jhereas it has an additional, strong, 
non-competitive character in the RSS (Frankhuizen & Bonta, 1974). Pretreat-
ment of the RAS Hith phenoxybenzamine (I mg/1, 4°C, overnight) or replacement 
of phentolamine by phenoxybenzamine, resulted in a blockade of SHT (upto 10 
~g, 2.5 ml/min) in the presence of methysergide. A qualitative example of 
such blockade is shown in fig. 3.8. Thus, with phenoxybenzamine as well as 
methysergide in the antagonist mixture, a reasonable assessment of AA-meta-
bolites seemed to be impossible. However, not all potential agonists are 
blocked (eg. Bk, Angiotensin II), and mixtures of agonists (eg. PGs+ ADP or 
PGs + 5HT) may interfere with each other. Thus, extraction and separation of 
AA-metabolites is a prerequisite for quantitative determination. For TXA2 
this is impossible at the moment. 
3.4. Extraction and separation of PGs. 
~~~~~£~i~g. After addition of either 3H-PGE 1 or 3H-PGF 2a to the sample, 
an aliquot (usually 1 ml) was taken, and 0.9% NaCl (28 ~H indomethacin) \-Jas 
added to make the final volume 5 ml). This was stored (0-120 min) on ice. Im-
mediately after acidification to pH 3 (0. 1 N HCl, volume predetermined, de-
pendent on buffering capacity of sample) 5 ml diethyl ether was added and 
mixed on a vortex mixer. After centrifugation (10 min, 900 g, 4°C), the ether 
phase was aspirated and the procedure repeated with another 5ml ether. The 
combined ether fractions were dried under reduced pressure (37°C) and a small 
volume of ethyl acetate was added. If the extracts were not directly used 
50 
0 they were stored at -20 C (N 2 atmosphere). The efficiency of the extraction 
procedure, as determined by recovery of 3H-PGE 1 , was 85 _:::. 2% (30). 
In some experiments, a column separation step was included. Aliquots (I rnl) 
of centrifugated plasma (900 G, 0°C, 30 min) were applied on Arnberlite XAD-2 
(BHD) columns (bed volume 1. 0 x 3. 0 em; 138). The flow rate had been adjusted 
to 0.5 ml/min, and the columns were \-Jashed 1vith 30 ml saline (containing 28 
~M indomethacin). The PGs were eluted with 5ml methanol (recovery (%): 
3H-PGE 1: 87.:::.2 (5), 
3H-PGF 2ct: 88::_3 (5)). The methanol eluates were stored at 
-20°C under N2 . After evaporation of methanol (stream of N2 , 60 min, 37°C), 
the residual Hater was diluted to 5 ml, acidified to pH 3 with 1 M citric 
acid and extracted three times with 5 ml chloroform. This method had some ad-
vantages when it is partially automated: 
~· A large number of samples was conveniently transferred in a more PG stabil-
izing medium (methanol- H2). ~- Host proteins were 1:-;rashed a\vay, which promoted 
phase separation during extraction. The introduction of an additional puri-
fication step was a disadvantage. 
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Fig. 3.9. Separation of PGB, PGE and PGF classes on silicagel columns. 
Tritiated AA (26,000 dpm), oxygenated AA (26,000 dpm), PGB 1 (20,000 
dpm), PGE1 (20,000 dpm) and PGF2a (15,000 dpm) were loaded on silica-
gel columns, and eluted with chloroform, containing increasing volume 
percentages of methanol (% in fig.). Fractions (2 ml) were collected, 
transferred into scintillation vials, dried under N2 at 37°C and 
counted. 3H-PGBJ 'ivas prepared by heating 3H-PGEJ (1000C, 10 min) in 
0. I N NaOH, and extracted at pH 3 in chloroform. Oxygenated 3H-AA was 
prepared by the soya bean lipoxygenase method (see 278 and Bult & 
Bonta, 1976a). 
51 
~~E~E~!!~g-~f_I~~-£y_§ili~~g~!-~~!~~g-~bE~~~!~gE~EbY (see fig. 3.9.). 
The dried extracts were reconstituted in 0.5 ml chloroform (with 1 vol % me-
thanol) and loaded onto silicagel columns, as ''"here 2 \Vashings with 0.2 ml 
chloroform. The method of Hillier and Dilley (1974) was followed, using the 
same type of columns (bed volume 0.5 x 8, 0 em), but the silicagel (Merk, 
kieselgel, 70-325 mesh) was activated (120°C) overnight. Elution of different 
PG classes \vas performed using chloroform, containing increasing percentages 
(by volume) of methanol: 5 ml 0% (fatty acids), 10 ml 1% (15 hydroxyarachi-
donic acid), 10 ml 3.5% (PGA+PGB), 10 ml 6% (PGE) and 6 ml 15% (PGF 2a). The 
polarity needed for elution of PGA+ PGB and PGF, \Vas some\vhat higher than re-
ported. No appreciable dehydration of PGE 1 was noted. The average flow rate 
ranged bet\,'een 0.27 and 0.33 ml/min (gravity). 
§~E~E~!!Qg_Qy_!1g. Dried extracts were dissolved in a small volume of 
ethyl acetate and spotted on Fertigplatten Kieselgel 60 F 254, 0.2 mm (Merk). 
The plates 1:vere developed with freshly prepared chloroform-methanol-acetic-
acid-'tvater (90:8:1:0.8, by volume) until the front vws 17 em from the origin 
(System C, 1\ugteren and Hazelhof, 1973). 
3.5. Halon dialdehyde ('HDA) assay. 
:IDA 1:vas measured spectrophotometrically after fomation of the HDA-thio-
barbituric acid (TEA) adduct. Trichloroacetic acid (1 ml, 15% in 1 )J HCl) •vas 
added to 1 ml PRP (prepared as described in 4.3), and after mixing, the pre-
cipitated proteins 'ivere removed by centrifugation (15 min, 4°C, 900 G). The 
supernatant •vas filtered through a cotton wool plug and I ml TBA reagent Has 
added to 1 ml filtrate. After heatinp, (15 min, 100°C), the absorption \..'aS 
measured (532 nm, 20°C, 1 em). TEA reagent was prepared daily by dissolving 
0.5 g TEA in 5 ml SN ~aOH, to which 30 ml ,,,ater Here added. The solution Has 
brought to pH 9-10 with 70% perchloric acid and diluted to 50 m1 Hith 'ivater 
(1% TEA). Just before use, 2 volumes of the 1% TBA solution were mixed Hith 
volume 7% perchloric acid, giving the final TEA reagent. 
Standard. 1,1 ,3,3-tetraethoxypropane (TEP) ,,Tas used as standard and hy-
o -5 drolyzed during heating (15 min, 100 C) of a mixture of 1 ml TEP (0-10 H), 
I ml 15% TCA (in 1 N HCl) and 2 ml TEA reagent. The extinction coefficient 
(532)· was: 1.46+ 0.02 (7) L.mole- 1 .cm- 1 . If the }fDA-TEA complex was formed 
in the presence of precipitated proteins (as described by Stuart et al., 1975), 
reduced extinction coefficients •vere measured Hith increasing doses (0-1 0 
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mg/ml) of albumin. 
Recovery. A possible disadvantage of this ~IDA assay is the loss of MDA as 
a result of binding to proteins and loss of }IDA after removal of denaturated 
proteins. lfhen }IDA (10-5 M) was incubated with PRP no significant loss •vas 
observed. 
~~~~£~~~~~~~~-~!-~~~-i~-~~~· The method can provide satisfactory results 
in PRP. PRP and PPP (final volume 1 ml) were stirred with a 1 2 x 8 x 8 mm bar 
at 100 rpm. Under these conditions saline-treated PRP did not produce more 
TEA positive material than saline-treated PPP. Stronger stirring resulted in 
high extinction values of saline-treated PRP. Rat plasma contained a large 
amount of TEA positive material and incubations with PPP or PRP, stimulated 
with saline, were absolute requirements for a reliable measurement of MDA 
production by platelets. In table 3.1 the net }IDA production by collagen ag-
gregated rat platelets is shmm. Extinction values of PPP have been subtract-
ed before calculating the amount of MDA produced by platelets. The reaction 
seemed to be cyclo-oxygenase specific, since it was inhibited by indomethacin. 
Thus, it is unlikely that the AA lipoxygenase (2. 1 .7) contributed to tiDA pro-
duction. 
Table 3.1. Measurement of TEA positive material in rat PRP (4.3). 
Pretreatment !viDA (nmol/1 0 9 platelets) 
Saline (50 "1) 0.47 + 0.06 ( 1 0) 
IM ( 1 0 "M) 0.02 + 0.05 ( 5) 
TYA (30 "M) 0. 10 + 0.03 (5) 
PRP was preincubated with saline, indomethacin (IM) or eicosatetra-
ynoic acid (TYA) and aggregated with collagen (40 ~g/ml). After 5 
min the reaction was stopped by addition of I ml 15% TCA as describ-
ed above. TBA positive material 1:vas measured as described. 
3.6. Additional techniques. 
£~~~Y-~~!~-~~~~E~i~~~!2~_2f_~2~~l_liEi~~-!£2~-~EY!~E2~Y!~~· After centri-
fugation (30 min, 950 G) of blood (4.3) plasma and "buffy" coat were removed. 
The erythrocytes were 1:vashed three times •vith 10 mM EDTA in saline. Lipids in 
5 ml packed cells were isolated (Folch et al., 1957) by two extractions with 
19 volumes of chloroform-methanol (2:1, v/v). Five mg dried extract tvas heat-
ed (2h, 70°C) in 9 ml methanol-HCl (2.6 gr HCl/100 ml methanol) under N2 . 
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Then 2 ml 8 N NaOH were added, and the mixture was again heated (1h, 70DC, 
N2 atmosphere). The saponified mixture was acidified (5 N H2so4 , pH 4) and 
extracted three times with 25 ml pentane. The combined pentane fractions were 
dried (Na2so2) and methylesters were prepared with a fresh ethereal diazo-
methane solution (R2 atmosphere). The pentane fraction was filtered, and 
dried (37°C) under reduced pressure. The dried residu was dissolved in a drop 
of pentane and 1-2 ~l was used for analysis. Fatty acids were separated on a 
4 ftx 3mm column (3% EGSS-X on gaschrom Q, Chrompack, The Netherlands) in a 
Hewlett Packard 9750 gas chromatograph. Temperatures: injector, 240°C; 
column: 175°C; flame ionization detector, 250°C. The equivalent chain length 
values were compared with those of a mixture of fatty acids and with the data 
of Hoffstetter (1965). Weight percentages were determined by triangulation. 
3 1is~i~-~~i~~ill~~i~~-~~~~~i~g. In most experiments recovery of H-PGs was 
measured in duplicate (or triplicate) samples. Aliquots were dissolved (if 
necessary after evaporation of the strongly quenching chloroform) in 10 ml 
scintillation fluid (I ,4 dioxane, containing per liter: 60 g naphthalene, 4 g 
PPO, 0.2 g POPOP and 100 ml methanol). Radioactivity was measured in a 
Packard Tri Carb Model 3375 liquid scintillation spectrometer. External 
standardization was used for quench correction. The conversion 
dpm was performed automatically. Average efficiencies: 3H, 43%; 
Dual labelling: 3H, 39%; 14c, 55%. 
of cpm into 
!4 c, 75%. 
~~~~i£~1~· PGE 1, PGE 2 and PGF 2a-tromethamine salt were gifts from Dr.J.E. 
Pike (Upjohn Company, Kalamazoo, Michigan); 9,1 I (15 S-hydroxy-9,1 1-(epoxy-
methano)-prosta-5 2,13 E dienoic acid) was a gift from Dr.G.L.Bundy (Upjohn 
Company, Kalamazoo, Michigan); PGH2 , PGD 2 , 15-hydroperoxyarachidonic acid, 
dihomo-y-linolenic acid, and 5,8,1 1 eicosatrienoic acid were gifts from 
Dr.D.H.Nugteren (UnileverResearch, Vlaardingen, The Netherlands). PGE 2 , PGE 1, 
PGF2a (10 mg/ml) and PGD 2 (50 ~g/ml) were dissolved in ethanol, stored at 
-20°C, and these stock solutions were diluted just before use. PGH2 was stor-
ed in diethyl ether (5 ~g/ml) at -7o 0c. After evaporation of the ether, 
glucose-free Krebs was added and the biological activity of an aliquot was 
immediately tested. 15-Hydroxyperoxy AA (100 ~g/ml) in ethanol was treated 
in the same way as PGH2. Eicosatetraynoic acid was a gift from Dr.A.L.Willis 
(Roche Products, Welwyn Garden City, England), and dissolved in ethanol (10 
mg/ml). Other fatty acids were stored in hexane (N2 atmosphere, -20°C) and 
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just before use, solutions were made up in saline, containing 0.02% Na2co3 . 
Ethanol (final concentration 10%) was sometimes needed in order to obtain ho-
mogenous emulsions, In these cases saline-Na2co 3 with 10% ethanol served as a 
control. BPP 9a was a gift of Dr.L.J.Greene (Ribeirao Preto, Brasil). The fol-
. ) . 14 . lowing chemicals were purchased: arachidon~c acid (99% , S~gma; 1- C-arach~-
donic acid (55 mCi/nunol), 5,6 3H-PGE 1 (59 Ci/nunol) and 9 
3H-PGF 2o: (15 Ci/nuncil): 
The Radiochemical Centre, Amersham, England; linoleic acid and serotonin 
creatinine sulphate, Merck; bradykinin and methysergide hydrogen maleinate, 
Sandoz; ADP, Boehringer Mannheim; indomethacin, Merck, Sharp & Dohme; aspirin 
(calcium acetylsalicylate), Amsterdamsche Chinine Fabriek ACF; heparin and 
dexamethasone, Organon Oss, The Netherlands; 1 ,1,3,3-tetraethoxypropane, 
Merck-Schuchardt; thiobarbituric acid and atropine-sulphate, Merck; phenoxy-
benzamine-HCl, Ciba-Geigy; phentolamine-Bel, Smith, Kline & French Labs; so-
talol-HCl, Mead-Johnson; mepyramine-HCl, SPECIA; adrenaline-bitartrate, 
Fluka A.G. 
IE~~~~E~Ei£~-~~~-~E~Ei~Ei£~1-~~~lY~i~-~~-~~E~· All data are expressed as 
means~ standard error of the mean, and when necessary, the number of obser-
vation is given between brackets {mean~ s.e.m. (n)}. If M values were below 
the limit of detection (a), this is indicated by : < a(H). \•Then 2 groups of 
data \vere being compared, a two tailed Student's t-test was employed. If there 
seemed to be either a non-normal distribution, or marked differences in the 
variances of the two grouns, the non-parametric I.Jilcoxon test Has employed. 
For comparisons of more than 2 groups, a one way analysis of variance (ANOVA) 
was carried out. The F-ratio (c) and the degrees of freedom (a,b) are given: 
F0 (a,b)o=c. If an overall treatment effect existed, Duncan's ne\v multiple 
range statistic was employed. For comparison of several treatments with one 
control the test of Dunnett 'iVas used (see fig. 6.3). 
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4. THROMBOXANE AND PROSTAGL&~DIN BIOSYNTHESIS AND RAT PLATELET BEHAVIOUR 
4. I. Abstract. 
PGE and thromboxane A2 (TXA2) were formed during incubation of heparinized 
rat platelet rich plasma (PRP) with collagen or arachidonic acid (AA). The en-
dogenous release of these products by EFAD platelets was drastically reduced. 
The oxygenated, endogenous AA products probably amplified aggregation induced 
by threshold doses of collagen. The addition of exogenous AA (or PGH2) to PRP 
did not completely mimick the collagen-induced formation of products, since 
more stable PGs and little TXA2 were formed in absence of aggregation. Cir-
cumstantial evidence indicated that TXA2 was the aggregation-inducing sub-
stance in rat PRP. Aggregation induced by ADP or high doses of collagen pro-
bably proceeded independently of TXA2 synthesis. 
4.2. Introduction. 
Platelets were chosen as an in vitro model of endogenous PG biosynthesis 
for several reasons: ~· It is relatively easy to obtain platelets. ~· Large 
amounts of oxygenated AA metabolites may be formed upon stimulation of plate-
lets. l· During their isolation, artificial PG release seems to be negligible, 
since homogenization -with concomitant PG synthesis- is not necessary, in 
contrast to spleen cells, kidney cells, etc. 
Human platelets played a central role in the discoveries of TXA2 , of PGI 2 
and of the first lipoxygenase in cells other than plant cells (see 2. I and 
2.4). PG-endoperoxides and TXA2 are implicated in the mechanisms of aggregat-
ion of human platelets (see 2.4). However, little is known about AA metabolism 
in rat platelets. Thus, it was of interest to see if rat platelets release PGs 
and TXA2 during aggregation, and to evaluate the significance of this release 
for their behaviour. Rat platelets differ from human platelets in some res-
pects: they are not aggregated by adrenaline, show no biphasic aggregation in 
response to ADP (see 2.4 and 175) and their aggregation is not inhibited by 
PGD2 (154,183), 
The studies were mainly restricted to the following questions: 1. Are rat 
platelets a useful in vitro model for the assessment of PG and TXA2 synthesis? 
2. Is it possible to demonstrate a substantial reduction in endogenous PG re-
lease during EFA deficiency? 2· What is the importance of oxygenated products 
of AA in rat platelet behaviour? 
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Thus, rat platelet aggregation and release of AA-derived products, induced 
by various substances, were studied in PRP. Then, the influence of EFA defi-
ciency on rat platelet behaviour was investigated. Finally, results obtained 
withcyclo-oxygenase inhibitors indomethacin and eicosatetraynoic acid (TYA; 
see 2.2) \..rill be presented. TYA is also an inhibitor of platelet AA-lipoxy-
genase (117). 
4.3. Methods. 
~~~£~~~~12~_2!-~~E~~~~!~~~-El~~~l~~-~i~h_El~~~~-i~~~l· Blood was obtained 
by cardiac puncture of ether anaesthetized normal and EFAD rats (see 3.1). The 
syringe (10 ml) and the needle (1 .2 x 40 mm) were rinsed with 0.3 ml heparin 
solution (Thromboliquine, Organon, Oss, The Netherlands; 5000 i.u./ml). After 
centrifugation (15 min, 200 G) the PRP \Vas carefully removed and diluted with 
platelet poor plasma (PPP), which was obtained by centrifugation (30 min, 900 
G), to an OD (602 nm, 1 em) of 0.9. PRP was prepared daily and stored (20°C) 
in capped, plastic vials. During the whole procedure glass contact was avoided. 
For some samples the platelet number was determined in a Coulter counter, 
-3 giving the following results (cells x 10 /~1): normal PRP, 669 + 25 (10) and 
EFAD PRP, 729 + 31 (5). 
~gg£~g~~i£~· Aggregation was studied with the turbidimetric method (Born, 
1962), using 8 volumes PRP, which were placed in siliconized, flat bottom cu-
vettes (6.5 x 45.0 mm) in an aggregometer (Payton Ass. Inc., Buffalo, N.Y.). 
PRP was preincubated for 3 min with 1 volume saline or Tyrode (mM: NaCl, 137; 
KCl, 2. 7; HgSo 4. 7 H2o, 1.1; NaHlo 4 , 0.42; NaHco 3 , 11.9; pH 7 .4), while stirr-
ing at 900 rpm and 37°C. At zero time the aggregation was started by the ad-
dition of 1 volume Tyrode (with inducers) or I volume collagen suspension. 
Collagen (Bovine achilles tendon, Sigma) was suspended in !8 nU1 acetic acid at 
a final concentration of 0.4 mg/ml. Drugs were pteincubated during 3 min. The 
final volume of the incubations Has either 0.25 or 0.5 ml, Aggregation Has ex-
pressed as percent increase in light transmission; 6transmission PPP-PRP=JOO%. 
~i£~~2~Y· The release of mediators was assessed on a cascade of isolated 
tissues (see 3.3), either directly or after extraction and separation of PGs 
by column chromatography (see 3.4). The amounts of biological activities were 
expressed as ng/ml incubation mixture. 
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g~~i~~~~~i~~!-~~~~Y-~!-~~yg~~~~~~-EE£~~~!~-~f-~· In some experiments PRP 
\Vas stimulated with collagen, 0.1 mM or 0.6 mM AA, in the presence of 14c-AA 
(final volume 0.5 ml). Indomethacin (20 ~1, final concentration 28 ~M) was 
added at 8 min after starting the aggregation, and the suspensions (0.5 ml) 
were extracted and the PGs were separated by TLC (see 3.4). 
4.4. Results. 
4.4.1 .Normal rat platelets and PG biosynthesis. 
Aggregation in normal PRP, induced by various substances is shown in fig. 
4.1. ADP (0.11, 0.21, 0.43, and 0.85 ~g/ml) and collagen induced a single wave 
of aggregation. AA (182 "f.lg/ml) on occasions induced only "shape changen of the 
platelets, indicated by increased turbidity and diminished oscillations, but 
the same dose, in another PRP, induced a monophasic aggregation. PGH2 at 0.5 
Fig. 4.1. Examples of aggregation 
of rat PRP. After 3 min preincu-
bation (not shown) different sub-
stances were added. This is indi-
cated by the increased transmiss-
ion, due to dilution of the PRP 
(see for example adrenaline,+). A 
subsequent decreased transmission 
and dimished oscillations, indi-
cating that the platelets are 
changing their shape, is often 
observed (see for instance lower 
doses of ADP and PGH2,+). When 
the platelets aggregate the 
transmission increases, and large 
oscillations occur (+). The latter 
are due to aggregates that whirl 
around. C~ collagen; 9,11 EM:9,11 
epoxyrnethano-analogue of PGH2. All 
concentrations in ~M, except for 
collagen (~g/ml). 
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~g/ml (1 .4 wM) only resulted in shape change of platelets, whereas 1 ~g/ml 
gave a small aggregation. Adrenaline (upto 100 ~M) and 9,1 I EM (upto 2.55 ~g/ 
ml) failed to aggregate rat platelets in PRP. The reasons for the variations 
in AA-induced aggregation in rat PRP are not exactly clear at this moment. 
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Fig. 4.2. Qualitative example of the release of different products 
during aggcegation. PRP 1-vas preincubated Hith saline (y) or 0.3 mM 
TYA (V) . At different times (min) , before and after addition of 
collagen (40 ~g/ml), aliquots (0. 1 ml) Here tested directly on a 
cascade of isolated tissues (2.5 ml/min), consisting of a rabbit 
aorta strip (RAS), pretreated Hith phenoxybenzamine, a rat stomach 
strip (RSS) and a control rabbit aorta strip. The Krebs contained 
methysergide and phentolamine (see 3,3). The tissues were calibrat-
ed (G) with serotonin (SHT) and PGE 2 (E 2). 
5 
om 
~9ll~g~g:~g~~£~~-£~!~~~~-2f_fQ_~g~-!~2 . Qualitative examples of biolo-
gical activities, released by aggregating rat platelets, are shown in figures 
3.8, 4.2 and 4.4. PRP Has incubated Hith collagen and aliquots were tested 
on a cascade of isolated tissues. Fig. 4.2 shows that at 7 and 30 min after 
starting aggregation, both a stable PG-like activity (RSS) and SHT-like ac-
tivity(RA~ were present. Like PGE 2 , the former activity is completely trapped 
during passage through a small Amberlite XAD-2 column, whereas the latter be-
haves like SHT in being only partially trapped (Bult & Bonta, 1976a). 
During the aggregation (I min), an additional, labile rabbit aorta con-
tracting substance (RCS) is formed. RCS contracts the RAS in the presence of 
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phenoxybenzamine and is neither PGE 2 nor 5HT. RCS disappears within 6 min, 
thus behaving like TXA2 or PG endoperoxides. It is likely that both this la-
bile activity and PGE-like activity are oxygenated AA products, since TYA 
blocks their formation. It is \-Jorth noting that TYA in this high concentrat-
ion did not suppress the 5HT release (RAS, 7 min). The RCS, Hhich is not 5HT, 
MDA, ADP or hydro(per)oxy fatty acid (Bult & Bonta, 1976a) is probably TXA2 , 
because of the follmving characteristics: 
1, RCS was lipid-soluble, since it \Vas trapped by quick filtration through a 
small Amberlite XAD-2 column (Bult & Bonta, 1976a). 
2. The half-life (t 1 ) of RCS, after removal of platelets in order to avoid 
' de novo formation, was 32 ~ 6 s (5), whereas the half-life of PGH 2 in PPP 
was significantly longer (125 ~ 46 s (8), p <0.05, 'h1ilcoxon). In order to 
determine t ~ of TXA2 , the platelets were removed (1vithin 30 s) twenty s 
after addition of collagen, by filtration through a milipore filter (0.45 
"[lH pore size) under reduced pressure. Thereafter, aliquots were tested at 
different times (0, 20, 40, 80 s) on a cascade with 3 aorta strips and the 
t 1 values 
' 
were estimated from linear plots of the logarithms of rabbit 
aorta contractions against time. The t 1 of RCS 
' 
is identical to the t 1 of 
' TXA2 , generated by \vashed human platelets (see 120, and 2. 1). The estimat-
ed t 1 of PGB2 in plasma \Vas much shorter that the values obtained in buf-
' fer (120,189), This finding has been confirmed in human PRP (232). 
3. RCS stimulated the rabbit coeliac strip (see fig. 4.4). This tissue is not 
contracted either by PGH2 or by PGE 2 (47; Bult & Bonta, 1976b), whereas 
it is contracted by TXA2 (47). 
4. The appearance of RCS is inhibited by NaN3 , whereas PG-like (or PG endo-
peroxide-like) activities are unaffected (Bult & Bonta, 1976b). A similar 
result has been obtained \vith TXA2 synthetase inhibitor (172) imidazole 
(Vincent & Zijlstra, personal communication). 
These results confirm the suggestion that RCS is mainly composed of TXA2 
(120), although it has recently been reported that TXA2 has a longer t~ in 
human plasma (232), This discrepancy might be due to species differences or 
due to differences in the technique employed, since only the disappearance of 
biological activity was measured in the present study. 
The stable PG-like material (PGL) behaved like PGE 2 during differential 
bioassay on the rat stomach strip and rat colon. The high concentrations, ob-
tained by direct bioassay on the RSS (44 ~ 3 ng PGE/ml); see table 4.1) seem-
ed rather suspect since other reports indicated that citrated human PRP ge-
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nerated about 10 times less PGE 2 in response to collagen (eg. 227,232). The 
latter finding was confirmed: in 3 samples of citrated human PRP, stimulated 
\Vith collagen (67 1-lg/ml), 8.0, 4.5 and 4.8 ng PGE/ml were found, whereas PGE 
was undetectable (<2 ng PGE/ml) in 3 samples of aspirin pretreated (1 mg/ml) 
human PRP. In order to substantiate the results obtained by direct bioassay, 
the PGE of aggregated rat PRP was partially purified (see table 4.1). After 
extraction and column chromatography the major PG activity was indeed found 
in the PGE fraction. Moreover, like PGE 2 , its biological activity disappeared 
after heating (5 min, 100°C) in 0.1 N NaOH, Hhereas the activity of PGF 20'. did 
not. 
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Table 4.1. Generation of PGs by normal PRP: a comparison between 
direct bioassay and assay after extraction and column chromatography. 
Activity on RSS PPP 
n=S 
Direct PGE 2 (ng/ml) <5 
PGF la (ng/ml) <SO 
PGE 2 (ng) 
recovery ( 3H,%) 
PGE fraction 
(6% Methanol) 
PGE 2 (ng/ml) 
(15% Methanol) 
PGF 2 (ng) a 3 
recovery ( H, %) 
PGF fraction 
PGF2ct (ng/ml) 
PRP + 
3HPGEJ 
n:::5 
44 + 3 
23 + 3 
49 + 2 
46 + 6 
<5 + 
PRP + 
3HPGF2a. 
n=5 
>150 
19 + 2 
<4; 7 ** 
52 + 4 
<8; 3.5 ** 
Aggregation was induced by collagen (40 1-1g/ml, Smin). After addition 
of 3HPGE1 (77.000 dpm) or 3HPGF2o: (25.000 dpm) and centrifugation (30 
min, 900 G), an 0.1 ml aliquot of the supernatant Has bioassayed di-
rectly (cascade with 2 rat stomach strips and a rat colon, 2.5 ml/ 
min). A further 1.0 ml was extracted (using Amberlite XAD-2 columns) 
and added to silicagel columns (see 3.4). The fractions, eluted with 
6% and 15% methanol in chloroform, were used for bioassay. These sam-
ples were dried, 0.2 ml Krebs was added, and after mixing, 2 doses 
(0.02 and 0.1 ml) Here used for bioassay (cascade: see above), and 
0.01 ml (triplicate) was used for liquid scintillation counting in or-
der to determine the final recovery. 
* = 5 pooled fractions; ** 4 pooled fractions. 
The mean of the differences between direct assay and assay of the partially 
purified PGE compounds (- 3 ~ 5, n=5; calculated from data in table 4.1) was 
not significantly different from zero (p <0.05, paired Student's t-test). 
Thus, a PGE (probably E2) is the major contributor to the PGL observed with 
direct bioassay of aggregated rat PRP. 
The relationship bet\veen collagen concentrations and both PGE formation 
and aggregation are shmm in fig. 4.3. A linear regression Has calculated be-
tween the logarithm of the collagen dose and the amounts of PGE. Since the 
95% confidence limits of its slope do not include zero, a linear regression is 
present between 4 and 40 ug/ml. No correlation was found 
of aggregation and PGE formation (Spearman test, p >0.05). 
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Fig. 4.3. Influence of collagen concentration on aggregation (•) 
and PGE formation (o) by normal PRP. After incubation (5 min) the 
platelets were removed by centrifugation (30 min, 900 G). The pre-
sence of PGs in the supernatant was assessed by adding 0.05 and 
0.2 ml, cumulatively, to a cascade (2.5 ml/min) of 2 rat stomach 
strips and 1 rat colon. Cumulative doses of PGE2 and PGF2a served 
as standards. Since little PGF2a seemed to be present, the results 
are expressed as ng PGE2/ml, assessed on the 2 stomach strips. The 
mean value of the 4 estimations was calculated. PGE was undetect-
able in saline treated PRP (<5 ng/ml). Each point ~s the mean of 5 
incubations. 
a= 14.6; 95% confidence limits: -0.7<a<29.9. b= 17.2; 95% con-
fidence limits: 7.8<b<26.6. 
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Fig. 4.4. Qualitative comparison of the aggregation, and the release 
of different biological activities by PRP, stimulated with collagen 
(40 wg/rnl) or AA (0. 1 ~~). For collection of PRP and aggregation, 
see 4.3. Collagen and AA were added at zero time(+). The light trans-
mission was monitored as shown in the upper tracings (t). Samples 
(50 1Jl) of the incubations \.-rere added directly to a cascade (0.1 ml/ 
min) of superfused rat colon and rabbit coeliac artery strip, and to 
a second cascade (0. I ml/min) of superfused rabbit aorta and rat 
stomach strips, at 1, 7, and 15 min after the start of the aggregat-
ion. The differences in sensitivity of the tissues (especially the 
RCA and RC) is shown by test doses of PGE 2 and the 9,1 I epoxymethano 
analogue of PGH2 (9,11 EH). Thevertical bars represent I em. 
~~~:ig~~~~~-~~!~~~~-~f-~~~- A supra-maximal dose of ADP (25 ~M, cf. fig. 
4. 1) induced very little release of PGE in rat PRP. Five min after addition of 
either Tyrode or ADP, platelets were removed by centrifugation (30 min,900 G), 
and I ml tvas extracted (using XAD-2 columns, see 3.4). Extracts (n=5) were 
then tested for biological activity (2x RSS). Results (number of observations 
between brackets): Tyrode,<4 (5); ADP, 5.0+0.2 (3),<4 (2) ng PGE 2/ml. 
~:bg~~£~~-E~l~~~~-~!-~Q~· AA (0. 1 m}f) induced shape change without aggre-
gation, as shm,rn in fig. 4.4. However, PG endoperoxides had been formed, since 
RC, RAS, RSS and RCA were contracted. Several differences between collagen-
and AA-induced formation of biological activities appeared, With AA, more sta-
ble PGE was formed (RC and RSS, 15 min), but TXA2 concentrations seemed to be 
much lower (RCA, 1 min) and their formation seemed to be more prolonged and 
less explosive. Similar results, obtained in another experiment, are given in 
fig. 4.5. Again, in the absence of aggregation (0.1 m}1 AA) considerable PGE, 
but little TXA2 , was formed ~>.rhen compared with collagen-induced aggregation. 
Even if aggregation occurred (0.33 roM AA), the ratio between the activities 
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Fig. 4.5. Addition of collagen (40 1-lg/ml) or arachidonic acid (AA) to rat 
PRP led to different ratios betHeen TXA2 (--o--) and PGE (~). Their 
release was assessed on a cascade (0.1 ml/min) composed of rabbit coel-
iac artery strip (RCA, sensitive to TXA2) and a rat stomach strip (RSS, 
sensitive to PG endoperoxides and PGs) at different times after addit-
ion of collagen or AA. Results are expressed as ng PGE 2/ml (RSS) and 
ng 9,1 IEH/rnl (RCA). AA (0.1 rriM) did not induce aggregation. 
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on rabbit coeliac artery and rat stomach strip remained reversed (results not 
shown). 
In order to verify these observations, PRP was incubated with different 
14 
amounts of AA and a fixed amount of C-AA and the products were separated by 
TLC. TXB 2 has been reported to chromatograph between PGF2a and PGE 2 in the 
system used (Dr. D.H.Nugteren, Unilever Res., Vlaardingen, personal communi-
14 
cation; 158,178). Hith 0.1 m.:_"\.f AA, few C oxygenated products v1ere detectable 
(fig. 4.6), Hm.;rever, 1:vhen lysed PRP was incubated Hith 0.1 m}f AA, peaks ap-
peared at the expected TXB 2 site and a small amount of radioactivity co-chro-
matographed with PGE 2 . A similar pattern \Vas obtained if a higher (0.6 mM) 
concentration of i\A was used, which induced a small, reversible aggregation 
of the platelets. Both aggregation, and the appearance of radioactivity at 
TXB 2 and PGE sites, were blocked by indomathacin. Finally, less polar radioac-
tive products were formed. The solvent system used is not very suitable for 
the separation of hydroxyfatty acids, such as HHT and HETE (see 158), but the 
formation of the less polar products vas suppressed by indomathacin (28 JJM). 
Even in the presence of 0.6 mM AA, PRP produced few oxygenated products, since 
less than I% of all 14c AA 'i.;ras converted. 
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In similar experiments, both the biological activity and the radioactivity 
Table 4.2. Determination of lytic activity of AA. 
LDH (U /1) % n 
PPP 44 + 3 2.6 + 0.4 3 
PRP + saline 85 + I 0 4.9 + 0.7 3 
PRP + I mM AA 112 + 12 6.5 + 0.8 5 
Lysed platelets 1720 + 50 100 + 3 3 
Lactate dehydrogenase (LDH) Has measured in PPP, lysed PRP and PRP 
that had been incubated for 5 min with saline or AA (1 mM). PPP 'ivas 
prepared from PRP (7 x 108 pl/ml; 4.3). Lysed platelets vere obtain-
ed by resuspending the remaining platelet pellet in distilled water 
(0°C), in a volume equal to that of PPP. LDH was measured with a 
Monotest LDH opt, nr. 158186, Boehringer . The differences between 
incubations of PRP with saline or with 1 mH AA were not significant 
(Student's t-test, p >0.05). 
~20 
10 (cml 
Fig. 4.6. Stimulation of rat PRP with different concentrations of AA. 
Lower section: separation of radioactive products produced by PRP 
and lysed PRP in the presence of 0.1 mM AA. Middle section: reference 
spots of PGs and separation of radioactive products produced by PPP 
and PRP, with or without indomethacin (Hi), during incubation 'ivith 
0.6 mH AA. Top section: corresponding aggregation patterns. PRP (0.4 
ml, 2.4 x 108 cells) was preincubated (3 min) with saline (50 wl) or 
U1 (28 "f.!M). M (1.0 or 6.0 mH, 50 "f.ll, containing 7.4 x 10S dpm 14c-
AA) \Vas added and after 8 min the reactions were stopped by addition 
of IM (see 4.3). A sample of PRP was lysed ultrasonically (10 s) in 
the presence of 0.1 mM AA. The products were extracted, separated by 
TLC and radioactivity was determined in 0.5 ern silicagel strips (3.4 
& 3.6). Not shown: AA reference (13.5 em) and front (17.3 ern). TXB 2 
moves between PGF2a CF2a) and PGE2 (E2) in this solvent system. D2: 
standard of PGD2. 
were measured in the silicagel fractions. Moreover, tritiated PGF2a and PGE 1 
were added as internal standards. An example is shown in fig. 4.7. After in-
cub at ion of PRP with 0. I m~ AA some biological activity was found at the PGE 2/ 
b 14c a· ·· a bl ·h a fAA(06 PGD 2 site, 
lTh'vf) did not 
ut ra 1oact1Vlty was un etecta e. A h1g er ose o . 
cause aggregation of the PRP (not shown), but small 14c peaks 
appeared in the PGE 2/PGD 2 region and the TXB 2 region. The peaks were of about 
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equal heights. As expected, a larger amount of PGE 2 was measured by bioassay 
(RSS), In some other experiments relatively more PGF-like activity \vas found 
to be present. In the fraction, which contained the peak of tritiated PGE 1 
marker, the amount of PGE2-like activity 1:vas I .5 ng. According to the amount 14 
of C dpm, approximately 9 ng was to be expected. The reason for this dis-
crepancy between the calculated and the estimated amounts of PGE 2-like acti-
vity is unclear at this moment. 
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'hlhen collagen was used to aggregate PRP, which was preincubated 1:vith 
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Fig. 4.7. Formation of AA-derived biologically active and radioactive 
products by rat PRP, stimulated with collagen (40 ~g/ml) or AA (0.1 
and 0.6 m:i). In the examples shmm, no aggregation occurred with 0.1 
and 0.6 mM AA. PRP (0.4 ml, 0.29 x ]09 cells) Has preincubated with 
saline (0.05 ml) or 14c-AA (1 .2 x 106 dpm). After 3 min, AA (0.05 ml, 
I and 6 mM with 1.0 x 106 dpm 14c-AA) was added to the saline-prein-
cubated samples. Collagen (0.05 ml, 0.4 mg/ml) was added to 14c-AA-
preincubated samples. After 8 min, indomethacin (28 11H) \vas added, 
together \Vith 3.6 x 10 4 dpm 3H-PGE] and 14.4 x 104 dpm 3H-PGF 2 . Af-
ter extraction and separation by TLC, both radioactivity (dpm ?4c= e, 
dpm 3H= ) and biological activity (--o--) were determined in 0.5 em 
fractions (see 3.4 & 3.6). Biological activity Has determined on a 
OA 
0.2 
RSS (0. 1 ml/min) and expressed as ng PGE2/fraction (see 3.4) The spots 
refer to references of PGE2 CE2), PGD2 (D2), PGF2a (F2a) and AA on the 
same plate. TXB2 moves between F2a and E2 in this solvent system. 
14
c-AA, the ratio between the 14 c peaks at the TXB 2 and PGE 2 sites, was shift-
ed towards the thromboxane path\vay. This confirmed the results obtained by 
direct bioassay. Again biological activity was found at the PGE 2 site. Hhen 
compared v.rith the samples that were stimulated 1:vith exogenous AA, the amounts 
of less polar radioactive products were higher 1:vhen PRP >vas stimulated with 
collagen. 
It is unlikely that AA-induced lysis of the platelets, since significant 
leakage of the cytoplasmic marker, lactate dehydrogenase (LDH), Has not ob-
served -.vith AA upto 1 mH AA (as shown in table 4.2). Addition of the lys2d 
platelet ureparation (see table 4.2) to PRP at a final concentration of 16%, 
failed to induce aggregation. Finally, the AA-induced aggregation in PRP was 
inhibited by indomethacin (28 ]JH), whereas ADP-induced aggregation >vas not 
suppressed at this concentration of indomethacin (see table 4.6). These re-
sults ruled out the possibility that AA-induced aggregation was due to ADP, 
that had been liberated from lysed platelets. 
4.4.2. Influence of EFA deficiency on rat platelet behaviour. 
A fatty acid analysis gives the best indication of EFA deficiency. For 
practical reasons the fatty acid spectrum of normal and EFAD rats was deter-
mined in erythrocytes, and not in platelets. The erythrocyteS of 4 norma] and 
4 EFAD rats were used for a fatty acid analysis, as shov.m in table 4.3 . 
Table 4.3. Fatty acid composition of total lipids from normal and 
EFAD rat erythrocytes. 
Fatty acid Normal EFAD 
% •veight % weight 
16:0 29.8 + 1. 3 28.9 + 0.9 
18:0 20.0 + 1. 5 17.5 + 2. I 
18:1' n-9 10.2 + 1.1 19.8 + 0. 7 
18:2' n-6 7.6 + 0.7 0.8 + 0.04 
20:3, n-6 0.2 + 0.04 tr. 
20:3, n-9 tr. 8.7 + 0.9 
20:4, n-6 IS. 6 + 1. 7 4.5 + 0.6 
The fatty acid analysis was performed as described in 3.6. 
tr.: trace ( < 0.1%). Each value is the mean of 4 rats. 
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The linoleic acid family (n-6) was decreased in favour of the oleic acid (n-9) 
family in EFAD cells, although a residual percentage of AA (24%) was still 
present. 
Aggregation, induced by several stimuli, 1vas measured in both normal and 
EFAD PRP (table 4.4). The PG endoperoxide PGH2 gave small, but equal responses 
in both types of PRP. Preincubation of PRP with a high concentration of lino-
leic acid, in order to suppress binding of PGH2 by albumin, did not result in 
enhanced aggregation. This enormous linoleic acid concentration did not in-
fluence the shape of platelets in either type of PRP. Huch smaller doses of 
AA induced an indomethacin-resistant swelling (cf. fig. 4.1). No significant 
differences were observed between EFAD and normal PRP in any condition 
(p > Q.OS, one way analysis of variance ; ANOVA). 
ADP induced equal aggregation in normal and EFAD PRP, except for the 
lowest dose, when EFAD PRP aggregated less than normal PRP. EFA deficiency did 
Table 4.4. Comparison between aggregatory capacity of normal and 
EFAD PRP. 
Normal PRP EFAD PRP 
Aggregation inducer % aggregation % aggregation 
PGH2 "g/ml 25.0 + 5.5 (4) 17.9 + 4.0 (3) 
LA(IOmM) + PGH2 )Jg/ml 14.7 + 4.3 (3) 15.5 + 2.7 (3) 
ADP 2.50 "M 95.7 + 2.6 ( 5) 90.8 + I .5 (5) 
0.80 uM 76.9 + 5.4 (5) 75.7 + 3.9 (5) 
0. 25 "M 25.9 + 3.0 ( 5) 14.5 + 2.4 (5) + 
collagen 40 "g/ml 95.2 + I. 6 (5) 95.3 + I. 6 (5) 
4 n/ml 53.6 +10.3 (5) 3. I + I. 5 (5) .. 
PRP (200 )Jl) was preincubated (for 3 min at 37°C) with 25 JJl 
Tyrode or with 25 )Jl Tyrode containing 100 mM linoleic acid (LA), 
and aggregation was started by addition of 25 wl inducer. Results 
are expressed as percentages of maximal aggregation, induced by 
40 wM ADP, added in 10 wl at 5 min after starting aggregation. 
AKOVA of PGHz effects: Fo(3,12)= 1.11, Fo. 95 (3,12)= 8.74, p>0.05. 
!IE= p < 0.05, **"" p < 0.01 (Wilcoxon test, tHo-sided, EFAD vs normal). 
not alter the aggregating efficiency of high collagen doses (40 wg/ml), but 
almost completely (94%) prevented the aggregation induced by a dose giving 
approximately an half maximal response in normal PRP. 
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Fig. 4.8. Time courses of aggregation and generation of TXA2, PG 
endoperoxides and PGE by normal (--.--) and EFAD (--o--) PRP, ag-
gregating after addition of collagen (40 ~g/ml, arrow). Aliquots 
(0. 1 ml) were added directly to superfused (2.5 ml/min) strips of 
rabbit aorta and rat stomach. The upper part shm.;rs an aggregation 
pattern, together Hith release of TXA 2 (expressed as "Cnits/rnl; 1 
Unit= 1 ng PGH2). The lower part shows rat stomach contractions, 
calibrated with PGE2. Unless otherwise indicated each point re-
presents the mean of 4 observations. 
EFAD PRP, stimulated with high doses of collagen, formed far less TXA2 
(84% reduction at 1 min) and less PGE (75% reduction at 7 min, 89% reduct-
ion at 120 min) than normal PRP. These data were obtained by direct bioassay 
of TXA2 and PG release, assessed on RAS and RSS, as shown in fig. 4.8. Bio-
logical activities were not detectable during preincubation. At 20 s after 
the addition of collagen, \.Jhen aggregation was starting, TXA2 was almost 
maximally generated by normal PRP. TXA2 levels were unaltered at 30 s 
light transmission increased steeply. At 1 min, when aggregation was complet-
ed for 75%, TXA2 Has already disappearing and when maximal aggregation \.Jas 
observed (3 min), hardly any TXA2 was detectable. EFAD PRP generated only 
16% of the TXA2 released by normal PRP, but aggregation of EFAD PRP was un-
altered with this high (40 vg/rnl) dose of collagen (see also table 4.4). The 
contractions of the RSS showed a similar pattern, but a residual, stable PGE 
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was observed (7 min, !20 min). The generation of PGE by EFAD PRP was markedly 
suppressed. The initial peak of RSS-stimulating activity was possibly composed 
of a mixture of PG-endoperoxides. 
Finally, the cyclo-oxygeanse activity of both types of PRP was tested in 
the presence of exogenous AA (fig. 4.9). Normal PRP generated increasing a-
9 
mounts of PGE (assessed on a RSS, and expressed as ng PGE 2/l0 platelets) 
when increasing concentrations of AA were added. Since PGE was assessed at 7 
min after addition of AA, it might be partly composed of PC endoperoxides, due 
to the fact that PG production seemed to be more prolonged when platelets were 
stimulated with exogenous AA (fig.4.4). A relatively high concentration of 
indomethacin inhibited the PGE production in the presence of 0.66 mM AA. 
EFAD PRP generated as much as PGE as normal PRP, when incubated with 0.33 mM 
AA. In similar experiments }IDA production was measured in both types of PRP. 
Like the release of TXA2 , MDA formation needed higher concentrations of AA. 
The data represent the net MDA formation by platelets, since the extinction 
measurements were corrected for incubations \vith PPP. 
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Fig. 4.9. Comparison of cycle-oxygenase activity in normal (__.__) 
and EFAD PRP (--o--). After preincubation (3 min), PRP was exposed 
to different concentrations of AA. The amount of biological activi-
ty \Vas assayed on rat stomach strips, 7 min after starting the ag-
gregation. Although this activity probably consisted of a mixture 
of stable PGs and PG endoperoxides (see time curve in fig. 4.4) it 
is expressed as nmol PGE2/10 9 platelets. PGE was also measured in 
the presence of l .38 mM indomethacin (IM). In a separate experi-
ment MDA was measured as described in the text (3.5). 
No differences were observed between normal and EFAD PRP with respect to MDA 
production. Thus, the reduced endogenous generation of PG endoperoxides (and 
PGE) and TXA2 by EFAD PRP is not due to a diminished cyclo-oxygenase activity. 
Finally, high doses of collagen induced an equal release of SHT-like ma-
terial from both normal and EFAD PRP (table 4.5). Significant differences 
were not observed at 7 min 
RSS). An unimpaired release 
(assessed on RAS), nor at 120 min (assessed on 
14 
of C labelled 5HT by EFAD PRP, in response to 
high doses of collagen, has been described previously (260). Therefore, the 
above findings were not further substantiated by a fluorimetric assay. 
Table 4.5. Direct bioassay of 5HT-like material, released from nor-
mal and EFAD PRP during collagen (40 1Jg/ml) induced aggregation. 
Tissue Time Normal PRP EFAD PRP 
min "g SHT/ml (n) "g SHT/ml(n) 
RSS 120 0.32 + 0.05 ( 6) 0.21 + 0.07 (4) 
RAS 7 0.46 + 0.06 ( 5) 0.43 + 0.07 (4) 
Small aliquots of aggregated PRP (5-10 lJl) were added to a superfu-
sed (2.5 ml/min, Krebs without methysergide) RSS. In this way, PGE 
was diluted too much to cause any contraction by itself. The acti-
vities on the RAS (2.5 ml/min, without phenoxybenzamine) were as-
sessed after disappearance of TXA2 in 0.1 ml aggregated PRP. Hith 
both methods, no statistical differences were found between EFAD 
and normal PRP (p> 0.05, Student's t-test). 
4.4.3. Effects of drugs on platelet aggregation and PG biosynthesis. 
IC50 values for TYA and indomethacin are given in table 4.6. Indomethacin 
was more potent than TYA as an inhibitor of endogenous TXA2 and PGE product-
ion. Both drugs were equally active against TXA2 and PGE release. Doses of 
indomethacin, which suppressed endogenous TXA2 and PGE release by 50%, also 
produced half-maximal inhibition of aggregation induced by a threshold dose 
of collagen. This threshold dose of collagen (2 1Jg/ml) produced approximately 
50% aggregation in normal PRP. Indomethacin (upto 200 1JM) failed to suppress 
a:;gregation induced by a dose of ADP (D.lllH)that produced 50% aggregation. 
Finally, indomethacin did interfere with MDA production by AA stimulated 
PRP. 
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Table 4.6. Inhibitory effects of indomethacin and TYA in PRP. 
Effect Inducer Indomethacin TYA 
IC50 ( "'!) (n) IC50 ("M) (n) 
TXA2 (I min) Col., 40 "f.lg/ml 5.5 + I. 0 ( 8) 61.2 + 8.6 (5) 
PGE (7 min) 
" 
8.2 + 1. 4 ( 7) 53.2 + 5. I (5) 
Aggregation Col., 2 "g/ml 5.5 + I. 5 (5) 
Aggregation ADP, 0. I "M > 200 (3) 
MDA (5 min) AA, mM 5.0 + I. 5 ( 5) 
PRP was at random preincubated (3 min) >vith Tyrode or Tyrode containing 
5 to 6 different concentrations of drugs, and then exposed to the induc-
ers of aggregation. The rc50 'ivas estimated from linear plot'> of response 
vs log (dose of inhibitor). The number of estimated IC50 values is given 
(n). The following effects were measured: the release of TXA2 (at 1 min, 
mm contraction of superfused RAS, 2.5 ml/min, induced by 0.1 ml PRP), the 
release of PGE (at 7 min,ng PGE0/0. I ml, assessed on superfused RSS, 2.5 
ml/rnin), release of MDA (see 3.5) and percent maximal aggregation (see 
4.3). Release of TXA2 and PGE was determined in the same incubations. ICso 
values of both TYA and indomethacin against TXA2 and PGE formation show-
ed no statistical differences(p > 0.05, Paired Student's t-test). Col.: col-
lagen. 
TYA and indomethacin had little effect on release of SHT and aggreation 
induced by high doses of collagen. TYA (310 "f.!M) then inhibited the release of 
TXA2 by 89 %, but release of 5HT was unaltered ( see Bult and Bonta, 1977c and 
fig. 4.2). Indomethacin (152 "f.!~) completely blocked T:{A2 and PGE production, 
while the release of SHT \vas only inhibited by 50%. 
Finally, table 4.7 demonstrates the inhibitory effects of imidazole on 
MDA production and platelet aggregation. The two inhibitory effects appeared 
to parallel one another. 
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Table 4.7. Imidazole inhibits aggregation and release of MDA by PRP. 
Saline 
Imidazole 
Aggregation % 
I 00 (2) 
17 + ( 2) 
3.84 + 0.15 (7) 
0.96+0.11 (7) 
% 
100 + 4 
25 + 3 
PRP \vas preincubated (3 min, 37°C, 900 rpm) Hith either saline or 
imidazole (100 "f.lg/ml). Aggregation Has induced by 1 mM AA and "MDA 
production was measured as described in the text (3.6). 
4.5. Discussion. 
Collagen caused aggregation of rat platelets in PRP, with concomitant re-
lease of MDA, PG-like material (PGL) and RCS. MDA, PGL and RCS production 
were suppressed by cycle-oxygenase inhibitors, like indomethacin and TYA. The 
biological properties of RCS are in agreement with those of TXA2 , as discuss-
ed in 4.4.1. Since PGF 2a , PGD2 and other AA metabolites are much less ac-
tive than PGE 2 on the RSS (see fig. 3.5), it is likely that PGE compounds 
were the main contributors to the stable PGL, observed on the RSS during di-
rect assay of aggregated PRP. Indeed, PGL cochromatographed with PGE 2 (and 3H-PGE 1) on TLC plates and was eluted with 
3H-PGE 1 from silicagel columns. 
Unlike PGF 2a' it lost its activity during treatment Hith NaOH. Because of 
these characteristics it was assumed to be PGE. 
PGE formation by rat PRP is dependent on the dose of collagen. Collagen 
enhances AA release from human and rabbit platelets, and free AA is almost 
completely oxygenated (20,25,225). Therefore, the enhanced PGE formation with 
increasing doses of collagen is most likely due to an increased availability 
of AA. The finding that PGE is the major classical PG formed during aggregat-
ion with collagen, is consistent with observations in human PRP. 
The amounts of PGE, released by collagen, are higher in heparinized rat 
PRP (approximately 50 ng PGE/ml) than in citrated human PRP (less than 10 ng 
PGE/ml). The results with human PRP were in agreement with other reports 
(eg. 231). The discrepancy in release of PGE by human and rat PRP may be ex-
plained in several \-Jays, such as species differences, differences in platelet 
number, and in anticoagulant used and finally, the collagen concentration may 
directly influence the release of PGE (see above). It seems unlikely that the 
direct bioassay was inaccurate, since partial purification of PGE yielded si-
milar data as direct assay (table 4. 1). Moreover, following separation by TLC, 
relatively high amounts of endogenous PGE Here again detected in collagen 
aggregated rat PRP. 
It is possible that the anticoagulant may have influenced platelet activi-
ty and subsequent PG release. In other studies citrated PRP has often been 
used, which ,,Tas not the case in the present Hark. In one report (Dray et al., 
1976), plasma and serum PGE 2 levels (ng/ml; radioimmunoassay) in humans and 
rats have been compared: Human plasma: 0.005, rat plasma: 0.107; human serum: 
0.60, rat serum: 3.35. Since serum PGs are probably formed by thrombin-sti-
mulated platel~ts, these data indicate that rat platelets also formed more 
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PGE 2 ~n the absence of any anticoagulant. At least a part of the difference 
is probably explained by a higher number of platelets in rat PRP and rat blood 
(21). Moreover, rat platelets tend to be larger, judged from the optimal set-
tings of the Coulter counter. 
At the start of the aggregation induced by a high dose of collagen, there 
\.Jas a peak of TXA2 , which had already tapered off before maximal aggregation 
was reached (fig. 4.8). Only during aggregation with threshold doses of col-
lagen did the cycle-oxygenase products seem to be important for rat platelet 
behaviour. Under these conditions EFA deficiency markedly reduced aggregation 
(table 4.4) and indomethacin suppressed aggregation by 50% in doses that also 
caused a half-maximal inhibition of PGE and TXA2 production (table 4.6). 
These ICSO values \.Jere obtained after 3 min preincubation. A shorter prein-
cubation (1 min), resulted in higher ICSO values (data not sho~~), which 
might be explained by the irreversible nature of NSAID action (see 2.2.2). 
The free levels of the inhibitors were probably much lmver (159). 
Thus, threshold doses of collagen almost entirely failed to aggregate 
EFAD PRP, which released only limited amounts of PGE and TXA2 (fig. 4.8). 
Unfortunately, the AA levels in platelets were not determined in this study, 
but erythrocytes of EFAD rats sho•ved a marked reduction of AA. Since both 
cell-types are derived of bone-marrow, a similar pattern is expectable in 
EFAD platelets. It is likely that the reduction in EFAD platelets is even 
greater than in erythrocytes, since their turnover is higher. Haddeman and 
Hornstra (1974) measured AA in platelet lipids and observed about 93% reduct-
ion in EFAD platelets and a diminished collagen-induced aggregatio~ Cycle-oxy-
genase activity and sensitivity to PGH2 were unaltered in EFAD platelets~ig4.9) 
Higher collagen doses induced aggregation and release reaction I in rat 
PRP, independently of the AA-derived products (table 4.5). The doses of in-
domethacin needed for inhibition of aggregation with higher collagen doses, 
are about 100 times higher (260) than those required for inhibition of PG 
synthesis, and other mechanisms must be involved. This is reinforced by the 
observation that the ICSO of indomethacin against aggregation by EFAD plate-
lets is over 0.02 M, whereas an increased sensitivity of EFAD PRP is to be ex-
pected when cycle-oxygenase products are necessary for aggregation with high 
doses of collagen (260). The mechanisms of aggregation by "high" doses of Col-
lagen are unclear as yet, but it is unlikely that a residual release of PG-
endoperoxides, during EFA deficiency or in the presence of high doses of 
NSAIDs is responsible for a normal release reaction and aggregation by high 
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doses of collagen. }-foreover, \Vhen rat PRP Has incubated with exogenous AA, in 
loH concentrations, a reproducible formation of PGs was observed without ag-
gregation. This implies that rat PRP can form PG endoperoxides from exogenous 
AA without subsequent aggregation. Similar results have been obtained in dog 
PRP (55). Besides, only limited aggregation was observed 'ivith high doses of 
PGH2 (1 lJg/ml). The doses of endoperoxide needed for maximal aggregation of 
human PRP are below 0.5 vg/ml (1 16, 120). Finally, 9,11 EM, an endoperoxide 
analogue, failed to induce aggregation, Hhereas 200 ng/ml results in complete 
aggregation of human PRP (Malmsten, 1976). All these experiments indicate 
that rat platelets are less sensitive to exogenous PC endoperoxides than hu-
man platelets. 
During stimulation of rat PRP with AA, in doses which failed to aggregate 
platelets, there Has very little TXA2 synthesis. In comparison 'ivith the endo-
genous formation, the ratio betHeen PGE and TXA2 was shifted towards the for-
mer. Higher doses of AA induced an indomethacin (28 lJM) - sensitive aggregat-
ion. These doses were higher than those required in rabbit (max. aggregation 
at 60 ~M) or human PRP (max. aggregation with 500 lJ}f; 259), but the AA-induc-
ed aggregation showed daily variations in rat PRP. This is possibly explained 
by variations in binding of AA plasma proteins. Aggregation was accompanied 
by the appearance of TXA2 , although its ratio towards PGE was still different 
from that obtained with endogenous release. Preloading of the PRP with lino-
leic acid resulted in enhanced formation of TXA2 (results of 3 experiments, 
not shown here). The release of TXA2 also tented to be longer than the explo-
sive, endogenous generation. Thus, the total synthesis of TXA2 could be 
greater than that expected from the direct bioassay, 'ivhich might also be in-
accurate due to interference with substances other than PGs, TXA 2 , ADP and 
SHT. Horeover, since TXA2 can not be quantified by bioassay the same experi-
. 14 
ments Y-Tere repeated 'inth C AA. TXB 2 and PGs Here separated by TLC, and their 
formation was followed by measuring radioactivity. The RF values of PGF 2a 
(0. 12), PGE 2 (0.27), PGD 2 (0.29) and A.._t,_ (0. 73) were somewhat lmver than those 
given by Nugteren & Hazelhof (1973). After aggregation, radioactive products 
Here detected Hhich behaved like TXB 2 , PGE 2 and/or PGD 2 . Their appearance, 
as Hell as that of some less polar products, was inhibited by indomethacin. 
Thus, these peaks were due to cyclo-oxygenase activity, and not to co-chro-
matography of AA 'ivith phospholipids or other materials. 
The results thus obtained supported the previous, bioassay findings that 
rat platelets formed larger amounts of PGE
2
, tvhen compared Hith t.mshed human 
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platelets (1 17 ,119) and that the formation of TXB 2 only became important if 
aggregation took place. Since PRP, instead of a washed cell suspension was 
used, the results do not permit a direct comparison with most other papers. 
In PRP, the platelets were probably less damaged, but it had the disadvantage 
that only very little AA was oxygenated. Moreover, in contrast to other pa-
pers, the biosynthesis of oxygenated products \vas also monitored in the pre-
sence of doses of AA that did not elicit aggregation. 
!~~-~~~~~~~~!~-f~~~~!i~~-£f_~Q~2 . Although no 14c PGE 2/PGD2 spots were 
detectable after incubation of PRP tvith 0. I rnM AA, the more sensitive laminar 
flm..r bioassay indicated the presence of PGE 2 . During lysis the conversion of 
.1. d d 14 14 free AA Has fascl ltate an both C-PGE 2 and C-TXB 2 became detectable. 
After aggregation, either with collagen or with 0.6 mH AA, a higher TXB 2 peak 
appeared, but in contrast to results with human platelet suspensions, it was 
not 100 times as high as the PGE 2 peak (I 17). A similar finding has recently 
been described. Microsomal preparations from rat platelets produced consider-
ably less TXB 2 than similar preparations from either human (Dr. Helen hTiite, 
Wellcome Res., N.C., U.S.A. personal communication) or guinea pig (S.Abrahams 
et al., 1977) platelets. Thus, the TXA 2 synthetase pathway seems less predomi-
nant in rat platelets and as a result, more classical PGs appear. 
~g~ 2_f~~~~~i~~-~~-~h~-~~~~~£~-~f-~~g~~g~~i~~· If no aggregation occurred, 
even less TXB 2 was fanned (eg. see fig. 4. 7). This confirmed the bioassay re-
sults showing that the ration TXA/PGE was reversed when 0. l mH AA, instead 
of collagen, Has used to stimulate PRP. Thus, exogenous AA can lead to even 
more predominant PGE production. This observation may be explained in several 
ways. It is possible that rat platelet TXA2 syochetase has a low affinity for 
PG endoperoxides, or that the subcellular sites of some of the cycle-oxygenase 
enzymes are not completely identical to that of the PGH2-rXA2 isomerase. Hotv-
ever, experiments with Hashed rat platelets are necessary to substantiate the 
finding that the TXA2/PGE ratio was reversed \Vhen exogenous AA was used to 
stimulate the platelets. 
Whichever explanation is correct, the experiments indicated that stimu-
lation of intact, non-lysed platelets 1:vith exogenous AA, failed to mimick all 
events that take place during collagen-induced aggregation in PRP. This 1:vas 
more or less to be expected. Even if all endogenous AA is derived from the 
plasma-membrane (which is not yet known), it does come from those phospholi-
pids (eg. Blackwell et al., 1977) that are predominantly present at the in-
side of the platelet plasma-membrane (54,244). Thus, exogenous AA first has 
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to penetrate to the inside of the platelet in order to become equivalent to 
the endogenous cycle-oxygenase substrate. In PRP a considerable amount of ex-
ogenous AA, or exogenous PGH2 (178) will never reach platelet cycle-oxygenase 
or TXA 2 synthetase, due to the fact that it is trapped by albumin. Aggregation, 
induced by exogenous AA, coincided \vith TXA2 formation. Thus, it is likely 
that TXA2 is the aggregation-inducing substance, either directly or after in-
duction of the release of ADP. The importance of TXA 2 is also indicated 
by the finding that imidazole, an inhibitor of PGH2-TXA2 isomerase (168), in-
hibits aggregation and also HDA release (and TXA2 release, bioassayed on rab-
bit coeliac artery; J.E.Vincent and F.J.Zijlstra, personal communication). 
The experiment with imidazole supported the suggestion that in platelets MDA 
is derived to a large extent from TXA2 (1 1 1). 
ADP induced aggregation in rat PRP independently of cycle-oxygenase pro-
ducts. During aggregation induced by a high dose of ADP, very little PGE was 
released. Horeover, for the inhibition of aggregation by threshold doses of 
ADP, enormous concentrations of indomethacin (above 0.1 mH) were needed. 
Abrahams et al., (1977) and Haddernan & Hornstra (1974) carne to similar con-
clusions in citrated rat PRP. Apparently rat platelets, which display only 
a single wave of aggregation, lack the aspirin sensitive secondary aggregat-
ion of human platelets. However, EFA deficiency led to reduced aggregation 
induced by threshold doses of ADP. The difference was less prominent than in 
collagen-induced aggregation, and might be due to membrane alterations, but 
no evidence was obtained for this suggestion. 
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5. THE PRESENCE OF PROSTAGLANDINS IN CARRAGEENIN-INDUCED HIND PAW EDEMA. 
5.1. Abstract. 
Release of prostaglandin-like material (PGL) during the development of 
carrageenin-induced pedal edema (CAR edema) was demonstrated with a perfusion 
technique. The release of PGL, Hhich was already detectable after hour, was 
not due to an experimental artefact. These findings have been confirmed in 
more quantitative experiments. Both indomethacin (2.5 mg/kg) and EFA deficien-
cy reduced the release of PGL in CAR edema. A parallel decrease in swelling 
was also observed. This supports the suggestion that an endogenous cycle-
oxygenase product, formed during CAR edema, has a pro-inflammatory activity 
in the early phase of this model of acute inflammation. 
5.2. Introduction. 
Carrageenin-induced pedal edema (CAR edema) is one of the most frequently 
used acute anti-inflammatory models. Reliable measurements of the mediators 
thought to be involved are scarce (see 2.5). Thus, the widely accepted hypo-
thesis (DiRosa et al., 1971) that PGs are involved in this edema from 3 h 
onwards, has never been supported by data on local levels of PGs, since in 
Willis 1 (1969) report, neither saline control values nor data on the time of 
collection were given. In order to substantiate PG mediation, attempts were 
undertaken to detect PGs in CAR edema under carefully controlled conditions. 
In spite of the fact that CAR-induced pleurisy is a more suitable model 
for quantitative measurements of mediators in edema fluid, the pedal edema 
was chosen for the follm..ring reasons: 
1, It is far more widely used than CAR pleurisy for the assessment of the 
anti-inflammatory activities of drugs. 
2. It is still used as a model for the evaluation of the roles of mediators 
in an acute inflammatory reaction (eg. Moncada et al., 1973). The results 
thus obtained, are often extrapolated to inflammation in general, although 
the validity of such extrapolations is questionable. 
3. It differs from the pleurisy model in some pharmacological respects, es-
pecially during its initial phase (Vinegar et al., 1976 .). 
The collection of exudate is a technical problem, which prevented most 
authors from investigating mediator levels during CAR edema. In these studies 
so 
an old perfusion technique, first described by Rocha e Silva & Antonio (1960) 
was used. The method was modified for later experiments, which permitted a 
quantification of the efficiency of the perfusion. Since anaesthesia might 
interfere \Vith the development of CAR edema, the rats Here anaesthetized just 
before the start of the perfusion. Hith this method, the effects of EFA de-
ficiency and indomethacin treatment were investigated. 
5.3. Nethods. 
5.3.1. Perfusion method 1 (see fig. 5.1.). 
Male Wistar rats (180-250 g) were randomized and anaesthetized with ure-
thane (25%)-chloralose (2%) and fixed on a warming apparatus (37°C). Poly-
thene cannulae (diameter= 3 mm) were inserted, subcutaneously, through a 
small incision in the lateral skin of the tarsus and pushed into the subplan-
tar region (see fig. 5.1). Perfusion of the paw with 6% dextran, in sterile, 
"=====1'\='"...- device to fix inner ond outer hind paw 
1\ 11 polythene tub'1ngs / 
~~U~w.···~,,o,=~,.~ .. 
immersed in ice x =pOint to Inject 
cold water 
Fig. 5.1. Coaxial perfusion method (after Rocha e Silva, 1960). The 
anaesthetized rats \Vere fixed on a warming apparatus (37°C). After 
insertion of the cannulae, sterile saline, at 37°C was supplied to 
the inner cannula using an infuse system. The extension of the inner 
cannula (A mm) was adjusted with the device shown left. 
pyrogen-free salin~was performed via an inner cannula (diameter I mm) that 
protruded~ 3mmbeyond the outer cannula into the subcutaneous space. The in-
fused fluid l.Jas collected through the outer cannula. The first perfusate (30 
min, 4ml/h) \.Jas discarded. Then, the perfusion was continued (30 min, 2 ml/h) 
in order to obtain basal levehof mediators. Thereafter, either CAR (I mg) or 
0.1 ml saline was injected into the foot (see 3.2). At different times after 
injection of saline or CAR the perfusion was again started for 30 min (2mVh). 
Perfusates Here collected in siliconized tubes on ice. 
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Biological activities in the perfusates were assessed directly on a cas-
cade (2.5 ml/min) of 2 rat stomach strips. Hethysergide \Vas omitted from the 
Krebs and introduced into the Krebs superfusing the lower tissue (see 3.3). 
The rats were anaesthetized during the development of the edema, in contrast 
to method 2. 
5.3.2. Perfusion method 2. 
For later experiments an improved technique was used. Randomized normal 
and EFAD (see 3.1) male Wistar rats (180-220 g) were injected intravenously 
serum albumin (The Radio Chemical Centre, Amersham). . 0 . 125 h w~th . 1 vCl I- uman 
Their hindpmvs were then injected with one of the two treatments: saline (0.1 
ml) in one paw only, or CAR (I mg) in one paw and saline in the contralateral 
paw. Perfusion was started 4h after these injections, at a flow rate of Sml/h. 
!~~~~!!~~i£~-£~-~b~-~~~~~!~~· Only one paw, either CAR- or saline-treated, 
1A7as perfused and three different protocols \Vere used: 
A. The rats Here anaesthetized with pentobarbitone (200 mg/kg), 3.75h after 
injection of the irritants. The stainless steel cannulae (see fig. 5.2) 
were then inserted and the perfusion \Vas started (at 4h). 
B. The rats ,,,ere anaesthetized (see A) and indomethacin (5 mg/kg, i.v.) \vas 
then administered, 5 min before installation of the cannulae and the per-
fusion was started (at 4h) , 
C. The rats >vere anaesthetized (see A), and killed (ether) 5 min before the 
installation of the cannulae and perfusion 1A'3S started (at 4h). 
T>vo different stainless steel, outer cannulae were employed, 'ivith different 
diameters (I. I, and 2.0 mm). The inner cannulae consisted of a polythene 
tube, which was secured with flexible tygonR tubing around the outer tube 
(see fig. 5.2). The tubes were discarded after use and the stainless steel 
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Fig. 5.2. Schematic dra'iving of the cannulae used in perfusion 
method 2. U1: indomethacin. 
cylinders were cleaned by ultrasonication in a detergent solution, washed se-
veral times 'ivith tap and distilled vmter, acetone and ethanol, dried and fi-
nally siliconized. 
Krebs, containing 28 )J'YI indomethacin (IH), V..1as used as the perfusion 
fluid, and perfusated were collected on ice, prior to extraction (see below). 
The follmving parameters 'ivere measured: 
In vivo: 
1. Paw diameter at Oh and 4h (see 3.2). 
2. 1251-radioactivity in inflamed pmv and the contralateral control paw 
(at 4h). In order to measure radioactivity, the paws Here placed in a 
fixed position under a gamma scintillation counter (Berthold, type 52 
20/20 H, Wildbad, GFR) connected to a rate meter-integrator (Berthold, 
type LB 241 K, Wildbad, GFR). The counting efficiency Has 37%. D. dpm 
(difference between control and treated paw) gives the amount of 1251 
albumin exudation. Percent exudation was calculated as ( 6 dpm/dpm 
control pa'iv) x 100. 
In perfusates: 
3. Volume (ml). 
4. Protein content in 0.1 ml, according to Lovry et al. (1971). Bovine 
serum albumin was used as standard. 
5. Radioactivity (dprn) in 0.1 ml \Vas determined with an automatic gamma 
counting system (Nuclear Chicago,1185 Series). The average counting 
efficiency \vas 67%. The recovery of 1251 albumin from the exudate was 
calculated as{dpm/6 dpm (in vivo)} x 100xvolurnex 10. 
6. Theperfusates 'ivere extracted (3.4) and PG-like activity (PGL) 'ivas bioas-
sayed on a cascade of RSS and RC (0. l ml/min), and expressed as ng 
PGE 2 . The values were uncorrected for recovery (recovery of 
3H-PGE 1 
91~2%,16). 
After removal of cannulae and killing the rats: 
7. Paw weights (see 3.2). 
8. Radioactivity in severed paws (see perfusates, 5). 
5.4. Results. 
The results obtained with anaesthetized rats (method 5.3.1) are summarized 
in table 5.1. PGL was generally not detectable in untreated paws. The prolong-
ed presence of the cannulae, failed to release PGL, as indicated by saline 
83 
treatment. PGL was released after injection of CAR, and was already detect-
able at 1 and 2 hours. At 4 and 6 hours after application of CAR the amount 
of PGL that was removed by the perfusion was significantly higher than before 
the administration of CAR. 
Table 5.1. Collection of prostaglandin-like activity (PGL) from rat 
hindpaws before (-30 min) and after treatment with CAR or saline. 
Perfusion time Saline treated CAR treated 
PGL PGL 
h ng PGE 2/perfusate ng PGE2/perfusate 
-0.5-0 < l .0 (8) < I .0 ( 1 0) , 1.1 ( 1 ) 
1-1.5 < 1. 0 ( 2) < 1.0' 1. 3 ( 2) 
2-2.5 < I. 0 ( 2) 2.0 ( 1 ) 
4-4.5 < I .0 ( 2) 2.9 + 0. 3 ( 4) * 
6-6.5 < l. 0 ( 2) 3.3 + 1. 2 (4) * 
Since the efficiency of the perfusion method was not estimated, the 
values are expressed as ng PGEz/perfusate. Numbers of observations 
are given in brackets. *= p< 0.05, when compared with zero-time 
controls (Wilcoxon test). 
g£~E~~~~£~_£f_~~~~~~-£f_~g~_£2!~~~~~-~~i~g-~iff~~~~!_i~~-~-~~~-~l_E~~i~~i£~ 
methods. 
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Fig. 5.3 shows the correlation between protein content of the perfusates and 
h f 1 25 l d b . t e recovery o I abelle al um~n from the CAR exudate at 4h. 
(%) 
10 
c 6 0 , 
0 
0 
' 
4 
2 
0 
84 
r = 0.953 
p < 0.01 
0 
0 
0 
00 0 
0 
.,<o 0 
'"· 0 2 
protein 
0 
4 (mg) 
Fig. 5.3. Correlation between protein content 
of perfusates and percent recovery of 125r 
albumin from the exudate. The data were ob-
tained with killed animals (method C). The 
paws were perfused \.Jith Krebs, containing 
28 ~M indomethacin. Recovery (%) and protein 
content (mg) were measured as described in 
5. 3. 2. 
•= diameter outer cannulae= l. 1 mm 
o= diameter outer cannulae= 2.0 mm 
A positive correlation existed between these activities, but the recovery was 
low, even 1vith the larger cannulae, which have been used in the following ex-
periments. 
The effects of the different perfusion methods on PG release are shown in 
table 5.2. It should be noted that PGE levels in rat plasma were below 50 pg/ 
ml (n=3), as determined on the RSS (0. 1 ml/min), after extraction of 3 ml 
3 plasma and TLC, and correction for recovery of H-PGE 1. Thus, the 1.29 ng 
PGE 2 , which was detected in perfusates from saline-treated paws, using method 
A, was probably an artefact, due to damage of small vessels or other tissue 
constituents. The presence of considerable amounts of protein in those perfu-
sates also indicated tissue damage. Killing the rats (Hethod C) reduced the 
amount of protein in perfusates of saline treated paws and tended to lowerPCL 
levels. This may imply that damage of vessels is responsible for artificial 
protein leakage and for the greater part of the PGL in saline-treated paws, 
perfused using Method A. Treatment of the rats with indomethacin (~ethod B), 
prior to insertion of the cannulae, also reduced the artificial release of PGL 
to levels belmv the limit of detection. 
Table 5.2. Comparison of different perfusion methods. 
Perfusate 
protein (mg) 
125 
recovery of I (%) 
PGL (ng PGE 2 ) 
PGL (ng PGE 2/exudate) 
protein (mg) 
125 
recovery of I (%) 
PGL (ng PGE
2
) 
PGL (ng PGE 2 /exudate) 
Saline-treated paws. 
Method A 
0.81 + 0.32 
1.29+0.8 
Hethod B 
0.31 + 0.21 
40 + 20 
< 0. 04 * 
< 0. 24 
Carrageenin-treated 
1. 72 + 0.43 00 
2.8 + 0.7 
0. 18 + 0.07® 
6.4 + 1. 2® 
Hethod C 
o.o6 + o.o1* 
52 + 28 
0.19+0.12 
0.30 + 0.09 
paws. 
2. 17 + 0.83® 
6. 1 + 2.0 
0.39 + 0. 15 
7.2 + 1. 4 ® 
Paws were perfused at 4 h after injection of saline or carrageenin. Hethod 
A, anaesthetized rats; Method B, anaesthetized rats, treated 1:vith indometha-
cin (5 mg/kg,i.v.) 5 min before insertion of cannulae; Method C, killed rats 
(see 5.3.2). Protein, recovery of 125r albumin and PGL were measured as 
described in 5.3.2. The in situ amount of PGL in the exudate was calculat-
ed using the percent recovery of 125r, and expressed as ng PGE?/exudate. 
Values represent mean +s.e.m of 4 experiments. * = p < 0.05, Hethod B or C 
vs Method A; til p < 0.05~ carrageenine vs saline (Hilcoxon test,two tailed) 
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The recovery of 125r albumin from saline-treated paws (determined with 
Methods B and C) showed considerable variation. This is explained by the small 
amount of exudation in these paws, \Vhich was hardly detectable .in vivo, In the 
eperiment sho\vn in table 5.2, the increase in exudation due to saline, ex-
pressed as a percentage of the radioactivity in the untreated paw (5.3.2), was 
7.4 + 8.7% (n=S) (cf. CAR-treated paws in table 5.3). Thus, in some cases no 
exudation was detectable, although a small amount of radioactivity appeared 
in the perfusates. In these situations the recovery was, arbitrarily, assumed 
to be 100%. On the other hand, some exudation was sometimes present, but hard-
ly any radioactivity was collected by the perfusion, possibly as a consequen-
ce of incorrect placing of the cannula. 
'h'hen corrected for recovery, the highest value calculated '(..'as less than 
240 pg PGL and on occasions even less than 40 pg PGL was present in the exu-
date of saline-treated pmvs ("Yiethod B). 
Since Method A was less suitable for detection of PG release in CAR edema, 
Methods B and C were used exclusively. Apparently, only a small, variable per-
centage of all extravascular albumin \Vas removable from the CAR exudate. In 
perfusates from CAR-treated paw, higher amounts of PGL were detectable, the 
difference being significant with Method B. The variation in the PGL values 
was reduced after correction for the recovery of the perfusion. Thus, measu-
rement of the recovery of the perfusion method is essential for an estimate 
of PGL levels in the exudate in situ. At 4h, the estimated in situ levels of 
PGL in CAR exudates were significantly increased (table 5.2), when compared 
\Vith saline-treated paws (Methods B and C). 
EFA deficiency and treatment with indomethacin resulted in lower levels 
of PGL in CAR exudates. The results of these experiments are given in table 
5.3. PGL was undetectable in perfusates of inflamed paws of EFAD rats. In 
perfusates of inflamed paws of indomethacin-treated normal rats, PGL was un-
125 detectable in3 out of 4 samples. After correction for recovery of I albu-
min, the estimated in situ levels of PGL in CAR edema, were significantly re-
duced in EFAD rats and in indomethacin-treated rats. Inflamed paws of EFAD 
rats displayed reduced swelling (%), but protein leakage, measured in vivo 
\Vith 125 I albumin and assessed from the protein contents of the perfusates, 
was not reduced in EFAD rats. Indomethacin suppressed swelling as well as 
86 
protein exudation. 
Table 5. 3. Influence of indomethacin (U1) and EFA deficiency on PGL 
levels and exudation in CAR edema at 4h. 
in vivo 
paw diameter (6 mm) 
paw swelling (%) 
exudation 1251 (%) 
perfusate 
volume (ml) 
protein (mg) 
125 
recovery of I (%) 
PGL (ng PGE
2
) 
exudate (in situ) 
PGL (ng PGE 2) 
protein (mg) 
swelling (g) 
Normal (8) 
5.0 + 0. 28 
132 + 6 
707 + 93 
2.58 + 0. 13 
2.06 + 0.33 
4.96 + 0.69 
0. 25 + 0.05 
5.33 + 5.0 
43.0 + 5.0 
0.99 + 0.09 
IM (4) EFAD (4) 
3.1 + 0.28+* 4.4 + 0.34 
74 + 7" 101 + s* 
332 + 91* 568 + 177 
2.93 + 0.34 2.38 + 0.05 
'fif 2.87 0.79 + 0. 14 + 0.49 
6.69 + 2.82 7.49 + 1. 34 
0.16; < 0.04 (3)* < 0. 04 * 
2.58; < 1.32 (3) + < 0.8 ** 
17.4 + I ~** q.) 39.0 + 2.6 
0.61 + 0.11 * 0.57 + 0.05 • 
Indomethacin (2.5 mg/kg, s.c.) was administered at -30 min and 3h. 
Perfusion with Krebs, containing 28 vM indomethacin was started 4 
hours after subplantar administration of CAR (~ethod C). For details: 
see 5.3.2. *= p<0.05, **= p<O.Ol, V.Tilcoxon test. Numbers of ob-
servations are given between brackets. 
5.5. Discussion. 
A perfusion method (Rocha e Silva & Antonio, 1960) was used to obtain 
exudate of CAR edema for assessment of PG-like activities. PGL was only de-
tectable in one out of 19 perfusates before injection of the irritants. After 
application of CAR, increased amounts of PGL were measurable in the perfusat-
es. Saline treatment did not raise the levels of PGL. Since PGL •v-as undetect-
able in saline-treated paws, it is unlikely that tissue irritation by the pro-
longed presence of cannulae is a source of PGL. 
After application of CAR, the levels of PGL increased with time, from 1h 
onwards. This indicated that the, so-called, "PG phase'' of CAR edema probably 
started before 3h, in contrast to an earlier suggestion (70). The number of ob-
servations in the first 2 hours were, however, too few to justify statiscally 
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significant conclusions. 
The method of Rocha e Silva & Antonio (1960) had several disadvantages 
such as the prolonged anaesthesia of the rats. Horeover, it did not provide 
any insight into the in situ PG levels. During edema development, part of the 
exudate is probably pushed into the perfusion system, since an additional 
(3 rd) period of perfusion (data not shown) always removed less PGL, which 
was often undetectable. 
In later experiments, the following improvements were implemented: 
I . The rats were not anaesthetized during the development of the edema. 
2. The efficiency of the perfusion was quantified. 
3. Indomethacin was included in the perfusion fluid in order to stop de novo 
formation of PGL during its collection. 
4. The perfusates were extracted before assay. 
5. The sensitivity of the bioassay was drastically increased. 
A disadvantage which was also noticed, was the release of PGL, as a con-
sequence of tissue damage during insertion of the cannulae, despite the pre-
sence of indomethacin in the perfusion medium.However, this method still 
seems more subtle than squeezing the exudate out of amputated paws, the me-
thod employed by Willis (1969). Thus, the only previous data on PGL levels in 
CAR edema, which have been obtained \Vith a rather harmful mangling machine, lack 
reliability, since data on non-inflamed paws were omitted. 
Simple protein measurements revealed that artificial leakage was greatly 
reduced when blood circulation through the pmv had been terminated by killing 
the rat (Method B), A complete reduction of the artificial PG release was ob-
tained by administration (i.v.) of indomethacin just before the insertion of 
the cannulae. Perfusates from inflamed paws contained more PGL then perfusates 
of saline-treated paws. This difference was significant when the artificial 
PG release during the operation was blocked by indomethacin (Method B). Indo-
methacin was also included in the Krebs used to wash out the subplantar area 
of the paws. If it was omitted, higher levels of PGL were observed in the 
perfusates (data not shown). This difference is explainable by biosynthesis 
of PGs in the coaxial cannula and in the collecting tube. Thus, in vitro PG 
biosynthesis by the cells that were washed away or stick to the superfusing 
system Has then probably assessed. Since the main purpose of this study \vas to 
measure in situ PG levels, and more appropriate techniques are available for 
the assessment of in vitro PG biosynthesis by different cell types (see 2.4., 
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and Zurier, 1976), indomethacin ;;.;ras al;;.;rays included in the perfusing Krebs. 
The efficiency of the perfusion was estimated from the amount of 125r al-
bumin, an exudate constituent which permitted 
d 1 125 lb . trapped. It was assume that al I a umLn, 
in vivo detection, that was 
that had accumulated in the in-
flamed paw, was present in an extravascular compartment. This assumption is 
not necessarily correct, since part of the increase might be due to an en-
hanced blood volume of the paw. However, other studies (Vincent & Zijlstra, 
submitted for publication) indicated that blood volume, measured with 51 cr 
labelled erythrocytes, increased by 
cumulation of 125 I albumin averaged 
approximately 10 percent, whereas the ac-
125 700%. Thus, the greater part of I al-
buminwas indeed extravascular. A significant, positive correlation was pre-
sent between the estimated recovery and the protein content of perfusates. 
Thus, the method permitted estimation of total protein leakage. Since classi-
cal PGs exhibit weak binding to albumin (eg. 222), it was assumed that the 
recovery, determined with albumin, was also applicable to PGL. Circumstantial 
evidence for this assumption was provided by the reduction of the variation 
in PGL levels in perfusates, after correction for recovery. 
The efficiency of the perfusion was low, which is not surprising, since 
CAR edema develops in the whole paw, whereas only the subplantar, subcutaneous 
region was perfused. Moreover, it has been reported on basis of histology that 
a large part of the edema is "tissue" bound, which means that the edema de-
velops within interstitial and muscle tissue (eg. Bechara et al., 1976). Thus, 
only extravascular fluid, in the proximity of the inlet of the coaxial cannu-
la was likely to be collected. Indeed, no correlation seemed to be present 
between perfusion time and the efficiency of trapping 125 I albumin (see also 
results with anaesthetized animals). 
In perfusates from inflamed pmvs, an acid, ether-extractable substance 
was detectable, that stimulated a RSS in the presence of a complete mixture 
of antagonists. The quantity of this material was exoressed in terms of ng 
PGE 2/exudate. The amounts were too small to permit a better characterization, 
eg. by NaOH treatment. It is not unlikely that, during CAR edema endoperoxide 
metabolites, other than classical PGs, are formed in large amounts. Experi-
. 14 
ments wLth C-AA, and subsequent extraction and separation on TLC have, how-
ever, not yet been performed. Similar in situ amounts of PGL were found in 
several experiments, using Methods Band C (compare table 5.2 & 5.3). Since 
the weight of the exudate at 4h 1:vas approximately I g (table 5.3), it would 
appear that at least 5 ng PGL/ml is then present in the CAR exudate. Since 
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PGs other than E
2 
(eg. n2 or r 2) are less potent stimulators of the RSS (see 
table 2.1 and fig. 3.5), these quantities of PGL are minimum estimates. PGE 2 , 
in doses of I ng, increases bloodflow significantly (Johnston, Hay & Movat, 
1976) without affecting exudation. Thus, the PGL present in CAR edudate may 
contribute to this pro-inflammatory activity of PGs. 
Although 5 ng PGL/ml seems quite a low level, it lS at least 100 times 
higher than the plasma concentration of PGE 2 , which was below 50 pg/ml. In 
order to achieve such a concentration gradient between plasma and exudate, PG 
biosynthesis must be extremely active, if a free exchange of PGs exists be-
tween plasma and exudate. Alternatively, the half life of PGs in exudates will 
be much longer if such a free exchange does not exist as suggested in ref. 24, 
since 15-hydroxy-PG dehydrogenase activity was absent in the exudate of CAR-
induced granuloma (Ohuchi et al., 1976). In fact, such prolonged persistence 
of PGs in an exudate seems a possibl2 explanation for the high levels of PGs 
that are claimed to be present in exudates of CAR-induced pleurisy (SO, 105, 
262) and CAR-induced granuloma (191 ,273,274). Unfortunately, data on the turn-
over of PGs and other putative mediators in exudates are lacking, despite the 
availability of labelled compounds and suitable models like CAR-induced pleu-
risy. 
In accordance with in vitro observations (see 4.4), indomethacin (2.5 mg/ 
kg) reduced PGL levels in CAR edema. The present results directly support the 
suggestion (eg. 83,255,274) that in CAR-induced hind-paw edema, a model that 
is so often used for the assessment of anti-inflammatory activity of ~SAIDs, 
indomethacin exerts its activity through inhibition of PG release. In three 
perfusates, no PGL was detectable and the calculated in situ quantities in 
the exudates were significantly reduced. This inhibition coincided with re-
duced 125 I albumin leakage, a reduced protein content of the exudate and 
reduced swelling. 
The results with EFAD rats directly support the idea that these animals 
can serve as a model in which PG biosynthesis is of minor importance. In the 
absence of PGs the development of CAR edema was impaired in EFAD rats. In-
terestingly, protein exudation, measured with two methods, was not signifi-
cantly reduced during EFA deficiency. This difference between edema develop-
ment and protein exudation is not explainable by a reduction in PG biosynthe-
sis, since it was not observed in indomethacin-treated rats. It may be due 
to changes in the functional properties of venules, or other blood vessels, 
during EFA deficiency. It is worth noting that EFA deficiency affects several 
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membrane properties (see 2.3.3). Because of the unchanged protein exudation, 
a smaller difference in osmotic pressures between intra- and extravascular 
compartments is likely to occur. This will facilitate water accumulation, and 
thus swelling of the tissue compartment in EFAD rats in spite of the reduced 
biosynthesis of PGs· Thus, any drug that interferes \Viththe "enhanced'' protein 
leakage during EFAD conditions, will further reduce edema formation. Moreover, 
the appearance of substrates that bind to albumin will be facilitated by the 
unchanged leakage of proteins in the inflamed area. 
In conclusion, experiments with both EFAD and indomethacin-treated rats in-
dicated that PG biosynthesis contributed to the development of CAR edema. 
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6. THE CONTRIBUTION OF PROSTAGLANDINS TO THE DE\~LOPMENT OF CARRAGEENI~­
INDUCED HIND-PAW EDEMA. 
6.1. Abstract. 
The reduction (from 2h omvards) of carrageenin-induced hindpaw edema (CAR 
edema) in EFA deficient rats was probably caused by a shortage of PG precur-
sors. The local supplementation of arachidonic acid (AA) restored CAR edema 
to normal levels in EFA deficient rats. This suggested that the cycle-oxyge-
nase activity of EFA deficient rats was unaltered (cf. Chapter 4). Moreover, 
EFA deficient rats shoved an unaltered response to>vards edema~ens (bradykinin 
and serotonin). PGE 1 was a >Veak edemagen in the rat pa>v, PG"Fzo: was inactive. 
Circumstantial evidence indicated that the bradykinin mediated component of 
CAR edema was unaltered during EFA deficiency. 
Simultaneous injection of PGE 1, AA or dihomo-y-linolenic acid, together 
with CAR, enhanced CAR edema in normal rats. The stable 9,1 I epoxymethano 
analogue of PGH2 , eicosatetraynoic acid and 5,8,1 I eicosatrienoic acid were 
inactive in this respect. The possibility that release of a vasodilator PG 
endoperoxide-derived product is a rate limiting factor in CAR edema develop-
ment, is discussed. 
6.2. Introduction. 
Non-steroidal anti-inflammatory drugs, which are cycle-oxygenase inhibi-
tors, suppress carrageenin-induced pedal edema (CAR edema). Therefore, it is 
generally accepted that PGs are involved in this process (see 2.5.2). In the 
previous chapter it has been demonstrated that prostaglandin-like material 
(PGL) accumulated in the exudate during CAR edema development. 
The role of PGs in CAR edema >vas further characterized using essential 
fatty acid deficient (EFAD) rats, which have a shortage of arachidonic acid 
(AA), the main PG precursor, as shown by the data on erythrocytes (table 4.3). 
Moreover, studies on platelets of EFAD rats revealed that endogenous PG endo-
peroxide production, measured as release of PGE and TXA2 , was drastically di-
minished, but cycle-oxygenase activity was unimpaired (see chapter 4). 
Reduced CAR edema has been described in EFA deficient rats (Bonta et al., 
1974), and has been confirmed and reinforced by measurements of PGL in CAR 
edema (see chapter 5). Since EFA deficiency does not only affect PG biosynthe-
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sis (see 2.2.3), the decreased swelling might be due to alterations in other 
inflammatory parameters. Some of the alternatives have been ruled out in the 
experiments described in this chapter. 
AA was administered locally to EFA deficient rats, in order to investigate 
whether PG precursor shortage or a change in cycle-oxygenase activity was res-
ponsible for the suppression of CAR edema. Local administration of AA potenti-
ated CAR edema in normal rats (eg. 149), but it was not knmm whether dihomo-
y-linolenic acid (PGE 1 precursor) or eicosatrienoic acid (n-9), \vhich accumu-
lates during EFA deficiency (see 2.3), were able to enhance CAR edema. 
The inflammatory activities of a stable PG endoperoxide analogue (9, 11 EM), 
PGE 1, PGF 2a, serotonin (5HT) and bradybinin (Bk) were investigated, both in 
normal and in EFAD rats. In order to evaluate the Bk component of CAR edema 
in EFAD rats, the effects of a bradykinin potentiating peptide (BPP 9a) were 
tested in both types of rats. 
6.3. Hethods. 
6~!~~!~· Both normal and EFAD male Wistar rats (220-280 g) were used (see 3. 1). 
In the experiment shmm in fig. 6.2, another inbred strain (R xU, C.P.B., 
Medical Faculty, Erasmus University, Rotterdam) vras used. 
~i~9:_p~~-~9:§:~~· Edema \Vas evoked by sub-plantar injection of 0.1 ml sterile 
pyrogen-free 0.9% NaCl, 0.1 CAR (1%), 0.1 ml irritant or a combination (in 0.1 
ml), and increase in paw-diameter or paw-volume \Vas measured (see 3.2). 
PG£ 1 , PGF 2a, 9, 11 EM, 5HT and Bk were dissolved in sterile pyrogen-free 0, 9% Na-
Cl. For the administration of the combination of fatty acids or PGE 1 and CAR 
an aliquot of the fatty acid stock solution (see 3.6) was dried under reduced 
pressure, if necessary, and dissolved in 1 volume ethanol (10 mg/ml), 9 Volum-
es of 0.9% NaCl, containing 0.2% Na2co3 , were then added, giving a solution 
of 1 mg fatty acid/ml. This solution was diluted 1:1 (v/v) \Vith 2% (w/v) CAR. 
Thus, the paws were injected with 1 rng CAR and 0.05 mg fatty acid in 5% etha-
nol and 0.1% Na2co3 . Controls received the same mixture without fatty acid. 
In one experiment (fig. 6.2), arachidonic acid (0.05 rnl, 1 mg/ml, prepared 
as described above) was administered at 2h after the injection of CAR. Con-
trols received 0.05 ml 0.9% NaCl containing 0.1% Na2co3 and 5% ethanol. 
Bradykinin potentiating peptide (BPP9a) was dissolved (1 mg/ml) in sterile, 
pyrogen-free 0.9% NaCl and was diluted (I :I, v/v) with 2/, CAR. 
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6.4. Results. 
6.4. I CAR edema in normal and EFAD rats. 
The EFAD and control rats used in these studies were of different ages 
(see 3.1), This does not seem to have been of importance, since the age of 
the rats had little influence on the development of edema in normal rats as 
shown in fig. 6.1, 
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Fig. 6.1. CAR edema in normal rats of different age. Both hind pa\.;rs 
of 5 rats of 8 weeks and 20 weeks were injected with 1 mg CAR and 
S\velling was expressed as percent increase in diameter. 
The reduced CAR edema of EFAD rats (see 34) was confirmed in several ex-
periments, in both R xU and Wistar rat strains. An example is given in fig. 
6.2. The swelling in EFAD rats differed significantly from that in normal rats 
after 2h (Student's t-test: p<O.OS). The difference between both types of 
rats disappeared after injection of 50 ~g AA into each paw at 2h (Student's 
t-test: p > 0.05, 3h, 4h). Vehicle-injected paws of EFAD and normal rats dif-
fered significantly from each other at each later measuring point (p < 0.01). 
The responsiveness towards different putative mediators was assessed in 
both normal and EFAD rats (fig. 6.3). PGE 1 alone, in doses of 5 ng and 10 ng, 
caused a small swelling (30 min) that was statistically different from the sa-
line controls. Only 20 ng PGE 1 induced swelling which was 5% above saline le-
vels (30 min) in normal rats. EFAD rats seemed more sensitive to PGE 1, since 
5 ng PGE 1 already produced a swelling, which was 5% higher than that due to 
saline. No dose-relationship was found for PGE 1 in EFAD rats. Therefore, the 
higher sensitivity of EFAD rats towards PGE 1 when compared with normal rats, 
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Fig. 6.2. Effects of AA on CAR edema in 20 normal and 20 EFAD rats. In 
this experiment R xU rats were used. CAR was injected at Oh into both 
paHs. Groups of 10 rats received 50 \Jg AA or Na?C03 (0. 1%, 0.05 ml) in 
both paws after 2h (t). Swelling was determined-by diameter measure-
ments (see 3.2). Normal rats: e, Na2C03, o, AA (SO )Jg); EFAD rats: 
II., Na2C03, ~. AA (50 \.1g). 
40 1%) 
0 l/2 2 3 0 l/< 2 3 0 l/2 
; "' 
"~ 10 
2 3 0 1/2 
' l 
time {h) 
Fig. 6.3. Pa\V swelling induced by saline, PGE 1, PGF2cp SHT (5 \.lg) and 
Bk (5 \Jg) in normal (~) and EFAD (--o--) rats. The irritants were 
injected in both paws. Swelling is expressed as percent increase in pa\v 
diameter. The numbers of observations were 20, unless indicated other-
wise. +: p < 0. 05, normal rats, treatment vs saline (Dunnett's test); 
*: p<0.05, EFAD vs normal rats (Student's t-test). 
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disappeared at 20 ng PGE 1 per paw. Thus, PGE 1 alone is a very poor edemagen 
in this dose range. PGF2a was not an edemagen in the rat paw. Bk and 5HT, in 
the high doses applied, are indeed edemagens, but no significant differences 
were observed between normal and EFAD rats. 
Bradykinin potentiating peptide (BPP9a) enhanced CAR edema in normal rats 
(fig. 6.4). This effect 't.;ras apparent between 1 and 5 hours. BPP 9a also in-
creased CAR edema in EFAD rats. The increase was approximately equal in both 
types of rats. 
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Fig. 6.4. Potentiation of CAR edema (C) by simultaneous subplantar 
injection (BPP + C) of a synthetic bradykinin potentiating peptide 
(BPPga, 50 ~g) in both paws of 5 normal and 5 EFAD rats. Swelling 
is expressed as percent increase in pa"t.;r diameter. 
6.4.2. Effects of locally administered fatty acids and PGs on CAR edema in 
normal rats. 
AA (50 ~g) potentiated CAR edema in normal rats, when given simultaneous-
ly with CAR (see fig. 6.5). After 2h the difference between AA- and vehicle-
supplemented CAR edema had disappeared (p> 0.05, \.Jilcoxon test). It is •vorth 
noting that the same dose of AA had much less effect when given at 2h after 
injection of CAR (fig. 6.2.). A qualitatively similar, but less pronounced 
enhancement of CAR edema was obtained by simultaneous administration of CAR 
and dihomo-y-linolenic acid (50 ~g), precursor of PGG 1. 5,8, 11 Eicosatrienoic 
acid, which is not a PG-precursor, and eicosatetraynoic acid, which is an 
oxygenase inhibitor, were without significant effects (u> 0.05, Wilcoxon test). 
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Fig. 6.5. Potentiation of CAR edema by the simultaneous administrat-
ion of CAR (I mg) and fatty acids (SO ~g/paw; see 6.3). Both hind-
paws of 4 (fig. A) and 5 (fig. B) rats \Vere injected and the diame-
ters of the pa\.;rs v.rere measured (see 3. 2) _ Symbols: AA, arachidonic 
acid; DHL, dihomo-y-linolenic acid; TYA·, eicosatetraynoic acid; ETA, 
eicosatrienoic acid (20:3,n-9); C, carrageenin+ vehicle without 
fatty acid. *: p < 0.05; fatty acid treated vs vehicle treated, 
Wilcoxon test. 
Table 6. I. Indomethacin (IM) and aspirin (A§A) suppress AA-induced 
potentiation of CAR edema. 
mg/kg CAR CAR + AA difference % 
mm (increase) mm (increase) mm 
-----
SAL 1. 48 + o_ JS 3.42 + 0. 13 1. 94 + 0. 19 100 + 9 
IM 5 1. 56 + 0. 14 2. 61 + 0. 13 1 .05 + 0. 19 51 + 9 
ASA 125 1-33 + 0. 10 2.28 + 0. 11 0.95 + 0. 15 46 + 7 
Six groups of 4 rats received indomethacin, asnirin or saline (SAL, 
0.2 ml/kg) subcutaneously, 30 min before injection of CAR (1 mg) or 
CAR + AA (0. 05 mg) in both pm.;rs. The increase in paw diameter (mrn) 
was measured after 30 min. 
Pretreatment of the rats with either indomethacin (5 mg/kg) or aspirin 
(125 mg/kg) inhibited the potentiation due to AA (table 6. 1). The drugs were 
administered 30 min before the injection of the irritants, and paw swelling 
was measured after 30 min. Both NSAIDs failed to inhibit CAR edema at 30 min. 
Thus, the potentiation of CAR edema by AA was, at least partially, due to 
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conversion of AA into PGs. 
Fig. 6.6. shaHs that CAR edema developed almost maximally within 1 hour 
when PGE 1 (SO ng) 'ivas given simultaneously Hith CAR. After 3h the difference 
betHeen PGE 1 and vehicle treatment had disappeared (p> 0.05, Wilcoxon test). 
The higher doses of PGE 1 (0. 1 mg) produced a similar potentiating effect. 
Ho·wever, the reduction of the later phase (24h) of CAR edema became signifi-
cant with this higher dose of PGE 1. This dose had systemic effects and caused 
diarrhoea. 
A high dose (O.OS mg) of the stable 9,11 epoxymethano analogue of PGH2 
(9, 1 J El''l) failed to induce sv.Telling when given alone, and displayed neither 
inhibiting nor enhancing effects \Vhen given simultaneously with CAR (see fig. 
6. 7) . 
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Fig. 6.6. Effects of PGEJ on CAR 
edema. PGE 1 (SO ng or 0. 1 mg) was 
injected simultaneously with l mg 
CAR (0. 1 ml). -18·-: CAR + vehic-
le without PGE1; --0--: CAR + 50 
ng PGEJ; .. o .. : CAR+ O. I mg PGE]. 
Increase in volume was measured 
(n=4) and expressed as percent of 
the volume at zero time. 
'*: p < 0. OS PGE 1, treated vs vehic-
le treated, 1dilcoxon test. 
Fig. 6.7. Local effects of the 
PGH2-analogue 9, II EM (SO ~g) 
in combination with sElline 
(0.1 ml) or CAR (1 mg). SAL= sa-
line with or without 9,1 I EM; 
CAR= carrageenin with or without 
9,11 EM. SHelling was expressed 
as percent increase in paw dia-
meter. '~-': p < 0.05. 9,11 EM treat-
ed vs saline treated; Wilcoxon 
test. 
6.5. Discussion. 
It is generally accepted that PGs are involved in the develo~ment of CAR 
edema. This assumption is based on indirect evidence, such as sensitivity of 
the model to cycle-oxygenase inhibitors (see 2.5, Vinegar et al., 1976, Vane 
1976), Direct reliable measurements of PGs in the CAR pedal edema were lacking, 
but have been reported in chapter 5. Further indications for the pro-inflam-
matory involvement of PGs in CAR edema have been obtained, using a different 
approach, in previous experiments carried out by Bonta et al. (1974). It Has 
shown that PG precursor deficient rats displayed a reduced CAR edema,,cllichHas 
almost insensitive tmvards inhibition by indomethacin. The reduction 'ivas 
rather selective, since chicken egg 'ivhite-induced edema, in which amines are 
probably the most important edemagens, was unaltered during EFA deficiency. 
In the present study, these findings have been confirmed. 
In all experiments, normal animals 'ivere matched for Height with EFA de-
ficient animals. Thus, EFAD rats were older (see fig. 3. 1). Since normal rats 
of both ages developed an equal inflammatory response, the reduced edema ln 
EFAD rats was probably not due to age-differences. The CAR edema curves 
showed no biphasic components, but if edema, produced by saline (fig. 6.3) in 
the contralateral paw, had been subtracted a biphasic curve ,,Tould have 
appeared. In most experiments described here, potentiation or reduction of 
CAR edema ln the later phases, where saline-induced edema becomes insignifi-
cant, has been studied and therefore, saline controls \.Jere often not neces-
sary. In accordance with other reports (eg. Lewis, A.L. et al., 1975), the 
maximal development of CAR edema showed daily variations (compare fig. 6.4 
and 6.6). 
If the reduced CAR edema in EFAD rats \Vas due to PG precursor shortage, 
then local supplementation of AA should, at least partially, restore the swel-
ling to normal levels. As shown in fig. 6.2, this assumption was shown to be 
true. The AA was administered 2h after the start of the edema, since from that 
moment the EFAD rats shmved a clear reduction in swelling. It was assumed that 
in EFA deficient rats the effects of exogenous AA should be relatively short 
lasting and indeed, the AA enhancement tapered off from 3h after its addition. 
In normal rats, AA hardly enhanced the edema at all, when given at 2h. 
The reduced edema in EFAD rats was not due to differences in sensitivity 
tmvards PGs of the E type (PGE 1), SHT or Bk. PGE 1 \Vas a weak edemagen in the 
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rat paw, which confirmed several more recent data (149,169,272). Interesting-
ly, EFAD rats showed an enhanced sensitivity towards PGE 1. Bk and SHT produc-
ed significant swelling, without any distinction being observed between nor-
mal and AA deficient rats. Thus, EFA deficiency did not interfere \-Jith the 
normal responses to SHT and Bk and despite the increased sensitivity towards 
PGE 1, EFAD deficiency resulted in a decrease in the "so-calledn PG-phase of 
CAR edema (Di Rosa et al., 1971). 
The bradykinin potentiating peptide (BPP 9a), when given simultaneously 
with CAR, enhanced the edema in normal rats by up to 5 hours. This is ~n 
agreement with a report in which BPP 9a increased CAR edema when given 0 to 6h 
after CAR (Ferreira et al., 1974). These and other studies (Crunkhorn & Mea-
cock, 1971) indicate that Bk is formed during the Hhole of the first Sh of CAR 
edema. The suggestion by DiRosa et al. (1971) that Bk is released transient-
ly after an initial release of 5HT and H has, therefore, to be rejected. 
BPP 9a enhanced the S\-Jelling of EFAD rats to the same extent as that of 
normal animals. It appears that the kinin-mediated components of CAR edema 
remained unaltered during EFA deficiency. It is a \-Jell documented fact that 
Bk enhances PG release in several situations (see Vane, 1976; cf. table 2.2). 
Apparently its action as edemagen is not strictly dependent on PC release, 
since EFAD rats responded in a normal way to both Bk alone and to the poten-
tiation of CAR edema by BPP9a. A similar result with BPP 9a was obtained when 
PG biosynthesis was blocked by a high dose of indomethacin (81). 
Local administration of AA at 2h after injection of CAR had little effect 
in normal rats (fig. 6.2). This picture changed when AA Has injected concomi-
tantly with CAR into pat.;rs of normal rats. In this t-Jay, the swelling developed 
maximally within 30 min. Availability of PG precursors may apparently be a 
limiting factor in the initial stages of CAR edema, and later administration 
of exogenous AA does not further increase the SHelling. Non-specific poten-
tiation by AA, not involving cycle-oxygenase conversion of the fatty acid, 
seemed unlikely, since eicosatrienoic acid (n-9) failed to enhance the swell-
ing. This fatty acid replaces AA during EFA deficiency and is not a cycle-
oxygenase substrate (see 2.1 .2). Moreover, the AA-induced potentiation was 
susceptible to inhibition by cycle-oxygenase inhibitors, like indomethacin 
and aspirin. Both of these findings are in agreement \-Jith reports in ,,Thich 
AA-induced potentiation of CAR edema, was suppressed by XSAIDs, but not by 
corticosteroids and with the finding that linolenic acid (18:3,n-3) lacked 
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this potentiating capability (149,270,271) 
The limited availability of PGs, in the early edema phase, is also demon-
strated by the potentiation of the early phase of CAR edema by PGE 1. This 
effect of PGs of the E type has also been found by several other authors C·ion-
cada et al., 1973, Le'\-.'is et al., 1975, Smith et al., 1974). Interestingly, 
PGE 1 in higher doses suppressed the swelling after 24h (see chapter 7). 
Dihomo-y-linolenic acid (20:3,n-6) was less potent than AA. This finding 
may be explained in several ways. It is possible that dihomo-y-linolenic acid 
is less efficiently oxygenated than AA. A more tempting explanation is that 
both EFA's are equally efficiently converted into endoperoxides, but that the 
PG endoperoxides derived from AA yield more potent pro-inflammatory products. 
PGE 1 (derived from 20:3 (n-6)) and PGE 2 (derived from AA) are generally equi-
potent as -indirect- inducers of plasma leakage in the rat skin (eg. 60). 
Thus, endoperoxide-derived substances, other than classical PGs, might be of 
more importance for edema development. Since PGG 1 and PGH 1 are not suitable 
substrates for either TXA2 synthetase (178,187) and PGI 2 synthetase, these 
pathways may deliver such pro-inflammatory substances. PGI 2 , a potent arterial 
smooth muscle relaxant, seems the best candidate, since a drastic increase in 
local blood flow is the most important pro-inflammatory feature of PGs (see 
2. 5). 
The stable 9, 11 epoxymethano analogue of PGH2 (9, 11 EM), Hhich shares phar-
macological properties \-vith PGH2 (:Halmsten, 1976) and TXA2 (see 3.2), but 
lacks their instability, seemed suitable for the evaluation of a possible in-
volvement of TXA2 (or PGH 2) in inflammation. In accordance Hith its lack of 
vasodilatory properties, a huge dose had no pro-inflammatory effect by itself 
nor in combination \-vith CAR. Xore studies are needed to establish the pro-
inflammatory role of PGI 2 or TXA2 , since both 6-keto- PGF 1a and TXB 2 have 
been detected in CAR-induced granuloma-pouch exudates (52,53). 
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7. ACUTE ANTI-I~FL~~TORY EFFECTS OF SO}ffi DRUGS IN PROSTAGLANDIN PRECURSOR 
DEFICIEKT RATS. 
7. I. Abstract. 
The anti-inflammatory activities of 2 types of anti-inflammatory drugs have 
been studied in EFAD rats, in which PG release is of minor importance. It ap-
peared that the main anti-inflammatory activity of indomethacin was explain-
able by its inhibition of PG biosynthesis. This drug was hardly active against 
carrageenin-induced hindpaw edema (CAR edema) in EFAD rats. Aspirin and dexa-
methasone exhibited normal inhibition of CAR edema ln this model. Thus, inter-
ference with PG biosynthesis did not fully explain their anti-inflammatory ac-
tivities. Indirect evidence for the hypothesis that aspirin inhibited pho~ho­
diesterase in_vivo '"as not obtained. Finally, when PGE 1 was given systemically, 
its anti-inflammatory effects (see Chapter 6) prevailed. This effect was 
probably exerted via adenylate cyclase stimulation, since theophylline potent-
iated the anti-inflammatory effect of PGE 1. The finding that PGE 1 can suppress 
CAR edema indicates that PGs may modulate this inflammatory reaction. 
7.2. Introduction. 
--------
Both NSAIDs and corticosteroids reduce carrageenin-induced hind paw edema 
(CAR edema), and the previous chapters have described the evidence which 
has been obtained for a pro-inflammatory role of PGs in the initial phase of 
this model. Part of this evidence was provided by studies on EFAD rats which 
displayed a reduced CAR edema. The reduction was explained by PC precursor 
deficiency and not by differences in cycle-oxygenase activity, or sensitivity 
towards PGs and other mediators. 
It is generally accepted that the anti-inflammatory activity of aspirin-
like drugs is mainly due to suppression of PG biosynthesis (Vane, 1971, 1976). 
This attractive idea has recently received some criticism (eg. Smith, 1975). 
Corticosteroids also interfere with the cellular release of PGs (see Gryglews-
ki, 1976; table 2.2.) and this might partially explain their anti-inflammatory 
activity. Therefore, it seemed worth testing the anti-inflammatory activity of 
2 NSAIDs (aspirin and indomethacin) and a corticosteroid (dexamethasone) on 
CAR edema in EFAD rats, under conditions where the role of the arachidonate 
system has largely been ruled out. 
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Even relatively high doses of indomethacin were inactive in this poorly-
developed model, while both aspirin and dexamethasone still displayed anti-
inflammatory activity. A few attempts have been made to find evidence for the 
hypothesis that the alternative mode of action of aspirin was due to phospho-
diesterase inhibition. Finally, the inhibition of pa>v swelling by PGE 1 was 
further investigated. 
7.3. Hethods. 
CAR edema was induced in normal and EFAD rats (see 3.1 & 3.2). Drugs were 
given subcutaneously (2 ml/kg). Indomethacin, aspirin and dexamethasone were 
administered at -! and 3h. The other drugs (PG£ 1, theophylline) were injected 
(s.c.) 30 min before the start of the inflammatory response. Control animals 
received saline. 
7.4. Results. 
7.4. I. The anti-inflammatory activity of indomethacin and aspirin in normal 
and EFAD rats. 
The inhibition of CAR edema by indomethacin is shown in fig. 7. I. Indome-
thacin was only partially effective in suppressing the reduced edema in EFAD 
rats. The reduction was significant at 2h whereas the inhibition of CAR 
edema in normal rats ,,Tas significant from 2h onwards. The results were similar 
to those obtained in earlier experiments (see Bonta, Chrispijn et al., 1974 
and Bonta, Bult et al., 1976), although the experiments on normal and EFAD 
rats \Vere not done on the same day. In pilot experiments, ,,1hich are not shmm 
here, anti-inflammatory doses of aspirin and dexamethasone were selected that 
were approximately equipotent to the doses of indomethacin, used in normal 
rats. Subsequently, indomethacin and aspirin were tested at the same time in 
normal and EFAD rats. Complete swelling curves are not shown here, but have 
been published (Bonta, Bult et al., 1977). The measurements, at Share summa-
rized in fig 7.2. Analysis of variance CANOVA), indicated that significant 
differences existed between the different groups, •vhich were further elaborat-
ed with Duncan's multiple range test. Indomethacin significantly (p < 0.05) re-
duced CAR edema in normal rats, although the inhibition Has less than that 
usually obtained. Indomethacin did not significantly reduce the suppressed 
(p < 0. OS) CAR edema in EFAD rats (cf. fig. 7. 1). This \Vas in contrast to as-
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Fig. 7.1. Effect of indomethacin (--o--) on CAR edema in normal and 
EFAD rats. Indomethacin (2.5 mg/kg, s.c.) was administered to 5 nor-
mal and 4 EFAD rats at the points indicated by A; controls (5 normal 
and 4 EFAD rats) received saline (2 ml/kg, s.c.). Results are expres-
sed as percent increase in diameter of the paw. *: p < 0.05, Wilcoxon 
test. EFAD and normal rats were not compared statistically since the 
experiments \vere not performed on one day. 
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Fig. 7.2. Effects of indomethacin (I) and aspirin (A) on CAR edema in 
normal (open columns) and EFAD (hatched columns) rats. Results show 
percent increase in diameter of the left paw at Sh (4 rats/group). 
Indomethacin (2.5 mg/kg, s.c.), aspirin (125 mg/kg, s.c.) and saline 
(S, 2 ml/kg) were administered at -~h and 3h. ANOVA: Fo(S, 18)= 7.03 
Fo.g5(5, 18)"" 4.59; p < 0.05. The means of the treatments that are not 
underscored with a common line, differ from one other significantly 
(p < 0.05, Duncan's test). 
pirin , which caused a significant (p < 0.05) reduction of the edema in both 
normal and EFAD animals. Thus, the anti-inflammatory activity of indomethacin 
was largely dependent on inhibition of PG biosynthesis, whereas aspirin acted, 
at least partially, via other mechanisms. 
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7.4.2. The anti-inflammatory activity of dexamethasone in normal and EFAD rats. 
The effects of dexamethasone on CAR edema in normal and EFAD rats have 
been presented earlier (Bonta, Bult et al., 1977a). The data at 5h after in-
jection of CAR are summarized in fig. 7.3. ANOVA revealed statistical differ-
ences between 4 groups and Duncan's test indicated that dexamethasone signi-
ficantly (p< 0.05) inhibited CAR edema in both EFAD and normal rats. Moreover, 
EFA deficiency again reduced CAR edema significantly (p< 0.05) when compared 
with normal rats. This indicated that this corticosteroid was still active, in 
rats \-;rhich had a shortage of PG precursors, It must be assumed that dexametha-
sone interfered with other processes apart from liberation of AA. 
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Fig. 7.3. Inhibition of CAR edema by dexamethasone 
(D) in normal (open columns) and EFAD (hatched co-
lumns) rats. The results sho>v the pe_rcent inCrease 
in paw diameter. Dexamethasone (125 mg/kg) or sa-
line (S, 2 ml/kg) was administered subcutaneously 
to groups of 5 rats at -~ and 3h. Swelling was 
measured Sh after subplantar administration of 
CAR. ANOVA: Fo (3,16)= 42.3 F0 , 99 (3.16)= 5.29; 
p<O.Ol. Duncan's test: 
normal rats; saline vs dexamethasone p < 0.05 
EFAD rats; saline vs dexamethasone p < 0.05 
normal rats vs EFAD rats (saline treated) p < 0.05 
7.4.3. Anti-inflammatory effect of PGE 1 in normal rats. 
The anti-inflammatory activity of PGE 1, which in vitro elevates cAMP le-
vels of several cell-types (eg 11 ,215,270) and theophylline, an inhibitor of 
phosphodiesterase, was investigated. PGE 1 (1 mg/kg) and theophylline (75 mg/kg) 
had little anti-inflammatory activity when given separately, but their com-
bined systemic administration completely abolished CAR edema (fig. 7.4). It is 
worth noting that PGE 1 displayed systemic effects, since it induced vasodilat-
ion (redness of hairless skin) and diarrhoea, and the combination of PGE 1 and 
theophylline was rather toxic, since 1 rat died. 
It seemed likely that PGE 1 exerted its effect via stimulation of adeny-
late cyclase. The concomitant systemic application of carbachol (0.2 mg/kg), 
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Fig. 7.4. Effects of systemic administration of PGE 1 and theophylline 
on CAR edema. PGE] (1 mg/kg), theophylline (75 mg/kg) and saline (2 ml/ 
kg) were administered (s.c.) to groups of 5 rats, 30 min before appli-
cation of CAR (I mg) into the left paw. The contralateral paw \Vas 
treated with saline; after 4h the rats vere killed, and the differences 
in weight (g) between the left and right pa'ivS were determined (3. 2). 
a guanylate cyclase stimulator (eg. 270), together with theophylline (75 mg/ 
kg) was without anti-inflammatory effect. 
When given locally, acute, pro-inflammatory effects of PGE 1 (0. 1 rng/paw) 
(see fig. 6.6) and theophylline (0.1 mg/paw; data not shown) prevailed. How-
ever, the late phase of CAR edema (24h) was always suppressed by PGE 1 (eg. fig. 
6.6). Thus, combined systemic administration of PGE 1 and theophylline abolished 
CAR edema, whereas acute pro-inflammatory effects dominated when both drugs 
were given locally. 
In several experiments PGE 1 and aspirin or indomethacin were administered 
systemically, and the anti-inflammatory activities of the seperate drugs and 
their combinations were investigated. An example of the anti-inflammatory ef-
fects of PGE 1 and aspirin is shown in fig. 7.5. Systemically asministered 
PGE 1 displayed a small (p > 0.05) edema suppressing effect at 4h after the in-
jection of CAR. Inhibition of the edema by PGE 1 was more substantial and sig-
nificant at 24h after application of CAR. Aspirin suppressed CAR edema, but 
PGE 1 failed to enhance the anti-inflammatory activity of aspirin (4h, 24h), 
in contrast to the potentiation observed with combination of PGE 1 and theo-
phylline. 
The results obtained with the combination of indomethacin and PGE 1 were 
very similar to those obtained with the simultaneous administration of aspirin 
and are, therefore, not sho\ro. Again PGE 1 did not enhance the anti-inflamma-
tory activity of indomethacin. 
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Fig. 7.5. Anti-inflammatory effects (4h and 24h) of systemically ad-
ministered PGE1 (hatched columns) and aspirin (ASA). CAR edema (I mg/ 
left paw) was evoked in groups of 5 rats, pretreated (-30 min) with 
saline (2 ml/kg), aspirin (125 mg/kg, s.c.), PGE 1 (I mg/kg, s.c.) or 
a combination of PGE 1 and aspirin. The administration of aspirin was 
repeated at 3h, \Vhile the other groups received saline. S\velling (ml) 
was measured volumetrically (see 3.2) at 4h and 24h after injection 
of CAR. 
ANOVA, 4 hours: Fo (3,16)= 6.70; Fo_gg (3,16)= 5.26; p<O.Ol 
Duncan's test: saline vs ASA, p<0.05; saline vs PGE 1 , p>O.OS 
in aspirin treated rats, saline vs PGEJ, p > 0.05 
ANOVA, 24 hours: FQ (3.16)~ 3.90; r 0 . 95 (3,16)~ 3.25; p<O.OS 
Duncan's test: sal~ne treated rats, PGE 1 vs saline, p < 0.05. No other 
statistically significant differences. 
7.5. Discussion. 
In the work described in the previous chapters, several indications were 
obtained, that supported a possible pro-inflammatory role for cyclo-oxygenase 
metabolites in early CAR edema. The anti-inflammatory activity of 2 typical 
NSAIDs has notv been evaluated in CAR edema under conditions where endogenous 
PG release is, for the greater part, absent (see chapters 4 and 5). 
The anti-inflammatory activity of lower doses of indomethacin is probably 
largely dependent on cycle-oxygenase inhibition. From 3h onwards, the dose of 
indomethacin used (2. 5 mg/kg), \Vhich is around the ED50 value (Vinegar et al., 
1976), had very little suppressive effect on CAR edema in EFA deficient rats. 
This dose does not inhibit neutrophil mobilization (Vinegar et al., 1976). 
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Even additional administration of indomethacin did not further suppress the 
late phase of CAR edema under EFAD conditions. Hotvever, indomethacin always 
had a small, but significant anti-edema activity at 2h during EFA deficiency 
(see also Bonta et al., !974). This may be explained in several ways (vide 
infra and Bonta, Bult et al., !977) but a plausible explanation seems that, 
even during severe EFA deficiency, some residual AA is always present in bio-
logical membranes (see table 4.3). This limited AA pool might be consumed 
during the initiation of CAR edema. Therefore, NSAIDs are likely to suppress 
the initial PG phase of CAR edema in EFAD rats. PG mediation of CAR edema was 
demonstrable from 2h onwards (see chapter 6), but it lS likely that, tvith more 
sophisticated techniques, the PG phase will be shown to start even earlier 
(cf. Vane, 1976). 
A dose of aspirin \vas selected in pilot experimets, tvhich \.Vas generally 
about equipotent to the dose of indomethacin used in normal rats, and which 
again turned out to be around the EDSO value given by Vinegar et al., 1976. 
In contrast to indomethacin, this dose of aspirin displayed an anti-inflamma-
tory activity during the whole course of CAR edema in PG precursor deficient 
rats. Thus, aspirin, which undoubtedly inhibits PG biosynthesis, can exert 
its anti-inflammatory activity, via other mechanisms, provided that the meta-
bolism and/or tissue distribution of aspirin \Vas not affected by EFA deficien-
cy. A simple control experiment for testing this statement \vould be to ad-
minister both aspirin and indomethacin concomitantly to normal rats. An anti-
inflammatory action of aspirin in normal rats, that were made PG deficient 
by means of indomethacin, would have supported the above statement. 
There are several possible explanations for the additional anti-inflamma-
tory activity of aspirin (see 2.2.2). It is likely that part of this activity 
is due to conversion to salicylate (see 148). This anti-inflammatory compound 
is devoid of significant anti-cycle-oxygenase activity in vitro (see 2.2.2). 
Due to the scarcity of EFAD rats, the anti-inflammatory activity of salicylate 
has not yet been tested in EFAD rats. It would be expected to be as active as 
in normal rats. It seems unlikely that inhibition of neutrophil mobilization 
constitutes an alternative action. Both aspirin and indomethacin display such 
activity at higher doses (eg. 262), but only aspirin was active in PG precur-
sor deficient rats. Moreover, both drugs were used in doses which do not af-
fect neutrophil migration in CAR-induced pleurisy (see 262). Unfortunately, 
the invasion of neutrophils in vivo was not measured in EFAD rats, but EFA 
deficiency did not affect peripheral 1.;rhite cell patterns (Vincent et al., 1975). 
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Aspirin and indomethacin have been reported to inhibit phosphodiesterase 
ln vitro (see 2.2.2). Elevation of c~~p levels of neutrophils in vitro leads 
to reduced release of lysosomal enzymes (eg. 270). Thus, inhibition of phos-
phodiesterase by aspirin might suppress inflammatory reactions, but no indi-
cations for such a role in vivo were obtained in the present study. The com-
bination of PGE 1 and phosphodiesterase inhibitor theophylline totally blocked 
CAR edema. PGs of the E type are potent stimulators of adenylate cyclase in 
several cell types, including platelets (2.4), mastcells (I I) and neutrophils 
(270). Thus, it is likely that the combined effect of PGE 1 and theophylline 
was due to enhancement of cAliT levels in several tissues. However, the inhi-
bition was probably affected by nnon-specificn systemic changes, since the 
combination was rather toxic (1 rat died) and might have involved a very 
marked hypotension 
PGE 1 failed to enhance the anti-inflammatory activity of aspirin and indo-
methacin. Both 1:\SAIDs, in this dose range, acted differently from theophylline. 
Additive anti-inflammatory effects of PGE 1 in combination with both NSAIDs 
have been described (69). The doses of the ii:SAIDs \vere, hmvever, much higher 
than in this study. Thus, it is possible that theophylline and high doses 
of the two NSAIDs ~re indiscriminable from each other with respect to en-
hancement of their activity by PGs of the E type. 
Dexamethasone Has as active in normal rats as in EFAD rats. Thus, its 
anti-inflammatory activity seems to be independent of inhibition of local AA 
release. Inhibition of neutrophil mobilization, observed in CAR pleurisy and 
in several other models, therefore, seems a more likely mechanism of its anti-
inflammatory activity (eg. Vinegar et al., 1976). 
Finally, the question arises as to \vhether PGE 1 is pro- or anti-inflarrnna-
tory. In accordance with most studies, local administration of PGE 1 enhanced 
acute CAR edema. However, 24h later the edema was reduced. The pro-inflamma-
tory activity of PGE 1 is probably due to increased vasodilation and increased 
local blood flow, facilitating both exudation and the supply of circulating 
pro-inflammatory cells. As a result of this potentiated inflammatory response, 
the irritant may be removed more rapidly and the resulting edema after 24h 
Hill be reduced. Locally administered theophylline had a similar effect. The 
anti-inflammatory activity of systemically administered PGE 1 must be based 
on different mechanisms. Again, vasodilation was induced, since redness of 
the hairless skin parts 'ivas observed, but the initial stages of CAR edema Here 
not potentiated. In fact, the anti-inflammatory effect of PGE 1 tended to start 
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earlier after systemic administration. A non-significant reduction of CAR e-
dema was often noticed after 4h (cf. 69). This initial reduction might pos-
sibly be due to a general vasodilation, resulting in hypotension. However, 
after 24h, CAR edema was markedly depressed, while the rats seemed to be nor-
mal (no redness, no diarrhoea). 
Thus, systemically administered PGE 1 exerted its anti-inflammatory ef-
fects at 24h via unkno.vn mechanisms. Possibilities include an inhibitory ac-
tion on release of amines by platelets (see 2.4) or mastcells (1 I), or an in-
hibition of release of lysosomal enzymes from neutrophils (270). These actions, 
which have all been demonstrated to occur in vitro, are exerted by those PGs 
which elevate cAMP levels (eg. PGE 1, PGI 2). The in_vivo significance of these 
feed-back systems is, hoHever, largely unknmm. Since high (0.1 mg/ml) levels 
of PGE 1 are needed for inhibition of the relase of lysosomal enzymes from 
neutrophils in vitro (Weissmann et al., 1976), this mechanism seems of little 
importance for the inhibition of CAR edema in rats, treated with "only" 1 mg/ 
kg PGE 1 . 
Whether endogenous PGs display an anti-inflammatory effect is not yet 
known. It is obvious that endogenous PGE 1 will be of little importance, in 
this respect due to the scarcity of dihomo-y-linolenic acid in most tissues. 
Therefore, PGI 2 tvhich is much more potent than PGE 1 as stimulator of platelet 
adenylate cyclase (99,242), seems to be a better candidate. The question as 
to tvhether PGs are pro- or anti-inflammatory might be dependent on the local 
or systemic site of action. It might also be possible that PGs, such as PGI 2 , 
initially promote exudation via a marked increase in local bloodflow (see 2.5), 
whereas in a later stage of CAR edema the same type of PG may locally at-
tenuate the inflammatory response via inhibition of the activity of invaded 
cells. 
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8. GENERAL DISCUSSION 
8.1. Bioassay. 
For the determination of nanogram quantities of prostaglandins (PGs), the 
cascade superfusion technique, described by Vane (1964), was used. The method 
permitted simultaneous parallel bioassay with several tissues (see 2.1. 7). 
Suspension of the tissues in mineral oil (Ferreira and De Souza Costa, 1976), 
enabled detection of PGs in the picogram range. Thereby, bioassay reaches the 
sensitivity of radioimmunoassay. The laminar flow technique was adapted to 
superfusion of several different tissues (Bult et al. ,1977, chapter 3). This 
improvement allowed a differential, direct bioassay or enhanced the specifity 
of the assay after extraction and silicagel chromatography of biological sam-
ples. A higher concentration of the agonist near its receptor site constitutes 
the fundamental difference between the mineral oil method and the classical 
cascade technique. It is important to realize that, using mineral oil, the 
sensitivity towards interfering substances is raised to the same extent as for 
the autacoids being tested. An illustration of this phenomenon is that upto 
0.2 ml of rat platelet poor plasma (PPP) never contracted rabbit coeliac ar-
tery or rabbit aorta strips, superfused at 2.5 ml/min, whereas 0.05 ml PPP al-
ways induced a small contraction of the same tissues, superfused at 0.1 ml/min 
in mineral oil. 
The superfusing Krebs contained a mixture of antagonists to rule out as 
many interfering substances as possible. In initial experiments, phentolamine 
was used to antagonize a-adrenergic agonists, and methysergide was used to 
block the effects of serotonin (5HT). Although the activity of 5HT on the rat 
stomach strips (RSS) was for the greater part blocked, 5HT then still con-
tracted the rabbit aorta strip (RAS). This explained the release of both a 
labile and a stable rabbit aorta contracting substance (RCS) by aggregating 
platelet rich plasma (PRP). Only the labile component was liable to inhibition 
by indomethacin (Bult, Bonta et al., 1976). SHT-induced contractions as well 
as stable RCS responses disappeared if the rabbit aorta was treated with the 
rather non-specific, irreversible a-blocker, phenoxybenzamine, together with 
methysergide. This indicated that methysergide alone is too week as a SHT-
antagonist to be used for reliable bioassays of TXA2 , which is probably the 
major constituent of RCS (120). 
For the determination of the potencies of different agonists and antago-
nists the cumulative method for obtaining dose-response curves was applied 
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to the superfused organ cascade (Bult & Bonta, 1976a). This had a consider-
able time-saving effect and produced data, such as maximal contraction and 
log DSO, that were not significantly different from those obtained by the 
stepwise procedure. These results indicated that the cumulative technique, 
which is often used for measuring dose-response curves with bathing tissues, 
is applicable to superfused tissues as well (Bult & Bonta, 1976a). 
8.2. Platelet studies (Chapter 4). 
Collagen-stimulated rat PRP released malondialdehyde (MDA) and materials 
"t.;rhich behaved like SHT, PGE 2 and RCS (Piper & Vane, 1969) as determined by 
direct differential bioassay with a cascade of isolated tissues (Bult & Bonta, 
1976b, 1977). The release of MDA, PG-like material (PGL) and RCS was greatly 
reduced during essential fatty acid (EFA) deficiency and was liable to inhi-
bition by indomethacin, a cycle-oxygenase inhibitor (Vane, 1971). These 
findings indicated that HDA, PGL and RCS 'tvere derived from PG endoperoxides. 
PGL possessed pharmacological properties identiacal to those of PGE 2 and 
after extraction into an organic solvent, it co-chromatographed with PGE 1 in 
2 systems. Therefore, it seems most probable that PGL was identical to a PGE 
(PGE 2). Since its pharmacological properties and its half life matched the 
characteristics of thromboxane A2 (TXA2; 47, 120,178), RCS consisted probably 
mainly of TXA2 (cf. 120). Release of both PGE and TXA2 by rat platelets, ag-
gregated with collagen in heparinized plasma, was qualitatively similar to 
that obtained with washed human platelets, stimulated with thrombin (1 19). 
The endogenous formation of PGE 'tvas dependent on the dose of collagen. 
Endogenous AA, which is liberated from certain phospholipids during stimu-
lation of washed human platelets, is, for the greater part, oxygenated by both 
cycle-oxygenase and lipoxygenase (20,25). Thus, it seems likely that the en-
hanced formation of PGE by rat PRP "tvas due to an enhanced availability of 
non-esterified AA with increasing doses of collagen. No data have been ob-
tained which substantiated this assumption. Ho't.;rever, it is likely that an 
endogenous PLA2 is responsible for controlling the availability of AA, al-
though an increased supply of AA may be achieved in several ways (see 2.1 .2). 
Aggregation by threshold doses of collagen was suppressed by indomethacin, 
in concentrations that were similar to those needed for TXA2 , PGE and MDA in-
hibition. This suggested that, under these conditions, the formation of cyclo-
oxygenase products Has essential for rat platelet aggregation. In EFAD 
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platelets, the formation of TXA2 and PGE 'ivas drastically diminished during 
stimulation with supra-maximal doses of collagen. Decreasing the collagen dose 
would be expected to even further decrease the supply of cycle-oxygenase 
products. As a result, it was not surprising that threshold doses of collagen, 
which seem to aggregate normal rat platelets largely by releasing oxygenated 
AA products, were less effective in EFAD PRP. Indeed, under conditions where 
AA supply was rate-limiting for aggregation in normal PRP, the EFAD platelets 
almost failed to aggregate. The impaired aggregation was not due to an altered 
sensitivity tmvards PG endoperoxides, and in the presence of exogenous AA the 
cycle-oxygenase activity in EFAD platelets was unchanged. These findings are 
in agreement with the pro-aggregatory effects of either endoperoxides or TXA2 
in human platelets (1 16,120,231), 
The lipoxygenase pathway may supply oxygenated fatty acids both in the 
presence of indomethacin and during EFA deficiency ( 119,186, see also 2. I . 7). 
Under both conditions an impaired aggregation with threshold doses of collagen 
was observed, which indicated that the AA lipoxygenase path'ivay did not contri-
bute to rat platelet aggregation in vitro. 
Peak levels of TXA2 coincided with the start of aggregation in rat PRP 
(Bult & Bonta, 1976b). This finding has been confirmed in washed human plate-
lets, aggregated by addition of AA (101). In the latter report the levels of 
TXA2 were measured by radioimmunoassay after conversion of TXA 2 into mono-0-
methyl-TXB2. This suggested that TXA2 rather than the endoperoxides, was the 
pro-aggregatory metabolite of AA. If, as has been suggested (Haddeman et al., 
1977), platelet MDA was mainly derived from TXA2 , and not from endoperoxides, 
the importance of TXA2 in rat platelet aggregation was supported by the find-
ing that both aggregation and MDA production were suppressed by imidazole, an 
inhibitor of PGH 2-TXA 2 isomerase (168). 
Aggregation induced by higher doses of collagen, occurred independently 
of cycle-oxygenase products. The possibility that residual TXA 2 formation 'iVas 
responsible for normal aggregation in the presence of indomethacin or during 
EFA deficiency, seemed unlikely. Doses of indomethacin and TYA which complete-
ly blocked TXA2 , MDA and PGE production in normal PRP, failed to interfere 
with aggregation and SHT release. Even the combination of EFA deficiency and 
enormous doses of indomethacin did not suppress aggregation (Vincent et al., 
1975). Thus, the mechanisms involved in aggregation with maximal doses of 
collagen are unclear. The attachment of a large 
may alter platelet membrane properties a11mving 
number of collagen 
2+ . f . Ca 1.n lux, 'iVh1.ch 
fibers 
wi 11 lead 
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to release of ADP and aggregation (see scheme in 2.4). It must be realized 
that rat platelets will aggregate as soon as ADP has been released, by what-
ever stimulus (see below). 
PG biosynthesis 1vas not involved in ADP-induced aggregation of heparinized 
rat PRP. Even supra-maximal doses of ADP did not release significant amounts 
of PGE. Moreover, the aggregation of rat PRP by threshold doses of ADP was 
not inhibited by indomethacin at concentrations which completely suppressed 
TXA2 , MDA and PGE release. The fact that threshold doses of ADP only partial-
ly aggregated EFAD PRP, seems to be in contradiction to this assumption, but 
may be explained by membrane alterations during EFA deficiency (see 2.3.3). 
It is impossible to obtain information on the absolute amounts of TXA2 
usin:?. direct bioassay. Therefore, rat 
14
c-AA and the formation of 14c-TXB 
, 2 
PRP was stimulated in the presence of 
and 14c-PGE 2 was assessed. It is ob-
vious that, in this way, not all the TXA2 metabolites \-Jere measured, since 
conversion of TXA2 to HHT and HDA (84, 111 ,239), ivas not measured. In all ex-
periments, ~A'hether in the presence of collagen or not, the ratio of TXB 2/ 
(PGE 2+PGD2) was much smaller than in studies tvith human platelets (eg. 1 19). 
Similar results, also indicating that the conversion of PG endoperoxides to 
TXB 2 is less predominant in rat platelet preparations, have recently been re-
ported by other authors (Abrahams et al., 1977). 
In the presence of exogenous AA, rat PRP formed PG endoperoxides with 
little release of TXA2 (bioassay) or TXB 2 (TLC). At higher concentrations, AA 
induced both aggregation and a more significant release of TXA2 (or TXB 2). 
This again suggested that the thromboxane path1:vay is more important for aggre-
gation than endoperoxide formation per se. Possible explanations for the re-
lease of PGE without TXA2 (or TXB 2), which seemed at first sight to contra-
dict the results obtained tvith human platelets (120,178), have been proposed 
in section 4.5. Hhatever explanation may be correct, the fact remained that 
experiments, where PG and TXA2 biosynthesis was measured, follmving additions 
of exogenous AA to PRP, provided results that were not directly comparable to 
those obtained when endogenous AA was converted into PGE and TXA2 by PRP. A 
similar discrepancy has been described in human PRP, where exogenous PGH2 \vas 
not converted into TXA2 (178). 
The physiological significance of the observation that rat platelets can 
form PGE, and therefore PG endoperoxides, from exogenous AA, without aggregat-
ing, still has to be determined. However, it is likely that it is of little 
physiological importance, since even in inflammatory exudates, it is difficult 
114 
to imagine how free AA will ever reach concentrations of 0. 1 mM. The situation 
changes, however, when high doses of free AA are administered locally to an 
organism (see 8.3). 
In conclusion, it can be stated that rat platelet aggregation, induced in 
vitro by threshold doses of collagen, is amplified by cycle-oxygenase pro-
ducts, particularly TXA2 . Both ADP and high doses of collagen may induce ag-
gregation without the involvement of AA-derived products. The relevance of 
these in vitro studies to in vivo platelet behaviour is unclear. However, it 
is tempting to explain the tendency towards decreased arterial thrombosis for-
mation in EFAD rats (review: Hornstra, 1973) on the basis of the decreased 
responsiveness of EFA platelets towards collagen. 
Finally, rat platelet aggregation in vitro is certainly a good model for 
the evaluation of factors involved in PG biosynthesis. NSAIDs are active in 
this model, mainly because of inhibition of cycle-oxygenase. Caution should, 
however, be exercised in extrapolating the results obtained in this in vitr~ 
model to inflammation. For instance, TYA, which blocked platelet cyclo-oxy-
genase, was without anti-inflammatory activity in CAR edema, when administer-
ed locally (upto 250 ~g/paw). 
8.3. Prostaglandin~ and carrageenin-induced hindpaw edema (CAR edema). 
In the experiments described in chapter 5, the presence of prostaglandin-
like material (PGL) in acute CAR edema (Winters et al., 1962) has been demon-
strated using a coaxial perfusion method (214). Under carefully controlled 
conditions, very little, if any PGL was detectable in saline-treated paws. 
Thus, tissue damage was ruled out as a major source of PGL. An earlier report 
(Hillis, 1969) claimed the presence of PGL in CAR pedal edema. However, this 
paper is not very reliable, since data on levels of PGL in saline-treated 
paws and on the time of collection of the exudate were omitted. Such control 
data are indispensable for an evaluation of the reliability of the techniques 
employed. In the present study, PGL was already detectable one or two hours 
after administration of CAR to the paw. This indicated that the involvement 
of PGs started in the very early phase of CAR edema. Vane (1976) came to a 
similar conclusion, using rats immunized against PGE 1. Both findings are not 
in agreement with the suggestion that the PG phase starts at 3h (70). PGL was 
statistically different from 
By measuring in vivo the 
control values at 4 and 6h. 
d . f 125 1 . exu atlon o I a bumln, which was administered 
(i.v.) before application of CAR, it was possible to test the efficiency of 
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the perfusion technique. The recovery of I albumin from the exudate in the 
inflamed paw turned out to be very low. An estimation of in situ PGL levels 
4h after the injection of CAR, indicated the presence of approximately 5 ng 
PGE 2 equivalents/ml exudate. The real value may have been higher, since it is 
not unlikely that PGs other than PGE 2 , such as PGD 2 , PGI 2 and its metabolite 
6-keto PGFla' -which are considerably less, or not active at all on the RSS-
Here formed to a large extent. 
It is generally assumed that PG biosynthesis provides substances \vhich 
act as pro-inflammatory mediators (Zurier, 1974, Vane, 1976). Evidence for 
pro-inflammatory effects of AA metabolites in CAR edema, \-Jas obtained in tHo 
different tvays. Firstly, EFA deficiency resulted in a reduced AA content of 
rat erythrocytes and ln reduced (80-90%) biosynthesis of TXA2 and PGE by rat 
platelets. The yield of PGL from CAR edema (4h) in EFAD animals, turned out 
to be belcH the limit of detection, a finding which correlated 'ivith a reduced 
sHelling. Secondly, it is wellknovn that aspirin-like drugs reduce CAR pedal 
edema, a model which contributed largely to the discovery of indomethacin. 
Inhibition of PG biosynthesis has been claimed to be the major anti-inflamma-
tory activity of indomethacin (Vane, 1971). Indeed, a reduction of CAR edema 
was associated with reduced PGL levels in situ in rats pretreated Hith indo-
methacin (2.5 mg/kg). 
Thus, a pro-inflammatory, cyclo-oxygenase product was formed during acute 
CAR edema. In fact, it seemed that its formation was rate-limiting for the 
exudation, since simultaneous administration of either PGE 1 or AA, together 
with CAR, resulted in an almost maximal swelling within one hour (Chapter 6). 
The endogenous origin of PGL during acute inflammatory reactions is still a 
matter of debate, especially with respect to the role of neutrophils (92,93, 
262). HoHever, when exogenous AA is administered, the potentiation might be 
mediated by platelets. This is based on the observation that rat platelets 
can form PG endoperoxides, without aggregating and without forming the vaso-
constrictor TXA2 (Chapter 4) . The PG endoperoxides preferently decompose to 
vasodilatory PGs, such as PGE 2 , and are suitable substrates for PGI 2 synthet-
ase which will again result in the formation of a pro-inflammatory vasodilator. 
Of course, it is also possible that a variety of other cell types transform 
exogenous AA into its pro-inflammatory products. 
The involvement of cycle-oxygenase in the potentiation of CAR edema by AA 
seems indisputable, since the potentiation was liable to inhibition by aspirin 
and indomethacin (see also 149,229). Moreover, 5,8,1 1 eicosatrienoic acid, 
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which accumulated during EFA deficiency, failed to enhance CAR edema. The ob-
servation that dihomo-y-linolenicacid was less potent than AA in potentiating 
CAR edema suggested that possibly TXA2 or PGI2 , rather than the classical PGs 
or PG endoperoxides, were of importance as pro-inflammatory substances. 
The reduced edema in EFAD rats was used as a model in which PG release was 
of minor importance (see above) and the anti-inflammatory activities of NSAIDs 
(indomethacin and aspirin) and a corticosteroid (dexamethasone) were tested 
on this model. Exogenous AA restored the suppressed CAR pedal edema in EFAD 
rats. Due to the difficulty in obtaining exudate, no fatty acid analysis of 
exudate was carried out; the results obtained in vitro with platelets, how-
ever, indicated that cycle-oxygenase substrate and not cycle-oxygenase acti-
vity was diminished during EFA deficiency. Moreover, EFAD rats were equally 
sensitive to subplantar administration of Bk, SHT and PGE. The bradykinin 
component of inflammation, which, in contrast to the suggestion of Di Rosa et 
al. (1971), lasted at least 5 hours (59,81), was unaffected in EFAD animals. 
This was judged from an experiment with the bradykinin potentiating peptide 
BPPga· Thus, PG precursor shortage, rather than alterations in PG-synthe-
tizing capacity or changes in sensitivity towards other autacoids, was res-
ponsible for the impaired edema development during EFA deficiency. 
Indomethacin was largely inactive in this PG precursor deficient model, 
especially during the later phase of the edema (4h), when PGs were not detect-
able (see Chapter 5). Thus, inhibition of PG biosynthesis (Vane 1971) seemed 
to be sufficient to explain the acute anti-inflammatory activity of this drug. 
The activity of indomethacin on the early phase (2h) of CAR edema in EFAD rats 
is most easily explained by a limited residual release of PGs during this 
phase, although no measurements of PGL were made in early CAR edema of EFAD 
rats to verify this assumption. At 4h, when indomethacin was inactive as an 
anti-inflammatory drug in EFAD rats, aspirin still exerted a marked, repro-
ducible, anti-inflammatory activity. Therefore, the anti-inflammatory activity 
of aspirin is not completely explainable on the basis of its inhibition of PG 
synthetase. This finding may be explained in several ways (see Chapter 7), but 
the in vivo conversion of aspirin into salicylate (eg. 148) seems the most at-
tractive, but fails to explain the mode of action of salicylate. It is well-
known that salicylate is as potent as aspirin on CAR edema, but salicylate 
does not inhibit PG biosynthesis in vitro (eg. 82,230,254). 
The anti-inflammatory activity of indomethacin and aspirin -in contrast 
to that of theophylline- was not potentiated by PGE 1. Thus, it was unlikely 
that both NSAIDs, in the doses used, exerted an in vivo action similar to 
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that of theophylline, namely phosphodiesterase inhibition. 
Recently, it has been demonstrated that corticosteroids interfere with 
the liberation of AA, and thereby vith the release of PGs (see revietv by Gry-
glevski, 1976, 2.2.2). Since dexamethasone was effective in the EFAD inflam-
matory model, its anti-inflammatory activity was not completely explainable 
by inhibition of PG release. 
Finally, PGs may be regarded as modulators of the CAR response. All 
classical PGs fail to induce 11 true 11 inflammation on their own, but they po-
tentiate responses to other autacoids (eg. Williams & Morley, 1973). Thus, CAR 
edema developed when PG biosynthesis was greatly reduced (NSAIDs, EFA defi-
ciency), but the inflammatory process tvas less severe. The acute, pro-inflam-
matory effects of PGs are, at this moment, mainly explainable on the basis of 
their marked ability to increase local blood flow. On the other hand, certain 
PGs (eg. PGE 1) have anti-inflammatory effects on CAR edema (see Chapter 7) as 
tvell as on a chronic experimental inflammatory reaction (Bonta, Farnham et 
al., 1977). In both types of inflammatory models, the anti-inflammatory acti-
vity of PGE \vas potentiated by the phosphodiesterase inhibitor theophylline. 
However, the exact anti-inflammatory mechanism(s) and site of action of PGE 1 
are unknown at this moment. 
The latter observations question the anti-inflammatory mode of action of 
drugs that interfere with PG biosynthesis. Undoubtedly, ~SAIDs reduce svell-
ing and fever and are peripheral analgesics, but on the other hand, they may 
remove those endogenous PGs \Vhich possibly shorten the inflammatory process. 
Thus, a rational therapy of inflammation might be impossible vith PG syn-
thetase inhibitors. In general, anti-inflammatory -not anti-edemagen- drugs 
are used emprically, without basic knowledge about their mode of action. This 
is largely due to the fact that 11much of tvhat He knmv about the inflammatory 
process was known in 1900" (Ebert & Grant, 1974). Even for a simple model, 
such as CAR edema, it is almost impossible to construct a pathway leading to 
inflammation (Vinegar et al., 1976) and even less is known about endogenous 
factors ivhich terminate this process. 
CAR edema vill probably not contribute to the development of nev, empiric, 
anti-inflammatory agents of clinical importance. HoHever, basic studies on 
this model, \Vith recently developed research techniques, ,,Till probably be 
essential for understanding of exudation, changes in blood flow, properties 
for vascular endothelium, the origin, site of action and turnover of PGs and 
other autacoids, the attraction of inflammatory cells, and the mutual inter-
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actions between these events. Therefore, CAR edema and similar 11 simple11 
models, are able to provide possible mechanisms for more complex, chronic si-
tuations, where, upto now, it has been impossible even to start developing 
an hypothetical step-by-step pathway leading to inflammation. 
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9. SUM;!ARY 
This thesis describes studies carried out to investigate the importance 
of prostaglandin (PG) biosynthesis in the development of carrageenin-induced 
hind-pa'tv edema (CAR edema) in the rat. In addition, PG and thromboxane A2 (TXA2) 
biosynthesis by rat platelets, and its relevance for aggreF,ation, was studied in 
vitro. Some of the experiments were performed 1:vith essential fatty acid defi-
cient (EFAD) rats, \vhich contained very little arachidonic acid (AA), the main 
PG percusor. 
The formation of PGs and/or TXA 2 was generally measured by bioassay on 
isolated tissues, using the cascade superfusion technique described by Vane 
(1964). It was found that a ncumulative" procedure for obtaining dose-response 
curves was conveniently applicable to superfused tissues. Under specified 
conditions it was possible to assay TXA2 on a rabbit aorta strip, despite the 
concomitant presence of serotonin. Finally, the sensitivity of the bioassay 
was greatly improved by superfusing the tissues in the cascade with a laminar 
flm,, (chapter 3). 
The in vitro experiments are summarized in chapter 4. Upon stimulation 
with collagen or AA, rat platelets in heparinized, platelet rich plasma, syn-
thetized malondialdehyde (MDA), PGE and TXA2 . Follmving both types of stimuli, 
this biosynthesis was dose-dependent and liable to inhibition by indomethacin, 
aspirin and eicosatetraynoic acid. During EFA deficiency the release of PGE 
and TXA2 was greatly reduced, but the activity of the cycle-oxygenase, which 
catalyses the transformation of AA into PG-endoperoxides, seemed to be unal-
tered. 
The oxygenated endogenous AA products, especially TXA2 , amplified the ag-
gregation induced by threshold doses of collagen. The addition of exogenous 
AA to rat platelet rich plasma did not completely mimick the reactions induced 
by collagen, since, in the absence of aggregation, more stable PGs and less 
TXA2 were formed. 
Aggregation induced by ADP or high doses of collagen tvas independent of 
TXA 2 synthesis in rat platelets. Moreover, the platelets of this species are 
relatively insensitive to the exogenous PG endoperoxide PGH2 , and the stable 
9,1 I epoxymethano analogue of PGH 2 . 
The experiments described in chapter 5 were performed in order to 
detect PGs during CAR edema under carefully controlled conditions. For the 
collection of exudate from CAR edema, a coaxial perfusion method was used. 
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In perfusates from inflamed pm.,rs prostaglandin-like material (PGL) was detect-
able at 1, 2, 4 and 6 hours. PGL Has neither measurable before aplication of 
CAR, nor after administration of saline to the paHs. 
These results Here confirmed at 4 hours after administration of CAR, using 
a more quantitative approach. Both EFA deficiency and pretreatment Hith indo-
methacin (2.5 mg/kg) led to decreased biosynthesis of PGL in the inflamed 
area, \vhich coincided with diminished S\velling. Thus, during thedevelopment of 
CAR edema a pro-inflammatory PGL was formed. 
The involvement of PGs in the development of CAR edema was further esta-
blished in the experiments described in chapter 6. It appeared that the re-
duction of the CAR edema (from 2 hours onHards) in EFAD rats was most probably 
caused by a shortage of AA. The impaired inflammatory response in these ani-
mals Has not due to diminished cycle-oxygenase activity (cf. chapter 4). 
Horeover, the sensitivity towards edemagens (bradykinin and serotonin), as 
well as the bradykinin component of CAR edema, Here unaltered in EFAD rats. 
These experiments further indicated that release of AA, and its subsequent 
conversion into a PG ,,Tith "vasodilatory properties", is possibly a rate-li-
miting factor in edema development. 
Finally, the anti-inflammatory activities of aspirin and indomethacin, 
which inhibit the cyclo-oxygenase, and dexamethasone, a corticosteroid that 
may interfere Hith the cellular liberation of PGs, were studied on CAR edema 
in EFAD rats in which endogenous release of PGs is of minor importance (see 
chapters 5 & 6). Indomethacin (2.5 rug/kg), almost failed to suppress there-
duced CAR edema in EFAD rats. However, aspirin (125 mg/kg) and dexamethasone 
(0. 125 rug/kg), in doses that were approximately equipotent to those of indo-
methacin in normal rats, still displayed anti-inflammatory activities in EFAD 
rats. Thus, the main anti-inflammatory activity of indomethacin HaS probably 
based on its inhibition of PG biosynthesis, but aspirin and dexamethasone 
possessed addional anti-inflammatory properties. 
Circumstantial evidence for the hypothesis that inhibition of phospho-
diesterase \Vas responsible for the additional anti-inflammatory activity of 
aspirin, was not obtained in vivo. However, in these experiments, it \vas 
found that PGE 1 (1 mg/kg), when administered systemically, suppressed the 
later phase (24h) of CAR edema. This might indicate that PGs modulate this 
model of acute inflammation and that biosynthesis of PGs enhances the acute 
phase of the edema, but may also contribute to the termination of the inflam-
matory process. 
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I 0. SAl1ENVATTING 
Het verkrijgen van meer inzicht in de rol van prostaglandines (PGs) in 
ontstekingsreakties was het doel van de experimenten die in dit proefschrift 
beschreven zijn. Daartoe Herd het carrageenine (CAR) oedeem, een akute ont-
stekingsreaktie in de achterpoot van de rat als model gekezen. Omdat het moei-
lijk is prostaglandines op betrew:vbare vijze in ontstoken Heefsel te meten, 
werd ter endersteuning van de resultaten tevens de biosynthese van prostag-
landines in vitro bestudeerd. Dit gebeurde met gelsoleerde bloedplaatjes van 
de rat. 
In hoofdstuk 2 lS literatuur over verschillende as pecten van het onderzoek 
samengevat. Het bleek daaruit dat de verming van prostaglandine-endoperoxiden 
uit arachidonzuur gekatalyseerd \-vordt door het enzyme cycle-oxygenase. tit de 
prostaglandine-endoperexiden kunnen andere biologisch aktieve prostaglandines 
gevormd worden, zeals PGE 2 en prostacycline, of het instabiele thromboxaan A2 
(2. 1). Kiet sterolde ontstekingsremrnende farmaka, zeals aspirine (acetylsali-
cylzuur) en indomethacine, onderdrukken PG-biesynthese omdat zij de cycle-
oxygenase remmen. Sterolde entstekingsremmers, zoals dexarnethason, kunnen 
prestaglandine vorming tegengaan door het beschikbaar komen van arachidonzuur 
te belemmeren (2.2). Bij het onderzoek is gebruik gernaakt van essentieel vet-
zuur (EFA) deficiente ratten. Deze werden groat gebracht met een dieet zonder 
linolzuur, en kunnen daardeor geen arachidonzuur produceren. Een EFA deficient 
organisme zal dus minder substraat bezitten voor endogene vorming van PGs en 
thromboxaan A2 (2.3). Vorming van thromboxaan A2 treedt o.a. op bij de aggre-
gatie van menselijke bloedplaatjes, en is een van de faktoren die van belang 
is voer de haemostatische funktie van bloedplaatjes. De teegenomen kans ep 
bloedingen na gebruik van aspirine berust ep de irreversibele remrning van 
thromboxaan A2 produktie (2.4). Tens lotte gaf de literatuur aam-vijzingen dat 
prostaglandines een rel spelen bij hct carrageeninc oedeem. 
In bet experimentele deel van dit proefschrift \Verd nagegaan of PGs aan-
toonbaar waren in de ontstoken poten, en of PGs uitsluitend een ontstekings-
bevorderende rol hebbcn. De proeven Hcrden ten dele uitgevoerd met EFA defi-
cii2nte ratten. Met deze proefdieren Herd enderzocht of de ontstekingsreiTL.'llende 
1:verking van aspirine, indomethacine en dexamethason berust te op een onderdruk-
king van het vrijkomen van prostaglandines. 
PGs en thromboxaan A2 , die veclnl slechts ln minieme hoeveelheden gevorrod 
worden, \-verden bepaald met een biologisclw ijking. Gelsoleerde m:gaanpreparaten 
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met glad spierweefsel,zoals strips van rattemaag en konijneaorta,werden onder 
elkaar bevestigd.Een fysiologische zoutoplossing werd via het bovenste weefsel 
successievelijk over de lagere organengeleid (cascade techniek). Door verschillen-
de organen te kiezen,kunnen meerdere biologisch aktieve stoffen tegelijkertijd 
in een monster bepaald worden aan de hand van de contrakties van de geisoleer-
de weefsels. De contrakties werden geijkt met standaarden van die stoffen, die 
de organen stimuleren (agonisten), ten.;rijl storende stoffen geblokeerd \.Jerden 
met 11 antagonisten". Ten opzichte van andere meetmethoden heeft de biologische 
ijking een voordeel: door het dynamische, snelle karakter is bet mogelijk zeer 
labiele verbindingen, zoals thromboxaan A2 aan te tonen. In hoofdtuk 3 zijn 
modifikaties van de methode beschreven. Deze versnelden de bepaling en maakten 
bet mogelijk om prostaglandines en thromboxaan A2 in aawezigheid van serotoni-
ne te meten. De gevoeligheid van de ijking werd tenslotte vergroot met behulp 
van een "Laminar flow techniquen, \.Jaardoor het mogelijk werd PGE 2 vanaf 20-50 
-12 picogram (10 g) aan te tonen. 
De experiment en met bloedplaatjes van de rat zijn samengevat ln hoofdstuk 4, 
Er werd nagegaan of bloedplaatjes van EFA deficiente ratten minder endogene 
prostaglandines en thromboxaan A2 vormden. Tegelijkertijd werd de nog groten-
deels onbekende rol van prostaglandine metabolisme voor bet funktioneren van 
rattebloedplaatjes bestudeerd. Dit werd gedaan in plaatjes rijk plasma dat met 
heparine onstolbaar gemaakt was. 
Na toedienen van collageen aggregeerden de bloedplaaajes en dartrbij b.;ram 
malondialdehyde, thromboxaan A2 en PGE vrij. Verschillende cycle-oxygenase 
remmers onderdrukten de vorming van deze produkten. Thromboxaan A2 was reeds 
20 seconden na toedienen van collageen in maximale hoeveelheden ontstaan en 
was nag voor de voltooiing van de aggregatie in veel mindere mate aantoonbaar. 
De bloedplaatjes van EFA deficiente ratten synthetiseerden slechts 10 a 20 
procent van de normale endogene hoeveelheid PGE en thromboxaan A2 . 
Bij drempeldoses collageen was prostaglandine-endoperoxide vorming nood-
zakelijk voor het funktioneren van rattebloedplaatjes. Dit bleek uit het feit 
dat dan nog maar 10% van de EFA deficiente bloedplaatjes aggregeerde. Boven-
dien \.Jas indomethacine dan even effektief als cycle-oxygenase remmer en als 
renuner van de aggregatie van normale bloedplaatj es. Ui t experimenten met exogeen 
arachidonzuur bleek dat de cycle-oxygenase aktiviteit van EFA deficiente 
bloedplaatjes niet verminderd was. Bovendien werden aanwijzingen gevonden dat 
vooral de vorming van thromboxaan A2 van belang is voor de plaatjesfunktie. 
De aggregatie, en het vrijmaken van serotonine waren afhankelijk van de 
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thromboxaan A2 vorming als de bloedplaatjes met hoge doses collageen gestimu-
leerd werden. Tot zover leken de thrombocyten van de rat op die van de mens. 
Er waren oak verschillen, omdat plaatjes van de rat meer PGE en relatief wei-
nig thromboxaan A2 vormden. Bovendien aggregeerden bloedplaatjes van de rat 
nauwelijks na toedienen van het prostaglandine endoperoxide PGH2 en is hun 
aggregatie onder invloed van ADP niet afhankelijk van rrostaglandine endo-
peroxide biosynthese. 
Omdat vermoed werd dat prostaglandines ontstaan bij het carrageenine oe-
deem in de achterpoot van de rat, werd getracht om prostaglandines aan te to-
nen in het ontstoken weefsel. Ontstekingsexsudaat werd daartoe verzameld met 
een coaxiale perfusietechniek, zoals beschreven is in hoofdstuk 5. Inderdaad 
was 4 en 6 uur, en waarschijnlijk al eerder, na het begin van de ontsteking 
een prostaglandine-achtige materie aantoonbaar in het exsudaat. In tegenstel-
ling tot de enige eerdere publikatie waarin dit onderzocht was, werd aange-
toond dat de prostaglandine vorming geen artefakt vas. 
Het een belangrijk verbeterde proefopzet 'iverden de waarnemingen, 4 uur na 
toedienen van carrageenine, bevestigd. Door gebruik te maken van radio-aktief 
gemerkt alburnine Has het mogelijk de efficientie van de perfusietechniek te 
klvantificeren. Indien artefakten tot een minimum beperkt werden, dan was ln 
de ontstekingsvloeistof 5 a 7 nanogram PGE 2-equivalenten aantoonbaar. Omdat 
ongeveer I ml exsudaat gevormd ~o.ras, was de lokale concentratie 11 PGE 2" minstens 
100 maal grater dan die in bloedplasma. Als de ratten voorbehandeld werden met 
indomethacine (2.5 mg/kg) dan werd zowel PG-vorming als pootzwelling en eiwit-
lekkage onderdrukt. In EFA deficiente ratten waren PG-vorming en pootzwelling 
afgenomen, maar de lekkage van plasma eiwitten was niet verminderd. Deze proe-
ven wijzen erop dat tijdens de eerste uren van de oedeemvorming biosynthese van 
ontstekingsbevorderende prostaglandines plaatsvindt. 
In hoofdstuk 6 is de bijdrage van PG-biosynthese tot het ontstekingsproces 
nader onderzocht. In EFA deficiente rat ten •vas de pootzwelling vanaf 2 uur na 
toedienen van carrageenine verminderd ten opzichte van normale ratten. Dit 
werd veroorzaakt door een verminderde beschikbaarheid van arachidonzuur, en 
niet door een afgenomen cycle-oxygenase aktiviteit (zie ook in vitro proeven). 
Andere kornponenten van het ontstekingsproces zoals de gevoeligheid voor plas-
malekkage veroorzakende stoffen als bradykinine en histamine, Haren onveran-
derd in EFA deficiente ratten. Dit alles duidt aan dat biosynthese van pros-
taglandines bijdraagt tot het ontstekingsproces, en dat EFA deficiente ratten, 
die minder endogene prostaglandines kunnen vormen, dientengevolge een vermin-
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derde pootzwelling vertonen. 
De beschikbaarheid van endogeen arachidonzuur is mogelijk een snelheids-
bepalende faktor in de oedeernvorrning. Een indirekte aanwijzing-duidde erop dat 
niet de prostaglandine-endoperoxiden of stabiele PGs, maar veeleer thrombo-
xaan A2 of prostacycline de pootzwelling bevorderen. Anderzijds bleek uit de 
experimenten in hoofdstuk 6 dat een prostaglandine (PGE 1 in een latere fase 
(24h) de pootz\velling ·kan reduceren. 
In hoofdstuk 7 werd onderzocht of onderdrukking van de biosynthese van 
prostaglandines (zie 2.2) het enige ontstekingsremmende effekt is van indo-
methacine, aspirine en dexamethason. Dit \verd onderzocht in EFA deficiente 
ratten in een fase van het ontstekingsproces (na 4 uur) Haarin prostaglandi-
nes niet aantoonbaar Haren in het ontstekingsexsudaat. Indomethacine (2.5 mg/ 
kg) was niet in staat het verminderde carrageenine oedeem in EFA deficiente 
ratten verder te remmen. De oedeemremmende werking van indomethacine berust 
dus grotendeels op onderdrukking van PG biosynthese. Omdat zowel aspirine als 
dexamethason de pootzwelling in J::FA deficiente ratten wel onderdrukten, moe-
ten beide farmaka, naast een eventuele belemmering van het vrijkomen van pros-
taglandines, nog een andere ontstekingsremrnende eigenschap bezitten. Het lijkt 
goed rnogelijk dat splitsing van aspirine in salicylaat de alternatieve ontste-
kingsremrnende werking van aspirine verklaart. Het werkingsmechanisme van de 
ontstekingsremmer salicylaat is nag onbekend, maar de stof remt de biosynthese 
van prostaglandines niet in vitro (zie 2.2). Tenslotte bleek opnieuw dat PGE 1, 
in farmakologische doses, de latere fase (24 uur) van de pootzwelling onder-
drukte. Dit berustte waarschijnlijk op stimulatie van cyclisch AMP vorming, 
maar nader onderzoek is nodig om dit te bevestigen. 
Dit alles wijst er op dat PGs het carrageenine oedeem moduleren. Zelfs als 
er veel minder prostaglandines gevormd worden, bijvoorbeeld na toediening van 
indomethacine of in EFA deficiente ratten, dan gaat de ontstekingsreaktie 
door. Echter, biosynthese van prostaglandines versnelt en/of versterkt de ont-
wikkeling van het carrageenine oedeem. Of endogene prostaglandines, net als 
PGE 1, het proces eveneens bekorten is nog niet bekend, maar lijkt niet uitge-
sloten. 
Nader onderzoek naar de ontstekingsremmende werking van PGs lijkt gewenst. 
Het zou kunnen leiden tot een herwaardering van de therapeutische waarde van 
ontstekingsremmende farmaka die voornamelijk werkzaam zijn via remming van PG-
biosyntese. Hoewel farmaka, als indomethacine symptomen van een ontsteking 
onderdrukken, leidt hun toediening mogelijk tevens tot een onderdrukking van 
een der faktoren die een ontstekingsproces afremmen. 
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